0001731122-20-000897.txt : 20200819 0001731122-20-000897.hdr.sgml : 20200819 20200819165055 ACCESSION NUMBER: 0001731122-20-000897 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 70 CONFORMED PERIOD OF REPORT: 20200630 FILED AS OF DATE: 20200819 DATE AS OF CHANGE: 20200819 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Advanzeon Solutions, Inc. CENTRAL INDEX KEY: 0000022872 STANDARD INDUSTRIAL CLASSIFICATION: HOSPITAL & MEDICAL SERVICE PLANS [6324] IRS NUMBER: 952594724 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-09927 FILM NUMBER: 201117575 BUSINESS ADDRESS: STREET 1: 3405 W. DR. MARTIN LUTHER KING JR. BLVD. STREET 2: SUITE 101 CITY: TAMPA STATE: FL ZIP: 33607 BUSINESS PHONE: 813-288-4808 MAIL ADDRESS: STREET 1: 3405 W. DR. MARTIN LUTHER KING JR. BLVD. STREET 2: SUITE 101 CITY: TAMPA STATE: FL ZIP: 33607 FORMER COMPANY: FORMER CONFORMED NAME: COMPREHENSIVE CARE CORP DATE OF NAME CHANGE: 19920703 FORMER COMPANY: FORMER CONFORMED NAME: NEURO PSYCHIATRIC & HEALTH SERVICES DATE OF NAME CHANGE: 19730501 FORMER COMPANY: FORMER CONFORMED NAME: NEURO PSYCHIATRIC & HEALTH SERVICES INC DATE OF NAME CHANGE: 19700402 10-Q 1 e2079_10q.htm FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2020

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ______________

Commission File Number: 1-9927

ADVANZEON SOLUTIONS, INC.

(Exact name of registrant as specified in its charter)

Delaware		95-2594724
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

2901 W. Busch Blvd. Suite 701

Tampa, FL

33618

(Address of principal executive offices)

(Zip Code)

813-517-8484

(Registrant’s telephone number, including area code)

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such fling requirements for the past 90 days. Yes☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☐	Smaller reporting company	☒
		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of August 10, 2020, the Registrant had outstanding 117,516,838 shares of its $0.01 par value Common Stock.

ADVANZEON SOLUTIONS, INC.

TABLE OF CONTENTS

		Pages
PART I.	Financial Information
Item 1.	Consolidated Financial Statements
	Consolidated Balance Sheets as of June 30, 2020 (unaudited) and December 31, 2019	3
	Consolidated Statements of Operations for the Three and Six-Month Periods Ended June 30, 2020 and 2019 (unaudited)	4
	Consolidated Statement of Stockholders' Deficiency For the Three and Six-Month Periods Ended June 30, 2020 and 2019 (unaudited)	5
	Consolidated Statements of Cash Flows for the Six-Month Periods Ended June 30, 2020 and 2019 (unaudited)	6
	Notes to Consolidated Financial Statements	7
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	17
Item 3.	Quantitative and Qualitative Disclosure about Market Risk	23
Item 4.	Controls and Procedures	23
PART II.	Other Information
Item 1.	Legal Proceedings	25
Item 1A.	Risk Factors	25
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	25
Item 3.	Exhibits	30

PART I – FINANCIAL INFORMATION

ITEM 1. Consolidated Financial Statements

ADVANZEON SOLUTIONS, INC.

CONSOLIDATED BALANCE SHEETS

June 30, 2020 (unaudited) and December 31, 2019

	June 30, 2020			December 31,
	(unaudited)			2019
ASSETS
CURRENT ASSETS
Cash	$	145,915		$	69,327
Restricted cash		845,340			—
Accounts receivable		40,990			29,769
Current portion of right of use asset		136,230			113,911
Other current assets		657,025			826,597
Total current assets		1,825,500			1,039,604

PROPERTY, PLANT, AND EQUIPMENT
Property and equipment, net		5,683			1,239
Leasehold improvements, net		—			—
Total property, plant, and equipment		5,683			1,239

RIGHT OF USE ASSET, NET OF CURRENT PORTION		179,221			146,880

TOTAL ASSETS	$	2,010,404		$	1,187,723

CURRENT LIABILITIES
Related party loans payable	$	102,229		$	342,670
Account payable		403,265			99,441
Debt		10,416,176			12,352,189
Contingent liability		642,659			642,659
Current portion of lease liability		136,230			113,911
Other accrued expenses		13,742,192			15,891,787
Total current liabilities		25,442,751			29,442,657

LEASE LIABILITY, NET OF CURRENT PORTION		179,221			146,880

TOTAL LIABILITIES		25,621,972			29,589,537

STOCKHOLDERS' DEFICIENCY
Preferred stock, $.001 par value; 1,000,000 shares authorized as of June 30, 2020 and December 31, 2019		—			—
Series C Convertible Preferred; $.001 par value; 14,400 shares authorized; 10,434 shares issued and outstanding as of June 30, 2020 and December 31, 2019		10			10
Series D Convertible Preferred; $.001 par value; 7,000 shares authorized; 250 shares issued and outstanding as of June 30, 2020 and December 31, 2019		—			—
Remaining Preferred stock; $.001 par value; 978,600 shares authorized as of June 30, 2020 and December 31, 2019		—			—
Common stock, $0.01 par value; 1,000,000,000 shares authorized; 13,201,582 shares reserved; 116,751,439 and 71,661,656 shares issued and outstanding as of June 30, 2020 and December 31, 2019, respectively		1,167,514			716,617
Additional paid in capital		35,361,980			28,719,246
Accumulated deficit		(60,141,072	)		(57,837,687	)
Total stockholders' deficiency		(23,611,568	)		(28,401,814	)

TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIENCY	$	2,010,404		$	1,187,723

The accompanying notes are an integral part of these consolidated financial statements.

ADVANZEON SOLUTIONS, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

For the Three and Six-Month Periods Ended June 30, 2020 and 2019 (unaudited)

	Three-Month Period Ended						Six-Month Period Ended
	June 30,						June 30,
	2020			2019			2020			2019

Revenues:
Obstructive sleep apnea (OSA)	$	103,444		$	90,453		$	230,992			158,376
Total revenues		103,444			90,453			230,992			158,376

Costs and expenses:
Costs of revenues		65,000			66,157			129,909			107,817
General and administrative		715,397			416,039			1,311,462			841,843
Depreciation and amortization		312			235			623			440
Total costs and expenses		780,709			482,431			1,441,994			950,100

Loss from operations		(677,265	)		(391,978	)		(1,211,002	)		(791,724	)

Other income (expense):
Interest expense		(707,774	)		(341,178	)		(1,102,403	)		(669,193	)
Interest income		—			5,994			20			5,994
Legal settlement		—			112,172			—			112,172
Forgivable SBA EIBL loan advance		10,000			—			10,000			—
Total other expense		(697,774	)		(223,012	)		(1,092,383	)		(551,027	)

Net loss	$	(1,375,039	)	$	(614,990	)	$	(2,303,385	)	$	(1,342,751	)

PER SHARE INFORMATION
Net Loss Per Common Share	$	(0.01	)	$	(0.01	)	$	(0.02	)	$	(0.02	)

Weighted Average Number of Common
Shares Outstanding		79,534,495			67,361,656			75,598,076			67,027,954

The accompanying notes are an integral part of these consolidated financial statements.

ADVANZEON SOLUTIONS, INC.

CONSOLIDATED STATEMENT OF STOCKHOLDERS’ DEFICIENCY

	Series C convertible Preferred Stock Number of Shares		Series C Convertible Preferred Stock Amount		Common Stock Number of Shares		Common Stock Amount		Additional Paid - in Capital		Accumulated Deficit			Total
Balance at December 31, 2018		10,434	$	10		66,661,656	$	666,617	$	28,012,007	$	(54,581,873	)	$	(25,903,239	)
Stock Issued for Services		—		—		200,000		2,000		14,000		—			16,000
Sale of Stock		—		—		500,000		5,000		10,000		—			15,000
Net Loss		—		—		—		—		—		(727,761	)		(727,761	)
Balance at March 31, 2019		10,434		10		67,361,656		673,617		28,036,007		(55,309,634	)		(26,600,000	)
Stock Issued for Services		—		—		—		—		—		—			—
Sale of Stock		—		—		—		—		—		—			—
Net Loss		—		—		—		—		—		(614,990	)		(614,990	)
Balance at June 30, 2019		10,434		10		67,361,656		673,617		28,036,007		(55,924,624	)		(27,214,990	)
Stock Issued for Services		—		—		—		—		—		—			—
Sale of Stock		—		—		—		—		—		—			—
Net Loss		—		—		—		—		—		(747,801	)		(747,801	)
Balance at September 30, 2019		10,434		10		67,361,656		673,617		28,036,007		(56,672,425	)		(27,962,791	)
Stock Issued for Services		—		—		4,300,000		43,000		430,000		—			473,000
Sale of Warrants		—		—		—		—		253,239		—			253,239
Sale of Stock		—		—		—		—		—		—			—
Net Loss		—		—		—		—		—		(1,165,262	)		(1,165,262	)
Balance at December 31, 2019		10,434		10		71,661,656		716,617		28,719,246		(57,837,687	)		(28,401,814	)
Stock Issued for Services		—		—		—		—		—		—			—
Sale of Warrants		—		—		—		—		—		—			—
Sale of Stock		—		—		—		—		—		—			—
Net Loss		—		—		—		—		—		(928,346	)		(928,346	)
Balance at March 31, 2020		10,434		10		71,661,656		716,617		28,719,246		(58,766,033	)		(29,330,160	)
Stock Issued for Services		—		—		—		—		—		—			—
Sale of Warrants		—		—		—		—		18,251		—			18,251
Sale of Stock		—		—		45,089,783		450,897		6,624,483		—			7,075,380
Net Loss		—		—		—				—		(1,375,039	)		(1,375,039	)
Balance at June 30, 2020		10,434		10		116,751,439		1,167,514		35,361,980		(60,141,072	)		(23,611,568	)

The accompanying notes are an integral part of these consolidated financial statements.

ADVANZEON SOLUTIONS, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

For the Six-Month Periods Ended June 30, 2020 and 2019 (unaudited)

	Six-Month Periods Ended
	June 30,
	2020			2019

CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$	(2,303,385	)	$	(1,342,751	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		623			440
Stock issued for services		—			16,000
Amortization of right of use assets		54,660			25,579
Net changes in assets and liabilities:
Accounts receivable		(11,221	)		(2,756	)
Other current assets		169,572			(712,065	)
Payments on lease liabilities		(54,660	)		(25,579	)
Accounts payable		51,383			210,951
Other accrued expenses		1,215,572			742,356
Net cash used in operating activities		(877,456	)		(1,087,825	)

CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of property, plant, and equipment		(5,067	)		(1,549	)
Net cash used in investing activities		(5,067	)		(1,549	)

CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from promissory notes		559,360			1,070,250
Proceeds from PPP loan		1,243,840			—
Payments on debt		(17,000	)		—
Sale of stock		18,251			15,000
Net cash provided by financing activities		1,804,451			1,085,250

Net increase (decrease) in cash		921,928			(4,124	)

CASH - Beginning of Year		69,327			25,036

CASH AND RESTRICTED CASH - END OF PERIOD	$	991,255		$	20,912

Supplemental disclosures of cash flow information:
Cash paid during the period for:
Interest	$	—		$	—
Income taxes	$	—		$	—

Recording of right of use assets under
lease agreements (ASU 2016-02)	$	135,075		$	119,640

Schedule of non-cash investing transactions:
Convertible promissory note and accrued interest
converted to common stock	$	7,075,380		$	—

The accompanying notes are an integral part of these consolidated financial statements.

ADVANZEON SOLUTIONS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

DESCRIPTION OF THE COMPANY’S BUSINESS AND BASIS OF PRESENTATION

The consolidated financial statements include the accounts of Advanzeon Solutions, Inc and its wholly owned subsidiary, and its respective subsidiaries (collectively referred to herein as, the “Company” ,“Advanzeon” ,“we”, “us” or “our”).

In the opinion of management, the accompanying unaudited financial statements contain all adjustments necessary to present fairly the Company's financial position as of December 31, 2019, the changes therein for the three and six-month periods then ended and the results of operations for the three and six-month periods ended June 30, 2020 and 2019.

The financial statements included in the Form 10-Q are presented in accordance with the requirements of the Form and do not include all of the disclosures required by accounting principles general accepted in the United States of America. For additional information, reference is made to the Company's annual report on Form 10-K for the fiscal year ended December 31, 2019, filed April 9, 2020. The results of operations for the three and six-month periods ended June 30, 2020 and 2019 are not necessarily indicative of operating results for the full year.

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Established in 1969, Advanzeon Solutions, Inc., (formerly Comprehensive Care Corp.) (“Advanzeon”, “we”, “Parent”, or the “Company”), through its wholly-owned subsidiary Pharmacy Value Management Solutions, Inc., and its wholly-owned subsidiaries during 2015, and partly in 2016, provided managed care services by acting as the administrator for certain administrative service agreements in the behavioral health and substance abuse fields. We primarily offered these services to commercial, Medicare, Medicaid, Children’s Health Insurance Program (“CHIP”) health plans, as well as self-insured companies. Our managed care operations consisted solely of servicing administrative service agreements. Starting in July of 2015, we implemented our comprehensive sleep apnea program, called “SleepMaster Solutions” ™. SleepMaster Solutions (“SMS”) utilizes an administrative system for the convenient identification/testing and therapy of Obstructive Sleep Apnea (“OSA”). We partnered with a national health care provider by initiating a sleep apnea wellness program whereby we screened, tested and when needed, offered treatment programs for treating this disorder. We also contracted with a union to treat its driver members. Beginning in 2017, our only business was our SMS sleep apnea program.

The Company has elected to not adopt the option available under United States generally accepted accounting principles (“GAAP”) to measure any eligible financial instruments or other items at fair market value at this time. Accordingly, the Company measures all of its assets and liabilities on the historical cost basis of accounting, except as otherwise required by GAAP.

Inter-company accounts and transactions have been eliminated in consolidation. Certain minor reclassifications of prior period amounts have been made to conform to the current period presentation.

Use of Estimates - The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates that affect the reported amounts. Actual results could differ from these estimates. Estimates involved in the determination of an allowance for doubtful accounts receivable are considered by management as particularly susceptible to material change in the next year. Other significant estimates relate to stock-based compensation, warrants and beneficial conversion features.

Accounts Receivable - Accounts receivable is carried at its estimated collectible value. Since customer credit is generally extended on a short-term basis, accounts receivable does not bear interest and are uncollateralized. We manage credit risk and determine necessary allowances by evaluating customers’ credit worthiness before extending credit and periodically for collectability, based primarily on customers’ past credit history and current financial conditions and general economic conditions, results of prior collection efforts, the relative strength of our relationship therewith and, in the event of a dispute, its legal position and the estimated cost of proposed collection proceedings. Management has not established a policy for when to charge off uncollectible accounts receivable or to use external collection agencies and makes such decisions on a case-by-case basis. The maximum losses that the Company would incur if a customer failed to pay would be limited to the carrying value of the receivable.

Revenue Recognition - In accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 606, "Revenue from Contracts with Customers", the Company recognizes revenue when obligations under the terms of a contract with the customer are satisfied. Generally, this occurs upon shipment of the CPAP to their customer or when the test is performed.

Property and Equipment - Property and equipment (Note 4) is stated at cost less accumulated depreciation. Depreciation and amortization are computed using the straight-line method over the estimated useful lives ranging from 2 to 12 years.

Leasehold Improvement - Leasehold improvement (Note 5) is stated at cost less accumulated amortization. Depreciation and amortization are computed using the straight-line method over the estimated useful lives ranging from 2 to 12 years. Leasehold improvements are amortized over the shorter of the lease term or the asset’s useful life.

Fair Value Measurements - The carrying amounts of cash, accounts receivable and accounts payable approximate their estimated fair value due to the short-term nature of these instruments. Since our other financial liabilities are not traded in an open market, we generally use a present value technique, which is a level 3 input, as defined in GAAP, to measure the estimated fair value of these financial instruments, except for valuing stock options and warrants (see below). The rate used for discounting expected cash flows is a risk-free rate adjusted for systematic and unsystematic risk.

The carrying amounts of long-term debt and estimated fair values of the attached warrants at June 30, 2020 and December 31, 2019 are as follows:

	June 30, 2020				December 31, 2019
			Estimated				Estimated
			Fair Value of				Fair Value of
	Carrying		Attached		Carrying		Attached
	Amount		Warrants		Amount		Warrants

Convertible promissory notes	$	5,956,533	$	—	$	7,564,173	$	—
Short term notes payable		3,215,803		—		4,788,016		—
Loan payable related party		102,229		—		342,670		—
PPP Loan		1,243,840		—		—		—
	$	10,518,405	$	—	$	12,694,859	$	—

During the six-month period ended June 30, 2020, there have been 10 additional convertible notes issued totaling $547,360. During the six-month period ended June 30, 2020, 53 convertible notes totaling $3,727,213 plus accrued interest was converted to stock.

Cost of Revenues - Costs of services consist of supplies and operating expenses. Supplies are recognized in the period in which a patient receives the supplies.

Right of Use Assets and Lease Liabilities - During the quarter ended March 31, 2019, the Company implemented Accounting Standards Update 2016-02, Leases. Under the new guidance, a lessee must record a liability for lease payments (referred to as the lease liability) and an asset for the right to use the leased asset during the lease term (referred to at the right of use asset) for all leases, regardless of whether they are designated as finance or operating leases. This election requires the lessee to recognize lease expense on a straight-line basis over the lease term. The right of use assets and corresponding right of use liabilities have been recorded using the present value of the leases. See Notes 10 and 11 within the financial statement for additional disclosure on leases.

Income Taxes - We are subject to the income tax jurisdictions of the U.S. and multiple state tax jurisdictions. However, our provisions for income taxes for 2020 and 2019 include only state income taxes.

Management has evaluated our tax positions taken or to be taken on income tax returns that remain subject to examination (i.e., tax years 2017 and thereafter federally), and has concluded that there have been no uncertain tax positions (as defined in GAAP) taken that require recognition or disclosure in the consolidated financial statements. In the event of any income tax-related interest or penalties are incurred, they would be included in general and administrative expense.

Concentration of Credit Risk - The Company maintains its cash and cash equivalents with a financial institution which management believes to be of high credit quality. Their accounts are insured by the Federal Deposit Insurance Corporation (FDIC) up to $250,000 in coverage. The Company had an uninsured cash balance of $595,340 as of June 30, 2020 and no uninsured cash balances as of December 31, 2019.

Stock Options and Warrants - We grant stock options and warrants to our employees, non-employee directors, note holders and certain consultants allowing them to purchase our common stock pursuant to approved terms. The estimated value of the warrants issued with debt instruments is recorded as a discount on notes payable and amortized as interest expense over the term of the notes using the effective interest method.

CURRENT ASSETS

Cash and Restricted Cash - On April 23, 2020, the Company’s wholly owned subsidiary, Pharmacy Value Management Solutions, Inc. (‘PVMS”) received a loan in the principal amount of $1,243,840 from Mechanics Bank (the “Bank”) pursuant to the Paycheck Protection Program “PPP”. On May 22, 2020, the Bank notified PVMS that the loan was in default as a result of false statements made in the loan application. PVMS disputes the Bank’s claim and believes that it made no false statements in it's PPP loan application. The statements relate to the number of employees and the monthly payroll amounts. As a result, PVMS’ account with Mechanics Bank has been frozen with a balance of $845,340. Both PVMS and the Bank are seeking guidance from the Small Business Administration as to how to resolve this dispute. Until resolved, it is likely that this account will remain frozen.

Cash and restricted cash consists of the following at June 30, 2020 and December 31, 2019:

	June 30, 2020		December 31, 2019

Cash	$	145,915	$	69,327
Restricted Cash		845,340		—

Total cash and restricted cash shown in the
consolidated statement of cash flows	$	991,255	$	69,327

Other current assets consists of the following at June 30, 2020 and December 31, 2019:

	June 30, 2020		December 31, 2019

Loans to others	$	34,406	$	42,676
Security and lease deposits		3,500		3,500
Capitalized portion of lease		1,237		1,808
Prepaid expenses		288,487		452,953
Miscellaneous receivable		329,395		325,660

Other current asset	$	657,025	$	826,597

PROPERTY AND EQUIPMENT

Property and equipment, net, consists of the following at June 30, 2020 and December 31, 2019:

	June 30, 2020			December 31, 2019

Property and equipment	$	6,616		$	1,549
Less accumulated depreciation		(933	)		(310	)
Property and equipment - net	$	5,683		$	1,239

Depreciation expense for the six-month periods ended June 30, 2020 and 2019 is $623 and $141, respectively. A laptop was acquired in January of 2020.

LEASEHOLD IMPROVEMENT

Leasehold improvement, net, consists of the following at June 30, 2020 and December 31, 2019:

	June 30, 2020			December 31, 2019

Leasehold improvements	$	2,992		$	2,992
Less accumulated amortization		(2,992	)		(2,992	)
Leasehold improvements - net	$	—		$	—

Amortization expense for the six-month periods ended June 30, 2020 and 2019 is $0 and $299, respectively.

RELATED PARTY LOANS PAYABLE

The Company has received financing from Management of the Company as well as from members of our Board of Directors. These individuals are deemed to be related parties to the Company and their indebtedness must be disclosed separately.

As of June 30, 2020 and December 31, 2019, there are the following related party notes payable:

	June 30, 2020		December 31, 2019

Related party loans payable	$	102,229	$	342,670

DEBT

As of June 30, 2020 and December 31, 2019, the balance was as follows:

	June 30, 2020		December 31, 2019

Notes payable	$	10,416,176	$	12,352,189

During the six-month period ended June 30, 2020, there have been 10 additional convertible-promissory notes totaling $547,360. There have been 53 convertible-promissory notes totaling $3,727,213 converted to 39,652,283 shares of common stock.

On April 23, 2020, the Company’s wholly owned subsidiary, Pharmacy Value Management Solutions, Inc. (‘PVMS”) received a loan in the principal amount of $1,243,840 from Mechanics Bank (the “Bank”) pursuant to the PPP. On May 22, 2020, the Bank notified PVMS that the loan was in default as a result of false statements made in the loan application. PVMS disputes the Bank’s claim and believes that it made no false statements in its PPP loan application. The statements relate to the number of employees and the monthly payroll amounts. As a result, PVMS’ account with Mechanics Bank has been frozen with a balance of $845,340. Both PVMS and the Bank are seeking guidance from the Small Business Administration as to how to resolve this dispute. Until resolved, it is likely that this account will remain frozen.

Break-out of debt between the parent company and our subsidiary PVMS is as follows:

	June 30, 2020		December 31, 2019

Advanzeon parent	$	3,381,163	$	5,010,016
PVMS		7,035,013		7,342,173
	$	10,416,176	$	12,352,189

At Advanzeon, the total notes issued year-to-date and their dollar values were as follows:

	June 30, 2020		December 31, 2019

Number of notes issued		2		—

Dollar value	$	165,360	$	—

All debts issued during the six-month period ended June 30, 2020 are short-term in nature and have a stated interest rate of 10%.

At PVMS, the total of notes issued year-to-date and their dollar values were as follows:

	June 30, 2020		December 31, 2019

Number of notes issued		8		51

Dollar value	$	382,000	$	2,289,250

All debt is short-term in nature, one-year maturity date. All debt issued has a stated interest rate of 12%.

CONTINGENT LIABILITY

Contingent liability consisted of 3 items:

A lawsuit against the Company for $450,000 from the son of a deceased promissory note holder. This matter has been dismissed twice by the judge but is ongoing due to appeals. The case has been dormant over a year. The Court has not dismissed it for lack of prosecution yet. The Court does this on its own motion and because of COVID, it is not doing this at this time.

Interest payable in the amount of $171,247 to the same person listed in (1). This interest is related to the lawsuit referenced in (1).

Advanzeon won a decision on a court case against Universal Healthcare. The attorney's fees relating to this matter total $21,412. This fee will be paid out of the proceeds of the case when collected.

As of June 30, 2020 and December 31, 2019, the balance of this indebtedness is as follows:

	June 30, 2020		December 31, 2019

Disputed note payable	$	450,000	$	450,000
Disputed interest payable		171,247		171,247
Pending attorney fees		21,412		21,412

Total contingent liability	$	642,659	$	642,659

OTHER ACCRUED LIABILITIES

As of June 30, 2020 and December 31, 2019, the balance of other accrued liabilities is as follows:

	June 30, 2020		December 31, 2019

Management compensation	$	8,907,258	$	8,873,802
Accrued interest non-related party		4,760,728		5,956,368
Board of Director fees		37,500		1,050,000
State fees		—		2,800
Payroll liabilities		14,047		—
Other accrued liabilities		22,659		8,817
Total other accrued debt	$	13,742,192	$	15,891,787

10.

RIGHT OF USE ASSETS

The Company entered into two leases, one for office space and one for an automobile lease that are classified as right of use assets and lease liabilities. The Company pays the lease payments on a residential unit in California that is used as an office/residential unit for certain of its marketing personnel. The lease is on a month-to month basis. The Company has occupied this unit for the past approximately 1-1/2 year period and intends to do so for the foreseeable future. The lease for the Company’s office space expire in June 2022.The lease for the automobile expires in June 2021.As the implicit interest rate is not readily identifiable in the leases, the Company calculated the present value of the leases using the average commercial real estate interest rate of 5.50% at the commencement of the office leases and the interest of 2.99% for the automobile lease. Applying the commercial rate, the Company calculated the present value of $339,833 for the office leases and $29,037 for the automobile leasing that are being amortized over the life of the leases.

As of June 30, 2020, the right of use assets associated with future operating leases are as follows:

Total present value of right of use assets
under lease agreements	$	368,870

Amortization of right of use assets		(53,419	)

Total right of use assets as of June 30, 2020	$	315,451

Total amortization expense related to the right of use assets under the lease agreements was $54,660 and $25,579 for the six-month periods ended June 30, 2020 and 2019, respectively.

11.

RIGHT OF USE LEASE LIABILITIES

As disclosed in Note 10, the Company entered into two leases for office space prior to the quarter ended June 30, 2020 that are classified as right of use assets and lease liabilities.

As of June 30, 2020, the lease liabilities associated with future payments due under the leases are as follows:

Total present value of future lease payments	$	368,870

Principal payments made as of the six month period ended June 30, 2020		(53,419	)

Total right of use lease liabilities as of June 30, 2020	$	315,451

The following is a schedule of future minimum lease payments under the right of use lease agreements together with the present value of the net minimum lease payments as of June 30, 2020:

Total future minimum lease payments	$	336,671

Less present value discount		21,220

Total right of use lease liabilities as of June 30, 2020		315,451

Less current portion due within one year		136,230

Long-term right of use liabilities	$	179,221

Total maturities of lease liabilities as of June 30, 2020 are as follows:

	Total future
	minimum lease		Present value		Right of use
	payments		discount		lease liabilities
2021	$	150,103	$	13,873	$	136,230
2022		146,568		6,358		140,210
2023		40,000		989		39,011
	$	336,671	$	21,220	$	315,451

12.

COMMON STOCK

During the six-month period ended June 30, 2020, the Company issued 45,089,783 shares of its common stock as follows:

On April 01, 2020, the Company issued 3,262,500 shares of its common stock to a board of director member who elected to convert director’s fees and salary totaling $652,500. The stock was issued at $0.20 per share.

On April 01, 2020, the Company issued 1,087,500 shares of its common stock to a board of director member who elected to convert director’s fees and salary totaling $217,500. The stock was issued at $0.20 per share.

On April 21, 2020, the Company issued 14,584,350 shares of its common stock to existing note holders who elected to convert promissory notes plus accrued and unpaid interest totaling $2,916,869. The stock was issued at $0.20 per share.

On April 21, 2020, the Company issued 1,327,252 shares of its common stock to an existing note holder who elected to convert promissory notes plus accrued and unpaid interest totaling $265,450. The stock was issued at $0.20 per share.

On April 21, 2020, the Company issued 2,156,515 shares of its common stock to an existing note holder who elected to convert promissory notes plus accrued and unpaid interest totaling $431,303. The stock was issued at $0.20 per share.

On May 15, 2020, the Company issued 1,263,745 shares of its common stock to an existing note holder who elected to convert promissory notes plus accrued and unpaid interest totaling $139,012. The stock was issued at $0.11 per share.

On May 15, 2020, the Company issued 4,284,565 shares of its common stock to an existing note holder who elected to convert promissory notes plus accrued and unpaid interest totaling $471,302. The stock was issued at $0.11 per share.

On May 15, 2020, the Company issued 7,210,168 shares of its common stock to an existing note holder who elected to convert promissory notes plus accrued and unpaid interest totaling $793,118. The stock was issued at $0.11 per share.

On May 18, 2020, the Company issued 700,751 shares of its common stock to an existing note holder who elected to convert promissory notes plus accrued and unpaid interest totaling $77,083. The stock was issued at $0.11 per share.

On May 21, 2020, the Company issued 502,434 shares of its common stock to an existing note holder who elected to convert promissory notes plus accrued and unpaid interest totaling $55,268. The stock was issued at $0.11 per share.

On May 25, 2020, the Company issued 319,627 shares of its common stock to an existing note holder who elected to convert promissory notes plus accrued and unpaid interest totaling $35,159. The stock was issued at $0.11 per share.

On May 25, 2020, the Company issued 333,824 shares of its common stock to an existing note holder who elected to convert promissory notes plus accrued and unpaid interest totaling $36,721. The stock was issued at $0.11 per share.

On May 26, 2020, the Company issued 781,206 shares of its common stock to an existing note holder who elected to convert promissory notes plus accrued and unpaid interest totaling $85,933. The stock was issued at $0.11 per share.

On May 28, 2020, the Company issued 884,555 shares of its common stock to an existing note holder who elected to convert promissory notes plus accrued and unpaid interest totaling $97,301. The stock was issued at $0.11 per share.

On May 29, 2020, the Company issued 937,116 shares of its common stock to an existing note holder who elected to convert promissory notes plus accrued and unpaid interest totaling $103,083. The stock was issued at $0.11 per share.

On June 1, 2020, the Company issued 1,024,189 shares of its common stock to an existing note holder who elected to convert promissory notes plus accrued and unpaid interest totaling $112,661. The stocks was issued at $0.11 per share.

On June 05, 2020, the Company issued 668,797 shares of its common stock to an existing note holder who elected to convert promissory notes plus accrued and unpaid interest totaling $73,568. The stock was issued at $0.11 per share.

On June 05, 2020, the Company issued 603,987 shares of its common stock to an existing note holder who elected to convert promissory notes plus accrued and unpaid interest totaling $66,439. The stock was issued at $0.11 per share.

On June 12, 2020, the Company issued 1,564,245 shares of its common stock to an existing note holder who elected to convert promissory notes plus accrued and unpaid interest totaling $172,067. The stock was issued at $0.11 per share.

On June 18, 2020, the Company issued 504,957 shares of its common stock to an existing note holder who elected to convert promissory notes plus accrued and unpaid interest totaling $55,545. The stock was issued at $0.11 per share.

During the six-month period ended June 30, 2019, the Company issued 700,000 shares of its common stock as follows:

On March 21, 2019, the Company issued 200,000 shares of its common stock to its Securities Exchange Commission counsel, who elected to take common stock in the Company as partial payment of its legal fees. The total value shares were valued at $0.08 per share on the total value of $16,000.

Additionally, on March 29, 2019, the Company issued 500,000 shares of its common stock to an existing shareholder and warrant holder, who elected to exercise his warrants to purchase 500,000 shares of the Company's common stock for $15,000. The warrants were issued during May of 2017 for $0.03 per share.

13.

LEGAL PROCEEDINGS

The Company previously reported that the litigation between Rotech Healthcare, Inc. and Pharmacy Value Management Solutions, Inc. settled. The Company rejected the draft settlement terms and continues to aggressively defend this litigation.

Except as disclosed above and in Item 1, all of the legal proceedings for the six-month period ended June 30, 2020, are disclosed in our annual report on Form10-K filed on April 9, 2020.

14.

SUBSEQUENT EVENTS

In accordance with ASC Topic 855, “Subsequent Events”, the Company evaluated subsequent events through August 19, 2020, the date these financial statements were available to be issued. During its evaluation, the following subsequent events were identified:

Issuance of debt and warrants

Subsequent to the balance sheet date, the Company has issued $56,180 of convertible-promissory notes. All of the debt matures in 2021 and has a stated interest rate of 22% and is unsecured. Concurrent with the issuance of debt, the Company has issued 300,000 warrants at an average exercise price of $0.25. At the time of issuance, all warrants had a three or five year term.

Stock issued for conversion of debt and accrued interest

The Company issued 765,399 shares of common stock for the conversion of debt and accrued interest. The total debt and accrued interest converted was $84,194 or $0.11 per share.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

General

The following information should be read in conjunction with the financial statements and notes thereto and in conjunction with Managements’ Discussion and Analysis of Financial Condition and Results of Operations in our Annual Report on Form 10-K for the fiscal year ended December 31, 2019.

This report includes forward-looking statements, the realization of which may be affected by certain important factors discussed previously above under Item 1A, “Risk Factors.”

Overview

The Company through its wholly owned subsidiary Pharmacy Value Management Solutions, Inc. administers and operates a medically driven sleep apnea program branded SleepMaster Solutions™ (“SMS”). Management believes that SMS is the largest provider of these combined services in the nation. We are in all 50 states and provide a turnkey solution designed to effectively keep drivers on the road with no down time, compliant with DOT regulations, improve their health, and significantly decrease legal liability risk for the employer. We are vertically integrated, and we provide a “Program” of services that addresses all the needs of a corporate transportation system, union or other driver-related organizations. We believe we are the only company capable of providing the full range of needed services in a timely manner.

Our services start with the identification of the target population and the potential risk the client currently has. We can do this through our SMS Program, which includes the ability to screen every driver to identify if signs and symptoms of sleep apnea are present. We can then take this data and provide the employer with a list of those drivers that should be tested and the statistical likelihood of the percentage of those drivers who will test positive for obstructive sleep apnea (OSA). Together with the employer/union, SMS provides a realistic time frame, actual total cost, and process for testing all drivers who need to be tested. For those drivers testing positive for OSA, we then provide the appropriate treatment such that the driver will meet the DOT requirements and remain on the road. We monitor 365 days per year driver’s usage of the treatment device according to DOT standards and we report that usage to all stakeholders as required/permitted. We utilize mathematical algorithms to determine if the driver is predicatively meeting the annual DOT requirements for usage. Using those predictive algorithms, we reach out to those drivers and provide case management, encouragement designed to solve problems such that the driver increases usage, if necessary, and remains compliant.

SMS constructed its model based upon the foregoing principles. The SMS Program includes all processes attended in sleep apnea screening, testing, treatment, monitoring and overall management of commercial drivers’ as well as their employers’ needs. We have successfully established relationships with national health care clinic providers, all with certified medical examiner (“CME”) status. These clinics total almost 1,000 throughout the U.S. We also have both formal and informal relationships with employers; municipalities; a significant veteran’s group; union and non-union driving organizations; suppliers of home sleep testing equipment and a variety of OSA treatment devices; and, a national network of telemedicine sleep specialists covering all 50 states. We have an internal medical team for governance and protocol purposes and a customer service department that interfaces directly with our drivers. We also have a marketing team that regularly interfaces with our existing accounts and markets our services to potential new accounts. Our services are performed utilizing a best medical practices model and an efficient, cost-effective delivery system. We obtain the required equipment on a per order basis from a durable medical equipment distributor.

Revenue is recognized when billed, which is approximately when the testing service is performed, or CPAP machine is shipped.

During the three-month period ending June 30, 2020, the majority of our revenue was received from patient referrals from only certain of the clinics operated by Concentra Health Services. During this period and as a result of the Coronavirus pandemic, the Department of Transportation (DOT), which had previously suspended the requirement that interstate commercial drivers have a prescribed DOT medical exam from a DOT certified medical examiner, extended the DOT medical exam suspension to expire September 30, 2020. This action by the DOT, coupled with the effect of the pandemic, caused a significant number of clinics that we rely upon for referrals to either continue to be closed, close anew or operate with reduced staffing and reduced capacity. All of the foregoing resulted in fewer patients. Additionally, many commercial drivers, who, but for the aforesaid medical exam suspension, would have gone to the Concentra clinics for their required DOT medical exam, elected to wait until the suspension expires. All of those events materially reduced our referral resources. We did continue to receive revenue from certain Concentra referrals, other clinic referrals and some of our in-house account, such as PG&E, the Veteran’s organization with whom we contract, and others, but this patient flow was materially reduced, as well. Our recently announced launch of our CoreChoice account (April 29, 2020), scheduled to launch this period, did not launch as a result of the pandemic. During this period, we successfully added new accounts which, principally due to the pandemic, have not yet launched. However, they are in the process of preparing to do so. As clinics reopen and staff returns, management expects to see revenue from these new accounts. We continue to experience the effect of these closures/reduced staffing and cannot predict when either our referral sources or our own operation will begin to normalize, resulting in more positive financial results. However, we continue to aggressively seek new accounts and work with our existing accounts to achieve increased patient flow.

Sources of Revenue

Three-month periods ended June 30, 2020 and 2019

A quantitative summary of our revenues by source category for the three-month periods ended June 30, 2020 and 2019:

		2020		2019		Change

OSA- related	$	103,444	$	90,453	$	12,991

Results of Operations

OSA services increased to $103,444 in 2020 from $90,453 in 2019. The increase was primarily the result of the Concentra account. Last year, on May 14, 2019, we reached an agreement with Concentra whereby Concentra engaged the Company, and the Company accepted the engagement, to serve as one of Concentra’s preferred national sleep apnea services provider. The launch was initiated during the fourth quarter of 2019.

While there was an increase in OSA services, the increase would have been greater without the clinics having to shut down due to the COVID-19 pandemic. As demonstrated in the first quarter of 2020, OSA services increased by $59,625 than in the comparable period of 2019. With the clinics having to be closed during the three months period ended June 30, 2020 due to the COVID-19 pandemic, there was only an increase of $12,990.

Cost of revenues decreased to $65,000 in 2020 from $66,157 in 2019. In 2019, the cost allocation was changed to reflect the cost and sales in the same month. This caused two months’ worth of charges in the month of April 2019. April 1, 2019 and April 30, 2019

General and administrative expense

General and administrative expense in total for the three month periods ended June 30, 2020 and 2019 was as follows:

2020	$	715,397
2019		416,039
Change	$	299,358
Percentage Change		71.95	%

We evaluate expenses at the Parent company level as well as at our PVMS subsidiary. Expenses at the Parent company level include overhead and the cost of being a public entity. Expenses at PVMS are solely related to the OSA services segment. A breakdown of these expenses for the three month periods ended June 30, 2020 and 2019 is as follows:

	2020		2019		Change		Percent Change

Parent	$	296,036	$	156,686	$	139,350		88.94	%
PVMS		419,361		259,353		160,008		61.70	%

Total	$	715,397	$	416,039	$	299,358		71.95	%

Parent Company Level

	2020			2019		Change			Percent Change

Professional fees	$	243,494		$	86,804	$	156,690			180.51	%
Travel expense		—			815		(815	)		-100.00	%
Board of Directors fees		57,500			37,500		20,000			53.33	%
Office supplies		417			287		130			45.30	%
Rent expense		(23,181	)		25,448		(48,629	)		-191.09	%
Other		17,806			5,832		11,974			205.33	%

Total G & A	$	296,036		$	156,686	$	139,350			88.94	%

Explanations of variations by line item follow:

Professional fees increased by $156,690. The increase is mainly due to new consulting service expenses in the total of $118,250 and an increase of $43,827 in legal fees in the three-month period ended June 30, 2020 compared to the three month period ended June 30, 2019.

Travel expense decreased by $815 due to due to the COVID-19 pandemic. Many clinics have been closed and those that are open have reduced staffs and we have been requested to not conduct any in person visits.

Board of Directors fees increased by $20,000 due to an additional $20,000 paid to a Board of director member.

Rent expense decreased by 48,629 due to office lease moving to subsidiary level as of January 01, 2020. The same will show as an increase on the subsidiary level.

Other general and administrative expense increased by $11,974. This increase was due to a new D&O Insurance expense of $14,205 while other miscellaneous items decreased by $1,421.

PVMS Subsidiary Level

	2020		2019		Change			Percent Change

Payroll related	$	243,871	$	110,167	$	133,704			121.36	%
Travel and related expense		9,059		51,897		(42,838	)		-82.54	%
Professional fees		57,265		39,250		18,015			45.90	%
Marketing costs		17,758		9,729		8,029			82.53	%
Dues and subscriptions		27		200		(173	)		-86.50	%
Office supplies		1,135		8,718		(7,583	)		-86.98	%
Rent expense		54,096		12,452		41,644			334.44	%
Other		36,150		26,940		9,210			34.19	%

Total G & A	$	419,361	$	259,353	$	160,008			61.70	%

Explanations of variations by line item follow:

Payroll related expenses increased $133,704. The company hired 4 employees in the three months ended June 30, 2020 that were not included in the comparable period in 2019. The Company paid our CEO $32,699 and accrued wages in the amount of $33,456 during the three months ended June 30, 2020.

Travel expense decreased by $42,838 due to due to the COVID-19 pandemic. Many clinics have been closed and those that are open have reduced staffs and we have been requested to not conduct any in person visits.

Professional Fees increased by $18,015. The increase is mainly due to an increase in accounting fees by $25,000 due to services for special projects. There was a decrease in legal fees by $13,485. The Company no longer used a law firm in the three months ended June 30, 2020 that were used in the comparable period in 2019.

Marketing costs increased by $8,029. The company hired an advertising firm in the 3rd quarter of 2019 to work on the company's website and other marketing responsibilities and is still with the company as of June 30, 2020.

Office supplies decreased by $7,583 due to office supplies were fully stocked going into the new year of 2020.

Rent expense increased by $41,644 due a decrease on to rent expense moving from parent level to subsidiary level as of January 01, 2020. The same will show as a decrease on the parent level.

Other general and administrative expense increased by $9,210. The increase is mainly due to a fraudulent charge of $9,500 and an increase in payroll taxes of $13,371 due to an increase in wages. There is a decrease in automobile expenses of $4,912 due to the COVID-19 pandemic.

Interest expense

Interest expense in total for the three-month periods ended June 30, 2020 and 2019 was as follows:

2020	$	707,774
2019		341,178
Change	$	366,596
Percentage Change		107.45	%

A breakdown of the interest expense for the three-month periods ended June 30, 2020 and 2019 is as follows:

	2020		2019		Change

Parent	$	492,340	$	163,093	$	329,247
PVMS		215,434		178,085		37,349

Total	$	707,774	$	341,178	$	366,596

Sources of Revenue

Six-month periods ended June 30, 2020 and 2019

A quantitative summary of our revenues by source category for the six-month periods ended June 30, 2020 and 2019:

		2020		2019		Change

OSA- related	$	230,992	$	158,376	$	72,616

Results of Operations

OSA services increased to $230,992 in 2020 from $158,376 in 2019. The increase was primarily the result of the Concentra account. Last year, on May 14, 2019, we reached an agreement with Concentra whereby Concentra engaged the Company, and the Company accepted the engagement, to serve as one of Concentra’s preferred national sleep apnea services provider. The launch was initiated during the fourth quarter of 2019.

Cost of revenues increased to $129,909 in 2020 from $107,817 in 2019 due to an increase in sales.

General and administrative expense

General and administrative expense in total for the six-month periods ended June 30, 2020 and 2019 was as follows:

2020	$	1,311,462
2019		841,843
Change	$	469,619
Percentage Change		55.78	%

	2020		2019		Change		Percent Change

Parent	$	539,259	$	352,821	$	186,438		52.84	%
PVMS		772,203		489,022		283,181		57.91	%

Total	$	1,311,462	$	841,843	$	469,619		55.78	%

Parent Company Level

								Percent
	2020		2019		Change			Change

Professional fees	$	409,870	$	211,265	$	198,605			94.01	%
Travel expense		67		3,815		(3,748	)		-98.24	%
Board of Directors fees		95,000		75,000		20,000			26.67	%
Office supplies		495		351		144			41.03	%
Rent expense		—		51,277		(51,277	)		-100.00	%
Other		33,827		11,113		22,714			204.40	%

Total general and administrative	$	539,259	$	352,821	$	186,438			52.84	%

Explanations of variations by line item follow:

Professional fees increased $198,605. The increase is mainly due to new consulting service expenses in the total of $236,500 and an increase of $55,023 in legal fees in the six-month period ended June 30, 2020 compared to the six-month period ended June 30, 2019. Audit fees decreased by $66,300 and accounting fees decreased by $22,957 due to the fact that the 2015 - 2017 10-K was filed in January 2019.

Travel expense decreased $3,748 due to due to the COVID-19 pandemic. Many clinics have been closed and those that are open have reduced staffs and we have been requested to not conduct any in person visits.

Board of Directors fees increased $20,000 due to an additional $20,000 paid to a Board of director member.

Rent expense decreased $51,277 due to rent expense moving from parent level to subsidiary level as of January 01, 2020. The same will show as an increase on the subsidiary level.

Other general and administrative expense increased by $22,714. This increase was due to a new D&O Insurance expense of $26,174 while other miscellaneous items decreased $3,463.

PVMS Subsidiary Level

								Percent
	2020		2019		Change			Change

Payroll related	$	419,743	$	212,312	$	207,431			97.70	%
Travel and related expense		75,224		91,324		(16,100	)		-17.63	%
Professional fees		109,057		81,747		27,310			33.41	%
Marketing costs		34,592		17,229		17,363			100.78	%
Dues and subscriptions		208		640		(432	)		-67.50	%
Office supplies		4,077		17,577		(13,500	)		-76.80	%
Rent expense		65,933		23,001		42,932			186.65	%
Other		63,369		45,192		18,177			40.22	%

Total general and administrative	$	772,203	$	489,022	$	283,181			57.91	%

Explanations of variations by line item follow:

Payroll related expenses increased $207,431. The Company hired 4 employees during the six months ended June 30, 2020 that were not included in the comparable period in 2019. The Company paid our CEO $32,699 and accrued wages in the amount of $33,456 during the six months ended June 30, 2020.

Travel expense decreased $16,100 due to the COVID-19 pandemic. Many clinics have been closed and those that are open have reduced staffs and we have been requested to not conduct any in person visits.

Professional Fees increased $27,310. There is an increase in accounting fees by $25,000 due to services for special projects. Consulting fees increased $33,750 because the company hired 5 new consultants to bring in additional revenue. There was a decrease in legal fees by $23,657. The Company no longer used a law firm in the six months ended June 30, 2020 that was used in the comparable period in 2019.

Marketing costs increased by $17,363. The company hired an advertising firm in the 3rd quarter of 2019 to work on the company's website and other marketing responsibilities and is still with the company as of June 30, 2020.

Office supplies decreased by $13,500 due to office supplies were fully stocked going into the new year of 2020.

Rent expense increased $42,932 due to rent expense moving from parent level to subsidiary level as of January 01, 2020. The same will show as a decrease on the parent level.

Other general and administrative expense increased by $18,180 due to a fraudulent charge of $9,500 and an increase in payroll taxes of $10,764 because of an increase in wages. Other miscellaneous items increased by $6,876 due to revamp of website, employee benefits, and printing and postage for a conference. Automobile expenses decreased $3,078 due to the COVID-19 pandemic. Bad debt expense decreased $3,510 due to a decrease in bad debt in the six months ended June 30, 2020 than in the comparable period in 2019.

Interest expense

Interest expense in total for the six-month periods ended June 30, 2020 and 2019 was as follows:

2020	$	1,102,403
2019		669,193
Change	$	433,210
Percentage Change		64.74	%

A breakdown of the interest expense for the six-month periods ended June 30, 2020 and 2019 is as follows:

	2020		2019		Change

Parent	$	636,453	$	326,185	$	310,268
PVMS		465,950		343,008		122,942

Total	$	1,102,403	$	669,193	$	433,210

Financial Condition

Liquidity and Capital Resources

During the six-month period ended June 30, 2020, we funded our operations from revenues and $547,360 in private borrowings. As a result of the coronavirus pandemic some of our traditional sources of private borrowing have not been accessible. We have had to obtain private borrowing on terms less favorable than we were able to prior to the pandemic. We will continue to fund our operations from these sources until we are able to produce operating revenue sufficient to cover our cost structure. In the event we are not able to secure such funding, our operations will be adversely affected.

Short Term: We funded our operations with revenues from sales and private borrowings.

On April 23, 2020, the Company’s wholly owned subsidiary, Pharmacy Value Management Solutions, Inc. (‘PVMS”) received a loan in the principal amount of $1,243,840 from Mechanics Bank (the “Bank”) pursuant to the Paycheck Protection Program. On May 22, 2020, the Bank notified PVMS that the loan was in default as a result of false statements made in the loan application. PVMS disputes the Bank’s claim and believes that it made no false statements in its PPP loan application. The statements relate to the number of employees and the monthly payroll amounts. As a result, PVMS’ account with Mechanics Bank has been frozen with a balance of $845,340. Both PVMS and the Bank are seeking guidance from the Small Business Administration as to how to resolve this dispute. Until resolved, it is likely that this account will remain frozen.

During the period we continued toward our goal to be able to uplist our Common Stock to another trading platform. Among the actions is our attempt to reduce our stockholder’s deficiency by, among, other things, being able to convert a large portion of our corporate debt to equity. For the six months ended June 30, 2020, $3,727,213 of debt plus accrued interest was converted into 39,652,283 shares of Common Stock. All of the holders of the converted debt agreed, subject to several different conditions, to a one year lock-up from publicly offering the shares. The primary condition being to not publicly sell the shares until the earlier of (i) one year from the date of the exchange, or (ii) until the shares are tradable on the NASDAQ or comparable national exchange. The other condition for a block of 14,584,350 shares received in an exchange has the lock-up as the earlier of one year or such time as our Common Stock has an average trading volume of no less than 500,000 shares for 30 consecutive trading days.

Subsequent Events

Subsequent to June 30, 2020, we issued a convertible promissory note in the principal amount of $56,180. The term of the note is 12 months and the interest rate is 10% per annum.

In August we announced that we will start using a disposable home sleep test device known as the WatchPAT™ ONE which utilizes cloud-based technology for the immediate upload of testing data. This feature will streamline the Company's receipt of test data and its ability to render faster obstructive sleep apnea (“OSA”) test results - critical, in light of the increased OSA testing reasonably to be anticipated when DOT-required medical exams resume. With the WatchPAT™ ONE, we can measure the patient's PAT® signal, heart rate, oximetry, actigraphy, body position, snoring, and chest motion. As discussed, in March of this year, the Federal Motor Carrier Safety Association (FMCSA) suspended the commercial driver's required annual/biennial medical exams. This suspension was a reaction to the COVID-19 pandemic, and the nation's need to keep its commercial drivers on the road delivering essential supplies. The suspension is currently scheduled to expire on September 30, 2020. We anticipate that almost seven months of drivers will need to schedule and complete their required medical exams shortly after September 30th. Thus, whenever the suspension is lifted, it is anticipated that there will be an increased number of drivers all needing completion of their medical exams including OSA testing (when indicated).. These drivers would be in addition to our new patient accounts acquired during the past four-month period. With our implementation of this new technology, we expect to not only be more efficient in our testing process, but to greatly enable our clinic partners to process the OSA portion of their drivers' DOT medical exams faster and more efficiently. While there is an additional cost to the Company for the WatchPAT™ ONE process, we have elected to not pass this cost on to the clinic, the driver or the driver's employer.

Item 3. Quantitative and Qualitative Disclosures about Market Risk:

As a smaller reporting company, we are not required to make any disclosure.

Item 4. Controls and Procedures

Our management is responsible for establishing and maintaining adequate internal control over our financial reporting. Internal control over financial reporting is a process designed to provide reasonable assurance to our management and board of directors regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with U.S. generally accepted accounting principles.

Our internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that in reasonable detail accurately and fairly reflect our transactions; (ii) provide reasonable assurance that transactions are recorded as necessary for preparation of our financial statements; (iii) provide reasonable assurance that receipts and expenditures of company assets are made in accordance with management authorization; and (iv) provide reasonable assurance that unauthorized acquisition, use or disposition of company assets that could have a material effect on our financial statements would be prevented or detected on a timely basis.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because changes in conditions may occur or the degree of compliance with the policies or procedures may deteriorate.

Our management assessed the effectiveness of our internal control over financial reporting as of June 30, 2020. This evaluation was based on criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission, or COSO, Internal Control-Integrated Framework. Based upon such assessment, our CFO concluded that, as of June 30, 2020, our internal controls over financial reporting were not optimally effective in the specific areas described in the paragraphs below.

As of June 30, 2020, our CFO identified the following specific material weaknesses in the Company’s internal controls over its financial reporting processes:

•

Policies and Procedures for the Financial Close and Reporting Process – During the period of this report, the Company’s policies or procedures did not clearly define the roles in the financial reporting process. The various roles and responsibilities related to this process should be defined, documented, updated and communicated. Not having clear policies and procedures in place amounts to a material weakness in the Company’s internal controls over its financial reporting processes.

•

Representative with Financial Expertise – For six-month period ended June 30, 2020, the Company did not continuously have an employee with the requisite knowledge and expertise to review the financial statements and disclosures at a sufficient level to monitor the financial statements and disclosures to the Company. Failure to have, continuously, an employee with such knowledge and expertise amounts to a material weakness to the Company’s internal controls over its financial reporting processes.

As a result of our retaining the services of an Outside Accountant in January 2018 and appointing an internal Company employee to interface with the Outside Accountant, we have instituted the following policies and procedures designed to address the material weaknesses cited above.

•

All billing invoices prepared by the billing department are sent to the Outside Accountant for review and approval before sending out to the customer.

•

Copies of all incoming payable invoices are sent to the Outside Accountant for review, approval and data entry into the accounting system. That way Corporate Office has the originals and the outside accountants have duplicate copies. Accounts Payable Aging Report is sent once a week from the Outside Accountants to the Corporate office. The Corporate office, along with Outside Accountants, decide on which bills to pay weekly. Electronic payments have a duel control approval system (one person is initiating the payment and another person is approving the payment).

•

Paperwork on all customer invoices, credit card payments and check payments received at Corporate are copied and forwarded to Outside Accountants. Customer invoices are recorded daily. Customer payments received are recorded daily. Customer payments are reconciled with the bank on a daily basis. Aged Accounts Receivable Reports are sent to Corporate by the Outside Accountants with suggestions on a regular basis.

•

All bank accounts are reconciled monthly.

•

Financial Statements are prepared and reviewed monthly.

The Company plans to further augment its addressing of material weaknesses, on an as-needed basis, by hiring additional accounting personnel once its initial corrective steps have been fully implemented, tested and found to be effective.

PART II-OTHER INFORMATION

Item 1. Legal Proceedings

With the exception of the matter set forth below, all of the legal proceedings for the six-month period ended June 30, 2020, are disclosed in our annual report on Form 10-K filed on April 9, 2020.

Item 1A. Risk Factors

In addition to the risk factors included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2019, we include the following:

Effect of the Coronavirus Pandemic

The coronavirus pandemic is adversely affecting and is expected to continue to adversely affect our business, financial condition and results of operations. We are unable to predict the extent or nature these effects will have on our business at this time.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

With the exception of the matter set forth below, the sale of unregistered securities for the six-month period ended June 30, 2020 were disclosed in our annual report on Form 10-K filed on April 9, 2020.

On April 15, 2020, we issued a convertible promissory note (the "Note”) in the principle amount of $109,180 with an original issue discount of $6,180. The Note matures on October 15, 2021, and the interest rate is 10%. This Note may not be prepaid in whole or in part except as follows. Should the Note be prepaid within the first ninety days from the date of issuance, the prepayment percentage is one hundred and twenty-five (125%) per cent of the outstanding principal and any accrued and unpaid interest. For the next ninety days the Note may be prepaid and the prepayment percentage is one hundred thirty (130%) per cent of the outstanding principal and any accrued and unpaid interest. Thereafter, the Note may not be prepaid.

On April 21, 2020, we issued a total of 14,584,350 shares of our common stock in exchange for $2,916,869 of our Senior Debt and accrued interest to seven holders of the Debt. We relied on Section 3(a) (9) of the Securities Act of 1933, as amended.

On April 21, 2020, we issued a total of 1,327,252 shares of our common stock in exchange for $265,450 of our convertible debt and accrued interest to the holder of the debt. We relied on Section 3(a) (9) of the Securities Act of 1933, as amended.

On April 21, 2020, we issued a total of 2,156,515 shares of our common stock in exchange for $431,303 of our convertible debt and accrued interest to the holder of the debt. We relied on Section 3(a) (9) of the Securities Act of 1933, as amended.

On May 13, 2020, we issued a convertible promissory note in the principle amount of $50,000 to an accredited investor. The interest rate was 12%. The Holder of the note has the right to convert all or a portion of the principle and any accrued interest into shares of our common stock at a per share price equal to the lesser of (i) 15% below the average daily closing price of our common stock for the immediately preceding twenty (20) business days or (ii) $0.11. The principal amount and any accrued but unpaid interest under the note shall be due and payable on the earliest to occur (i) the date which is twelve months from the effective date of the note or (ii) the receipt by the Company of payment on its account receivable owed to it by Universal Health Care, Inc. and Universal Health Care Insurance Company, which accounts receivable is currently being processed in the matter of The Receivership of Universal Health Care, Inc., a Florida corporation and The Receivership of Universal Health Care Insurance Company, Inc., a Florida corporation under case numbers 2013-CA and 2013-CA, respectively. The Company also granted to the purchaser a five-year warrant to purchase 100,000 shares of the Company’s common stock at an exercise price of $0.15 per share.

On May 15, 2020, we issued a total 1,263,745 shares of our common stock in exchange for $139,012 of our convertible debt and accrued interest to the holder of the debt. We relied on Section 3(a) (9) of the Securities Act of 1933, as amended.

On May 15, 2020, we issued a total 4,284,565 shares of our common stock in exchange for $471,302 of our convertible debt and accrued interest to the holder of the debt. We relied on Section 3(a) (9) of the Securities Act of 1933, as amended.

On May 15, 2020, we issued a total 7,210,168 shares of our common stock in exchange for $793,118 of our convertible debt and accrued interest to the holder of the debt. We relied on Section 3(a) (9) of the Securities Act of 1933, as amended.

On May 18, 2020, we issued a total 700,751 shares of our common stock in exchange for $77,083 of our convertible debt and accrued interest to the holder of the debt. We relied on Section 3(a) (9) of the Securities Act of 1933, as amended.

On May 21, 2020, we issued a total 502,434 shares of our common stock in exchange for $55,268 of our convertible debt and accrued interest to the holder of the debt. We relied on Section 3(a) (9) of the Securities Act of 1933, as amended.

On May 22, 2020, we issued a convertible promissory note in the principle amount of $25,000 to an accredited investor. The interest rate was 12%. The Holder of the note has the right to convert all or a portion of the principle and any accrued interest into shares of our common stock at a per share price equal to the lesser of (i) 15% below the average daily closing price of our common stock for the immediately preceding twenty (20) business days or (ii) $0.11. The principal amount and any accrued but unpaid interest under the note shall be due and payable on the earliest to occur (i) the date which is twelve months from the effective date of the note or (ii) the receipt by the Company of payment on its account receivable owed to it by Universal Health Care, Inc. and Universal Health Care Insurance Company, which accounts receivable is currently being processed in the matter of The Receivership of Universal Health Care, Inc., a Florida corporation and The Receivership of Universal Health Care Insurance Company, Inc., a Florida corporation under case numbers 2013-CA and 2013-CA, respectively. The Company also granted to the purchaser a five-year warrant to purchase 50,000 shares of the Company’s common stock at an exercise price of $0.15 per share.

On May 25, 2020, we issued a total 319,627 shares of our common stock in exchange for $35,159 of our convertible debt and accrued interest to the holder of the debt. We relied on Section 3(a) (9) of the Securities Act of 1933, as amended.

On May 25, 2020, we issued a total 333,824 shares of our common stock in exchange for $36,721 of our convertible debt and accrued interest to the holder of the debt. We relied on Section 3(a) (9) of the Securities Act of 1933, as amended.

On May 26, 2020, we issued a convertible promissory note in the principle amount of $100,000 to an accredited investor. The interest rate was 12%. The Holder of the note has the right to convert all or a portion of the principle and any accrued interest into shares of our common stock at a per share price equal to the lesser of (i) 15% below the average daily closing price of our common stock for the immediately preceding twenty (20) business days or (ii) $0.11. The principal amount and any accrued but unpaid interest under the note shall be due and payable on the earliest to occur (i) the date which is twelve months from the effective date of the note or (ii) the receipt by the Company of payment on its account receivable owed to it by Universal Health Care, Inc. and Universal Health Care Insurance Company, which accounts receivable is currently being processed in the matter of The Receivership of Universal Health Care, Inc., a Florida corporation and The Receivership of Universal Health Care Insurance Company, Inc., a Florida corporation under case numbers 2013-CA and 2013-CA, respectively. The Company also granted to the purchaser a five-year warrant to purchase 200,000 shares of the Company’s common stock at an exercise price of $0.15 per share.

On May 26, 2020, we issued a total 781,206 shares of our common stock in exchange for $85,933 of our convertible debt and accrued interest to the holder of the debt. We relied on Section 3(a) (9) of the Securities Act of 1933, as amended.

On May 28, 2020, we issued a total 884,555 shares of our common stock in exchange for $97,301 of our convertible debt and accrued interest to the holder of the debt. We relied on Section 3(a) (9) of the Securities Act of 1933, as amended.

On May 29, 2020, we issued a total 937,116 shares of our common stock in exchange for $103,083 of our convertible debt and accrued interest to the holder of the debt. We relied on Section 3(a) (9) of the Securities Act of 1933, as amended.

On June 1, 2020, we issued a convertible promissory note (the "Note”)in the principle amount of $56,180 with an original issue discount of $3,180. The Note matures on June 1, 2021, and the interest rate is 10%. This Note may not be prepaid in whole or in part except as follows. Should the Note be prepaid within the first ninety days from the date of issuance, the prepayment percentage is one hundred and twenty-five (125%) per cent of the outstanding principal and any accrued and unpaid interest. For the next ninety days the Note may be prepaid and the prepayment percentage is one hundred thirty (130%) per cent of the outstanding principal and any accrued and unpaid interest. Thereafter, the Note may not be prepaid.

On June 1, 2020, we issued a total 1,024,189 shares of our common stock in exchange for $112,661 of our convertible debt and accrued interest to the holder of the debt. We relied on Section 3(a) (9) of the Securities Act of 1933, as amended.

On June 5, 2020, we issued a total 668,797 shares of our common stock in exchange for $73,568 of our convertible debt and accrued interest to the holder of the debt. We relied on Section 3(a) (9) of the Securities Act of 1933, as amended.

On June 5, 2020, we issued a total 603,987 shares of our common stock in exchange for $66,438 of our convertible debt and accrued interest to the holder of the debt. We relied on Section 3(a) (9) of the Securities Act of 1933, as amended.

On June 12, 2020, we issued a total 1,564,245 shares of our common stock in exchange for $172,067 of our convertible debt and accrued interest to the holder of the debt. We relied on Section 3(a) (9) of the Securities Act of 1933, as amended.

On June 18, 2020, we issued a total 504,957 shares of our common stock in exchange for $55,545 of our convertible debt and accrued interest to the holder of the debt. We relied on Section 3(a) (9) of the Securities Act of 1933, as amended.

On June 21, 2020, we issued a convertible promissory note in the principle amount of $25,000 to an accredited investor. The interest rate was 12%. The Holder of the note has the right to convert all or a portion of the principle and any accrued interest into shares of our common stock at a per share price equal to the lesser of (i) 15% below the average daily closing price of our common stock for the immediately preceding twenty (20) business days or (ii) $0.11. The principal amount and any accrued but unpaid interest under the note shall be due and payable on the earliest to occur (i) the date which is twelve months from the effective date of the note or (ii) the receipt by the Company of payment on its account receivable owed to it by Universal Health Care, Inc. and Universal Health Care Insurance Company, which accounts receivable is currently being processed in the matter of The Receivership of Universal Health Care, Inc., a Florida corporation and The Receivership of Universal Health Care Insurance Company, Inc., a Florida corporation under case numbers 2013-CA and 2013-CA, respectively. The Company also granted to the purchaser a five-year warrant to purchase 50,000 shares of the Company’s common stock at an exercise price of $0.15 per share.

All of the convertible promissory notes listed above were issued to accredited investors, as that term is defined under the Section 501 of Regulation D, promulgated under the Securities Act of 1933, as amended. The warrants issued in connection with the promissory notes all have a cashless exercise feature.

On March 22, 2020, we issued 50,000 warrants to a member of our Medical Advisory Board, an accredited investor. The warrants have a term of three years and an exercise price of $0.25 per warrant.

On March 31, 2020, we issued 169,551 warrants to our Chief Executive Officer in lieu of 2020 first quarter salary. The warrants have a term of five years and an exercise price of $0.39 per warrant.

On April 14, 2020, we issued 96,058 warrants to a promissory note holder, an accredited investor, in lieu of interest. The warrants have a term of five years and an exercise price of $0.19 per warrant. The warrant has a cashless feature.

On April 19, 2020 we issued 50,000 warrants to a member of our Medical Advisory Board, an accredited investor. The warrants have a term of three years and an exercise price of $0.25 per warrant.

On April 21, 2020, we issued 101,599 warrants to a promissory note holder in exchange of their notes, principal amount plus accrued and unpaid interest. The warrants have a term of five years and an exercise price of $0.25 per warrant.

On April 21, 2020, we issued 230,630 warrants to a promissory note holder in exchange of their notes, principal amount plus accrued and unpaid interest. The warrants have a term of five years and an exercise price of $0.25 per warrant.

On April 21, 2020, we issued 146,811 warrants to a promissory note holder in exchange of their notes, principal amount plus accrued and unpaid interest. The warrants have a term of five years and an exercise price of $0.25 per warrant.

On April 21, 2020, we issued 1,589,044 warrants to a promissory note holder in exchange of their notes, principal amount plus accrued and unpaid interest. The warrants have a term of five years and an exercise price of $0.25 per warrant.

On April 21, 2020, we issued 368,804 warrants to a promissory note holder in exchange of their notes, principal amount plus accrued and unpaid interest. The warrants have a term of five years and an exercise price of $0.25 per warrant.

On April 21, 2020, we issued 1,095,253 warrants to a promissory note holder in exchange of their notes, principal amount plus accrued and unpaid interest. The warrants have a term of five years and an exercise price of $0.25 per warrant.

On April 25, 2020 we issued 50,000 warrants to a member of our Medical Advisory Board, an accredited investor. The warrants have a term of three years and an exercise price of $0.25 per warrant.

On May 1, 2020 we issued 50,000 warrants to a member of our Medical Advisory Board, an accredited investor. The warrants have a term of three years and an exercise price of $0.25 per warrant.

On May 10, 2020 we issued 50,000 warrants to a member of our Medical Advisory Board, an accredited investor. The warrants have a term of three years and an exercise price of $0.25 per warrant.

On May 11, 2020 we issued 50,000 warrants to a member of our Medical Advisory Board, an accredited investor. The warrants have a term of three years and an exercise price of $0.25 per warrant.

On May 19, 2020 we issued 50,000 warrants to a member of our Medical Advisory Board, an accredited investor. The warrants have a term of three years and an exercise price of $0.25 per warrant.

On June 3, 2020 we issued 50,000 warrants to a member of our Medical Advisory Board, an accredited investor. The warrants have a term of three years and an exercise price of $0.25 per warrant.

On June 6, 2020 we issued 50,000 warrants to a member of our Dental Advisory Board, an accredited investor. The warrants have a term of three years and an exercise price of $0.25 per warrant.

On June 8, 2020 we issued 50,000 warrants to a member of our Medical Advisory Board, an accredited investor. The warrants have a term of three years and an exercise price of $0.25 per warrant.

On June 10, 2020, we issued 200,000 warrants to our consultant. The warrants have a term of three years and an exercise price of $0.35 per warrant.

On June 11, 2020 we issued 50,000 warrants to a member of our Dental Advisory Board, an accredited investor. The warrants have a term of three years and an exercise price of $0.25 per warrant.

On June 14, 2020 we issued 50,000 warrants to a member of our Medical Advisory Board, an accredited investor. The warrants have a term of three years and an exercise price of $0.25 per warrant.

On June 20, 2020 we issued 50,000 warrants to a member of our Medical Advisory Board, an accredited investor. The warrants have a term of three years and an exercise price of $0.25 per warrant.

On June 22, 2020 we issued 50,000 warrants to a member of our Medical Advisory Board, an accredited investor. The warrants have a term of three years and an exercise price of $0.25 per warrant.

On June 24, 2020 we issued 50,000 warrants to a member of our Medical Advisory Board, an accredited investor. The warrants have a term of three years and an exercise price of $0.25 per warrant.

On June 27, 2020 we issued 50,000 warrants to a member of our Medical Advisory Board, an accredited investor. The warrants have a term of three years and an exercise price of $0.25 per warrant.

On June 30, 2020 we issued 50,000 warrants to a member of our Medical Advisory Board, an accredited investor. The warrants have a term of three years and an exercise price of $0.25 per warrant.

We relied on Section 4 (2) of the Securities Act of 1933, as amended and or Section 501 of Regulation D promulgated under said Act as the exemption from registration under the Act.

Item 3. Exhibits

Documents filed as part of this Report.

Exhibit 31.1 Advanzeon Solutions, Inc. CEO Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

Exhibit 31.2 Advanzeon Solutions, Inc. CFO Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

Exhibit 32.1 Advanzeon Solutions, Inc. CEO Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

Exhibit 32.2 Advanzeon Solutions, Inc. CFO Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		Advanzeon Solutions, Inc.
		Registrant

Date: August 19, 2020	By:	/s/ Clark A. Marcus
		Clark A. Marcus,
		Chief Executive Officer

Date: August 19, 2020	By:	/s/ Arnold B. Finestone
		Arnold B. Finestone,
		Chief Financial Officer

EX-31.1 3 e2079ex_31-1.htm EXHIBIT 31.1

EXHIBIT 31.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Clark A. Marcus, certify that:

I have reviewed this Quarterly Report on Form 10-Q of Advanzeon Solutions, Inc;

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, considering the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

Based on my knowledge, the financial statements, and other financial information included in this report, present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: August 19, 2020 By: /s/ Clark A. Marcus

Clark A. Marcus,

Chief Executive Officer

EX-31.2 4 e2079ex_31-2.htm EXHIBIT 31.2

EXHIBIT 31.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Arnold B. Finestone, certify that:

I have reviewed this Quarterly Report on Form 10-Q of Advanzeon Solutions, Inc;

10.

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: August 19, 2020 By: /s/ Arnold B. Finestone

Arnold B. Finestone,

Chief Financial Officer

EX-32.1 5 e2079ex_32-1.htm EXHIBIT 32.1

EXHIBIT 32.1

SECTION 906 CERTIFICATION

CERTIFICATION REQUIRED BY

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF THE

SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report of Advanzeon Solutions, Inc. (the "Company") on Form 10-Q for the quarterly period ended June 30, 2020, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), the undersigned hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1)

The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: August 19, 2020 By: /s/ Clark A. Marcus

Clark A. Marcus,

Chief Executive Officer

EX-32.2 6 e2079ex_32-2.htm EXHIBIT 32.2

EXHIBIT 32.2

SECTION 906 CERTIFICATION

CERTIFICATION REQUIRED BY

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF THE

SARBANES-OXLEY ACT OF 2002

(1)

The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: August 19, 2020 By: /s/ Arnold B. Finestone

Arnold B. Finestone,

Chief Financial Officer

EX-101.INS 7 chcr-20200630.xml XBRL INSTANCE FILE 0000022872 2020-01-01 2020-06-30 0000022872 2020-06-30 0000022872 2019-12-31 0000022872 us-gaap:SeriesCPreferredStockMember 2020-06-30 0000022872 us-gaap:SeriesDPreferredStockMember 2020-06-30 0000022872 chcr:RemainingPreferredstockMember 2020-06-30 0000022872 us-gaap:SeriesDPreferredStockMember 2019-12-31 0000022872 us-gaap:SeriesCPreferredStockMember 2019-12-31 0000022872 chcr:RemainingPreferredstockMember 2019-12-31 0000022872 2019-01-01 2019-06-30 0000022872 us-gaap:ConvertibleNotesPayableMember 2020-06-30 0000022872 chcr:ShortTermNotesPayableMember 2020-06-30 0000022872 chcr:LoansPayableRelatedPartyMember 2020-06-30 0000022872 us-gaap:ConvertibleNotesPayableMember 2019-12-31 0000022872 chcr:ShortTermNotesPayableMember 2019-12-31 0000022872 chcr:LoansPayableRelatedPartyMember 2019-12-31 0000022872 us-gaap:PropertyPlantAndEquipmentMember srt:MinimumMember 2020-01-01 2020-06-30 0000022872 us-gaap:PropertyPlantAndEquipmentMember srt:MaximumMember 2020-01-01 2020-06-30 0000022872 us-gaap:LeaseholdImprovementsMember 2020-06-30 0000022872 us-gaap:LeaseholdImprovementsMember 2019-12-31 0000022872 srt:ParentCompanyMember 2020-06-30 0000022872 chcr:PharmacyValueManagementSolutionsIncMember 2020-06-30 0000022872 srt:ParentCompanyMember 2019-12-31 0000022872 chcr:PharmacyValueManagementSolutionsIncMember 2019-12-31 0000022872 chcr:PharmacyValueManagementSolutionsIncMember 2020-01-01 2020-06-30 0000022872 chcr:PharmacyValueManagementSolutionsIncMember 2019-01-01 2019-12-31 0000022872 chcr:ShortTermOneNoteMember 2020-01-01 2020-06-30 0000022872 chcr:ShortTermOneNoteMember 2020-06-30 0000022872 2019-01-01 2019-12-31 0000022872 chcr:SonOfFormerNoteHolderMember 2020-01-01 2020-06-30 0000022872 chcr:SonOfFormerNoteHolderMember 2020-06-30 0000022872 us-gaap:AutomobilesMember 2020-06-30 0000022872 chcr:OfficeMember 2020-06-30 0000022872 chcr:N2021Member 2020-06-30 0000022872 chcr:N2022Member 2020-06-30 0000022872 us-gaap:CommonStockMember 2019-03-04 2019-03-21 0000022872 us-gaap:CommonStockMember 2019-03-11 2019-03-29 0000022872 us-gaap:CommonStockMember 2019-03-21 0000022872 us-gaap:CommonStockMember 2019-03-29 0000022872 2018-12-31 0000022872 us-gaap:CommonStockMember 2019-01-01 2019-06-30 0000022872 2019-04-01 2019-06-30 0000022872 2019-06-30 0000022872 2020-08-10 0000022872 2020-04-01 2020-06-30 0000022872 chcr:PPPLoanMember 2020-06-30 0000022872 chcr:PPPLoanMember 2019-12-31 0000022872 srt:ParentCompanyMember 2020-01-01 2020-06-30 0000022872 srt:ParentCompanyMember 2019-01-01 2019-12-31 0000022872 chcr:PharmacyValueManagementSolutionsIncMember chcr:PPPLoanMember chcr:MechanicsBankMember 2020-01-01 2020-06-30 0000022872 chcr:PharmacyValueManagementSolutionsIncMember chcr:MechanicsBankMember 2020-01-01 2020-06-30 0000022872 chcr:N2023Member 2020-06-30 0000022872 us-gaap:SubsequentEventMember chcr:ConvertiblePromissoryNotesMember 2020-07-30 0000022872 us-gaap:WarrantMember us-gaap:SubsequentEventMember 2020-07-30 0000022872 us-gaap:SubsequentEventMember 2020-07-01 2020-07-30 0000022872 us-gaap:SubsequentEventMember 2020-07-30 0000022872 chcr:BoardOfDirectorMember 2020-03-29 2020-04-02 0000022872 chcr:BoardOfDirectorMember 2020-04-02 0000022872 chcr:BoardOfDirector1Member 2020-03-29 2020-04-02 0000022872 chcr:BoardOfDirector1Member 2020-04-02 0000022872 chcr:BoardOfDirector2Member 2020-03-29 2020-04-02 0000022872 chcr:BoardOfDirector2Member 2020-04-02 0000022872 chcr:ExistingNoteHoldersMember 2020-04-01 2020-04-21 0000022872 chcr:ExistingNoteHoldersMember 2020-04-21 0000022872 chcr:ExistingNoteHolders2Member 2020-04-01 2020-04-21 0000022872 chcr:ExistingNoteHolders2Member 2020-04-21 0000022872 chcr:ExistingNoteHolders3Member 2020-04-01 2020-04-21 0000022872 chcr:ExistingNoteHolders3Member 2020-04-21 0000022872 chcr:ExistingNoteHolders4Member 2020-05-01 2020-05-15 0000022872 chcr:ExistingNoteHolders4Member 2020-05-15 0000022872 chcr:ExistingNoteHolders5Member 2020-05-01 2020-05-15 0000022872 chcr:ExistingNoteHolders5Member 2020-05-15 0000022872 chcr:ExistingNoteHolders6Member 2020-05-01 2020-05-15 0000022872 chcr:ExistingNoteHolders6Member 2020-05-15 0000022872 chcr:ExistingNoteHolders7Member 2020-05-01 2020-05-18 0000022872 chcr:ExistingNoteHolders7Member 2020-05-18 0000022872 chcr:ExistingNoteHolders8Member 2020-05-01 2020-05-21 0000022872 chcr:ExistingNoteHolders8Member 2020-05-21 0000022872 chcr:ExistingNoteHolders9Member 2020-05-01 2020-05-25 0000022872 chcr:ExistingNoteHolders9Member 2020-05-25 0000022872 chcr:ExistingNoteHolders10Member 2020-05-01 2020-05-25 0000022872 chcr:ExistingNoteHolders10Member 2020-05-25 0000022872 chcr:ExistingNoteHolders11Member 2020-05-01 2020-05-26 0000022872 chcr:ExistingNoteHolders11Member 2020-05-26 0000022872 chcr:ExistingNoteHolders12Member 2020-05-02 2020-05-28 0000022872 chcr:ExistingNoteHolders12Member 2020-05-28 0000022872 chcr:ExistingNoteHolders13Member 2020-05-01 2020-05-29 0000022872 chcr:ExistingNoteHolders13Member 2020-05-29 0000022872 chcr:ExistingNoteHolders14Member 2020-05-27 2020-06-01 0000022872 chcr:ExistingNoteHolders14Member 2020-06-01 0000022872 chcr:ExistingNoteHolders15Member 2020-06-02 2020-06-05 0000022872 chcr:ExistingNoteHolders15Member 2020-06-05 0000022872 chcr:ExistingNoteHolders16Member 2020-06-02 2020-06-05 0000022872 chcr:ExistingNoteHolders16Member 2020-06-05 0000022872 chcr:ExistingNoteHolders17Member 2020-06-02 2020-06-12 0000022872 chcr:ExistingNoteHolders17Member 2020-06-12 0000022872 chcr:ExistingNoteHolders18Member 2020-06-02 2020-06-18 0000022872 chcr:ExistingNoteHolders18Member 2020-06-18 0000022872 chcr:SeriesCConvertiblePreferredStockMember 2019-01-01 2019-03-31 0000022872 chcr:SeriesCConvertiblePreferredStockMember 2020-01-01 2020-03-31 0000022872 chcr:SeriesCConvertiblePreferredStockMember 2019-04-01 2019-06-30 0000022872 chcr:SeriesCConvertiblePreferredStockMember 2019-07-01 2019-09-30 0000022872 chcr:SeriesCConvertiblePreferredStockMember 2019-10-01 2019-12-31 0000022872 chcr:SeriesCConvertiblePreferredStockMember 2020-04-01 2020-06-30 0000022872 chcr:SeriesCConvertiblePreferredStockMember 2018-12-31 0000022872 chcr:SeriesCConvertiblePreferredStockMember 2019-03-31 0000022872 chcr:SeriesCConvertiblePreferredStockMember 2019-12-31 0000022872 chcr:SeriesCConvertiblePreferredStockMember 2020-03-31 0000022872 chcr:SeriesCConvertiblePreferredStockMember 2019-06-30 0000022872 chcr:SeriesCConvertiblePreferredStockMember 2019-09-30 0000022872 chcr:SeriesCConvertiblePreferredStockMember 2020-06-30 0000022872 us-gaap:CommonStockMember 2019-01-01 2019-03-31 0000022872 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0000022872 us-gaap:CommonStockMember 2019-04-01 2019-06-30 0000022872 us-gaap:CommonStockMember 2019-07-01 2019-09-30 0000022872 us-gaap:CommonStockMember 2019-10-01 2019-12-31 0000022872 us-gaap:CommonStockMember 2020-04-01 2020-06-30 0000022872 us-gaap:CommonStockMember 2018-12-31 0000022872 us-gaap:CommonStockMember 2019-03-31 0000022872 us-gaap:CommonStockMember 2019-12-31 0000022872 us-gaap:CommonStockMember 2020-03-31 0000022872 us-gaap:CommonStockMember 2019-06-30 0000022872 us-gaap:CommonStockMember 2019-09-30 0000022872 us-gaap:CommonStockMember 2020-06-30 0000022872 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0000022872 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0000022872 us-gaap:AdditionalPaidInCapitalMember 2019-04-01 2019-06-30 0000022872 us-gaap:AdditionalPaidInCapitalMember 2019-07-01 2019-09-30 0000022872 us-gaap:AdditionalPaidInCapitalMember 2019-10-01 2019-12-31 0000022872 us-gaap:AdditionalPaidInCapitalMember 2020-04-01 2020-06-30 0000022872 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0000022872 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0000022872 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0000022872 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0000022872 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0000022872 us-gaap:AdditionalPaidInCapitalMember 2019-09-30 0000022872 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0000022872 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0000022872 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0000022872 us-gaap:RetainedEarningsMember 2019-04-01 2019-06-30 0000022872 us-gaap:RetainedEarningsMember 2019-07-01 2019-09-30 0000022872 us-gaap:RetainedEarningsMember 2019-10-01 2019-12-31 0000022872 us-gaap:RetainedEarningsMember 2020-04-01 2020-06-30 0000022872 us-gaap:RetainedEarningsMember 2018-12-31 0000022872 us-gaap:RetainedEarningsMember 2019-03-31 0000022872 us-gaap:RetainedEarningsMember 2019-12-31 0000022872 us-gaap:RetainedEarningsMember 2020-03-31 0000022872 us-gaap:RetainedEarningsMember 2019-06-30 0000022872 us-gaap:RetainedEarningsMember 2019-09-30 0000022872 us-gaap:RetainedEarningsMember 2020-06-30 0000022872 2019-01-01 2019-03-31 0000022872 2020-01-01 2020-03-31 0000022872 2019-07-01 2019-09-30 0000022872 2019-10-01 2019-12-31 0000022872 2019-03-31 0000022872 2020-03-31 0000022872 2019-09-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure chcr:Number

0.001

1000000

14400

7000

978600

7000

14400

978600

10434

250

10434

250

10434

0.01

1000000000

116751439

71661656

116751439

71661656

Advanzeon Solutions, Inc. 0000022872 false --12-31 10-Q 2020-06-30 Q2 2020 Yes 1-9927 Non-accelerated Filer false true false DE Yes 117516838

2992

2010404

1187723

-23611568

-28401814

-60141072

-57837687

35361980

28719246

1167514

716617

-2303385

-1342751

-614990

-1375039

-0.02

-0.01

75598076

67027954

67361656

79534495

10518405

12694859

5956533

3215803

102229

7564173

4788016

342670

1243840

P2Y

P12Y

547360

6616

1549

623

141

2992 2992

299

10416176

12352189

3381163

7035013

5010016

7342173

382000

2289250

165360

One-year

All debt issued has a stated interest rate of 12%

0.10

0.12

0.22

0.11

547360

450000 450000 171247 171247 171247 21412 21412 21412 450000 -53419

315451

29037 339833 54660 25579

0.0299

0.0550

368870

-53419

0.08

0.20

0.11

300000

0.25

329395

325660

288487

452953

1237 1808

3500

34406 42676

933

310

13742192

15891787

22659

8817

14047

2800

37500

1050000

4760728

5956368

8907258

8873802

315451

136230

140210

39011

21220 13873 6358 989

336671

150103

146568

40000

16000 500000 15000 0.03

765399

991255

69327

25036

20912

119640

Use of Estimates - The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates that affect the reported amounts. Actual results could differ from these estimates. Estimates involved in the determination of an allowance for doubtful accounts receivable are considered by management as particularly susceptible to material change in the next year. Other significant estimates relate to stock-based compensation, warrants and beneficial conversion features.

Accounts Receivable - Accounts receivable is carried at its estimated collectible value. Since customer credit is generally extended on a short-term basis, accounts receivable does not bear interest and are uncollateralized. We manage credit risk and determine necessary allowances by evaluating customers’ credit worthiness before extending credit and periodically for collectability, based primarily on customers’ past credit history and current financial conditions and general economic conditions, results of prior collection efforts, the relative strength of our relationship therewith and, in the event of a dispute, its legal position and the estimated cost of proposed collection proceedings. Management has not established a policy for when to charge off uncollectible accounts receivable or to use external collection agencies and makes such decisions on a case-by-case basis. The maximum losses that the Company would incur if a customer failed to pay would be limited to the carrying value of the receivable.

368870

2000

652500

217500

200000

3262500

1087500

2010404

1187723

179221 146880 5683 1239

5683

1239

1825500

1039604

657025

826597

40990

29769

145915

69327

102229

342670

403265

99441

10416176

12352189

642659

136230

113911

13742192

15891787

25442751

29442657

179221

146880

25621972

29589537

845340

-1092383

-551027

-223012

-697774

10000 10000

5994

1102403

669193

341178

707774

-1211002

-791724

-391978

-677265

1441994

950100

482431

780709

623

440

235

312

1311462

841843

416039

715397

129909

107817

66157

65000

230992

158376

90453

103444

230992 158376 90453 103444

921928

-4124

1804451

1085250

18251

15000

1243840

559360

1070250

-5067

-1549

5067

1549

-877456

-1087825

1215572

742356

51383

210951

54660

25579

-169572

712065

11221

2756

54660

25579

16000

7075380 53 3727213

250000

595340

1243840

845340

The Company entered into two leases, one for office space and one automobile lease that are classified as right of use assets and lease liabilities. The Company pays the lease payments on a residential unit in California that is used as an office/residential unit for certain of its marketing personnel. The lease is on a month-to month basis. The Company has occupied this unit for the past approximately 1-1/2 year period and intends to do so for the foreseeable future. The lease for the Company’s office space expire in June 2022.The lease for the automobile expires in June 2021.As the implicit interest rate is not readily identifiable in the leases, the Company calculated the present value of the leases using the average commercial real estate interest rate of 5.50% at the commencement of the office leases and the interest of 2.99% for the automobile lease. Applying the commercial rate, the Company calculated the present value of $339,833 for the office leases and $29,037 for the automobile leasing that are being amortized over the life of the leases.

56180

<table cellspacing="0" cellpadding="0" style="width: 100%"> <tr style="vertical-align: top"> <td style="width: 0px"> </td> <td style="width: 0px; padding-bottom: 11pt; font: 12pt/106% Times New Roman, Times, Serif">4.</td> <td style="padding-bottom: 11pt; font: 12pt/106% Times New Roman, Times, Serif">PROPERTY AND EQUIPMENT</td></tr> </table>   Property and equipment, net, consists of the following at June 30, 2020 and December 31, 2019: <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">June 30, 2020</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">December 31, 2019</td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="3"> </td> <td> </td> <td colspan="3"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 58%">Property and equipment</td> <td style="width: 8%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">6,616</td> <td style="width: 1%"> </td> <td style="width: 8%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">1,549</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt">Less accumulated depreciation</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(933</td> <td style="padding-bottom: 1pt">)</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(310</td> <td style="padding-bottom: 1pt">)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt">Property and equipment - net</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">5,683</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">1,239</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table> Depreciation expense for the six-month periods ended June 30, 2020 and 2019 is $623 and $141, respectively. A laptop was acquired in January of 2020.

<table cellspacing="0" cellpadding="0" style="width: 100%"> <tr style="vertical-align: top"> <td style="width: 0px"> </td> <td style="width: 0px; padding-bottom: 11pt; font: 12pt/106% Times New Roman, Times, Serif">5.</td> <td style="padding-bottom: 11pt; font: 12pt/106% Times New Roman, Times, Serif">LEASEHOLD IMPROVEMENT</td></tr> </table>   Leasehold improvement, net, consists of the following at June 30, 2020 and December 31, 2019: <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">June 30, 2020</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">December 31, 2019</td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="3"> </td> <td> </td> <td colspan="3"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 58%">Leasehold improvements</td> <td style="width: 8%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">2,992</td> <td style="width: 1%"> </td> <td style="width: 8%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">2,992</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt">Less accumulated amortization</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(2,992</td> <td style="padding-bottom: 1pt">)</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(2,992</td> <td style="padding-bottom: 1pt">)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt">Leasehold improvements - net</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">—  </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">—  </td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>   Amortization expense for the six-month periods ended June 30, 2020 and 2019 is $0 and $299, respectively.

<table cellspacing="0" cellpadding="0" style="width: 100%"> <tr style="vertical-align: top"> <td style="width: 1px"> </td> <td style="width: 11px; padding-bottom: 11pt; font: 12pt/106% Times New Roman, Times, Serif">6.</td> <td style="padding-bottom: 11pt; font: 12pt/106% Times New Roman, Times, Serif">RELATED PARTY LOANS PAYABLE</td></tr> </table>   The Company has received financing from Management of the Company as well as from members of our Board of Directors. These individuals are deemed to be related parties to the Company and their indebtedness must be disclosed separately. As of June 30, 2020 and December 31, 2019, there are the following related party notes payable: <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">June 30, 2020</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">December 31, 2019</td></tr> <tr style="vertical-align: bottom"> <td style="width: 58%"> </td> <td style="width: 8%"> </td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: right"> </td> <td style="width: 1%"> </td> <td style="width: 8%"> </td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: right"> </td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt">Related party loans payable</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">102,229</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">342,670</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

<table cellspacing="0" cellpadding="0" style="width: 100%"> <tr style="vertical-align: top"> <td style="width: 0px"> </td> <td style="width: 0px; padding-bottom: 11pt; font: 12pt/106% Times New Roman, Times, Serif">9.</td> <td style="padding-bottom: 11pt; font: 12pt/106% Times New Roman, Times, Serif; text-align: justify">OTHER ACCRUED LIABILITIES</td></tr> </table> As of June 30, 2020 and December 31, 2019, the balance of other accrued liabilities is as follows: <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">June 30, 2020</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">December 31, 2019</td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="3"> </td> <td> </td> <td colspan="3"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 58%">Management compensation</td> <td style="width: 8%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">8,907,258</td> <td style="width: 1%"> </td> <td style="width: 8%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">8,873,802</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Accrued interest non-related party</td> <td> </td> <td> </td> <td style="text-align: right">4,760,728</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">5,956,368</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Board of Director fees</td> <td> </td> <td> </td> <td style="text-align: right">37,500</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,050,000</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>State fees</td> <td> </td> <td> </td> <td style="text-align: right">—  </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2,800</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Payroll liabilities</td> <td> </td> <td> </td> <td style="text-align: right">14,047</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—  </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt">Other accrued liabilities</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">22,659</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">8,817</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt">Total other accrued debt</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">13,742,192</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">15,891,787</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

Property and Equipment - Property and equipment (Note 4) is stated at cost less accumulated depreciation. Depreciation and amortization are computed using the straight-line method over the estimated useful lives ranging from 2 to 12 years.

Leasehold Improvement - Leasehold improvement (Note 5) is stated at cost less accumulated amortization. Depreciation and amortization are computed using the straight-line method over the estimated useful lives ranging from 2 to 12 years. Leasehold improvements are amortized over the shorter of the lease term or the asset’s useful life.

Income Taxes - We are subject to the income tax jurisdictions of the U.S. and multiple state tax jurisdictions. However, our provisions for income taxes for 2020 and 2019 include only state income taxes.  Management has evaluated our tax positions taken or to be taken on income tax returns that remain subject to examination (i.e., tax years 2017 and thereafter federally), and has concluded that there have been no uncertain tax positions (as defined in GAAP) taken that require recognition or disclosure in the consolidated financial statements. In the event of any income tax-related interest or penalties are incurred, they would be included in general and administrative expense.

Concentration of Credit Risk - The Company maintains its cash and cash equivalents with a financial institution which management believes to be of high credit quality. Their accounts are insured by the Federal Deposit Insurance Corporation (FDIC) up to $250,000 in coverage. The Company had an uninsured cash balance of $595,340 as of June 30, 2020 and no uninsured cash balances as of December 31, 2019.

Stock Options and Warrants - We grant stock options and warrants to our employees, non-employee directors, note holders and certain consultants allowing them to purchase our common stock pursuant to approved terms. The estimated value of the warrants issued with debt instruments is recorded as a discount on notes payable and amortized as interest expense over the term of the notes using the effective interest method.

Other current assets consists of the following at June 30, 2020 and December 31, 2019: <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">June 30, 2020</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">December 31, 2019</td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="3"> </td> <td> </td> <td colspan="3"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 58%">Loans to others</td> <td style="width: 8%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">34,406</td> <td style="width: 1%"> </td> <td style="width: 8%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">42,676</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Security and lease deposits</td> <td> </td> <td> </td> <td style="text-align: right">3,500</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">3,500</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Capitalized portion of lease</td> <td> </td> <td> </td> <td style="text-align: right">1,237</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,808</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Prepaid expenses</td> <td> </td> <td> </td> <td style="text-align: right">288,487</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">452,953</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1pt">Miscellaneous receivable</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">329,395</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">325,660</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt">Other current asset</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">657,025</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">826,597</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

Property and equipment, net, consists of the following at June 30, 2020 and December 31, 2019: <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">June 30, 2020</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">December 31, 2019</td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="3"> </td> <td> </td> <td colspan="3"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 58%">Property and equipment</td> <td style="width: 8%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">6,616</td> <td style="width: 1%"> </td> <td style="width: 8%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">1,549</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt">Less accumulated depreciation</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(933</td> <td style="padding-bottom: 1pt">)</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(310</td> <td style="padding-bottom: 1pt">)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt">Property and equipment - net</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">5,683</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">1,239</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

Leasehold improvement, net, consists of the following at June 30, 2020 and December 31, 2019: <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">June 30, 2020</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">December 31, 2019</td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="3"> </td> <td> </td> <td colspan="3"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 58%">Leasehold improvements</td> <td style="width: 8%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">2,992</td> <td style="width: 1%"> </td> <td style="width: 8%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">2,992</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt">Less accumulated amortization</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(2,992</td> <td style="padding-bottom: 1pt">)</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(2,992</td> <td style="padding-bottom: 1pt">)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt">Leasehold improvements - net</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">—  </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">—  </td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

As of June 30, 2020 and December 31, 2019, there are the following related party notes payable: <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">June 30, 2020</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">December 31, 2019</td></tr> <tr style="vertical-align: bottom"> <td style="width: 58%"> </td> <td style="width: 8%"> </td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: right"> </td> <td style="width: 1%"> </td> <td style="width: 8%"> </td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: right"> </td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt">Related party loans payable</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">102,229</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">342,670</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

Break-out of debt between the parent company and our subsidiary PVMS is as follows: <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">June 30, 2020</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">December 31, 2019</td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="3"> </td> <td> </td> <td colspan="3"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 58%">Advanzeon parent</td> <td style="width: 8%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">3,381,163</td> <td style="width: 1%"> </td> <td style="width: 8%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">5,010,016</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt">PVMS</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">7,035,013</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">7,342,173</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">10,416,176</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">12,352,189</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table> At PVMS, the total of notes issued year-to-date and their dollar values were as follows: <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">June 30, 2020</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">December 31, 2019</td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="3"> </td> <td> </td> <td colspan="3"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 58%">Number of notes issued</td> <td style="width: 8%"> </td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: right">8</td> <td style="width: 1%"> </td> <td style="width: 8%"> </td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: right">51</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt">Dollar value</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">382,000</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">2,289,250</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table> At Advanzeon, the total notes issued year-to-date and their dollar values were as follows: <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">June 30, 2020</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">December 31, 2019</td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="3"> </td> <td> </td> <td colspan="3"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 58%">Number of notes issued</td> <td style="width: 8%"> </td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: right">2</td> <td style="width: 1%"> </td> <td style="width: 8%"> </td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: right">—  </td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt">Dollar value</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">165,360</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">—  </td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

As of June 30, 2020 and December 31, 2019, the balance of this indebtedness is as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">June 30, 2020</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">December 31, 2019</td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="3"> </td> <td> </td> <td colspan="3"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 58%">Disputed note payable</td> <td style="width: 8%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">450,000</td> <td style="width: 1%"> </td> <td style="width: 8%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">450,000</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Disputed interest payable</td> <td> </td> <td> </td> <td style="text-align: right">171,247</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">171,247</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1pt">Pending attorney fees</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">21,412</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">21,412</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt">Total contingent liability</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">642,659</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">642,659</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

As of June 30, 2020 and December 31, 2019, the balance of other accrued liabilities is as follows: <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">June 30, 2020</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">December 31, 2019</td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="3"> </td> <td> </td> <td colspan="3"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 58%">Management compensation</td> <td style="width: 8%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">8,907,258</td> <td style="width: 1%"> </td> <td style="width: 8%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">8,873,802</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Accrued interest non-related party</td> <td> </td> <td> </td> <td style="text-align: right">4,760,728</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">5,956,368</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Board of Director fees</td> <td> </td> <td> </td> <td style="text-align: right">37,500</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,050,000</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>State fees</td> <td> </td> <td> </td> <td style="text-align: right">—  </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2,800</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Payroll liabilities</td> <td> </td> <td> </td> <td style="text-align: right">14,047</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—  </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt">Other accrued liabilities</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">22,659</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">8,817</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt">Total other accrued debt</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">13,742,192</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">15,891,787</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

As of June 30, 2020, the right of use assets associated with future operating leases are as follows: <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Total present value of right of use assets</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 71%">    under lease agreements</td> <td style="width: 10%"> </td> <td style="width: 1%">$</td> <td style="width: 17%; text-align: right">368,870</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt">Amortization of right of use assets</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(53,419</td> <td style="padding-bottom: 1pt">)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt">Total right of use assets as of June 30, 2020</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">315,451</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

17000

-112172

200000

500000

700000

14584350

1327252

2156515

1263745

4284565

7210168

700751

502434

319627

333824

781206

884555

937116

1024189

668797

603987

1564245

504957

2916869

265450

431303

139012

471302

793118

77083

55268

35159

36721

85933

97301

103083

112661

73568

66439

172067

55545

13201582

Cash and restricted cash consists of the following at June 30, 2020 and December 31, 2019:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">June 30, 2020</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">December 31, 2019</td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="3"> </td> <td> </td> <td colspan="3"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 58%">Cash</td> <td style="width: 8%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">145,915</td> <td style="width: 1%"> </td> <td style="width: 8%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">69,327</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt">Restricted Cash</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">845,340</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">—  </td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Total cash and restricted cash shown in the</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt">  consolidated statement of cash flows</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">991,255</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">69,327</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

3727213

39652283

84194

<table cellspacing="0" cellpadding="0" style="width: 100%"> <tr style="vertical-align: top"> <td style="width: 0px"> </td> <td style="font: 12pt/106% Times New Roman, Times, Serif; width: 0px; padding-bottom: 11pt">10.</td> <td style="font: 12pt/106% Times New Roman, Times, Serif; padding-bottom: 11pt; text-align: justify">RIGHT OF USE ASSETS</td></tr> </table> The Company entered into two leases, one for office space and one for an automobile lease that are classified as right of use assets and lease liabilities. The Company pays the lease payments on a residential unit in California that is used as an office/residential unit for certain of its marketing personnel. The lease is on a month-to month basis. The Company has occupied this unit for the past approximately 1-1/2 year period and intends to do so for the foreseeable future. The lease for the Company’s office space expire in June 2022.The lease for the automobile expires in June 2021.As the implicit interest rate is not readily identifiable in the leases, the Company calculated the present value of the leases using the average commercial real estate interest rate of 5.50% at the commencement of the office leases and the interest of 2.99% for the automobile lease. Applying the commercial rate, the Company calculated the present value of $339,833 for the office leases and $29,037 for the automobile leasing that are being amortized over the life of the leases.  As of June 30, 2020, the right of use assets associated with future operating leases are as follows: <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Total present value of right of use assets</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 71%">    under lease agreements</td> <td style="width: 10%"> </td> <td style="width: 1%">$</td> <td style="width: 17%; text-align: right">368,870</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt">Amortization of right of use assets</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(53,419</td> <td style="padding-bottom: 1pt">)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt">Total right of use assets as of June 30, 2020</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">315,451</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>   Total amortization expense related to the right of use assets under the lease agreements was $54,660 and $25,579 for the six-month periods ended June 30, 2020 and 2019, respectively. <table cellspacing="0" cellpadding="0" style="width: 100%"> <tr style="vertical-align: top"> <td style="width: 0px"> </td> <td style="font: 12pt/106% Times New Roman, Times, Serif; width: 0px; padding-bottom: 11pt">11.</td> <td style="font: 12pt/106% Times New Roman, Times, Serif; padding-bottom: 11pt; text-align: justify">RIGHT OF USE LEASE LIABILITIES</td></tr> </table> As disclosed in Note 10, the Company entered into two leases for office space prior to the quarter ended June 30, 2020 that are classified as right of use assets and lease liabilities. As of June 30, 2020, the lease liabilities associated with future payments due under the leases are as follows: <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 71%">Total present value of future lease payments</td> <td style="width: 10%"> </td> <td style="width: 1%">$</td> <td style="width: 17%; text-align: right">368,870</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1pt">Principal payments made as of the six month period ended June 30, 2020</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(53,419</td> <td style="padding-bottom: 1pt">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt">Total right of use lease liabilities as of June 30, 2020</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">315,451</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>  The following is a schedule of future minimum lease payments under the right of use lease agreements together with the present value of the net minimum lease payments as of June 30, 2020: <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 71%">Total future minimum lease payments</td> <td style="width: 10%"> </td> <td style="width: 1%">$</td> <td style="width: 17%; text-align: right">336,671</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1pt">Less present value discount</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">21,220</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Total right of use lease liabilities as of June 30, 2020</td> <td> </td> <td> </td> <td style="text-align: right">315,451</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1pt">Less current portion due within one year</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">136,230</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt">Long-term right of use liabilities</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">179,221</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>   Total maturities of lease liabilities as of June 30, 2020 are as follows: <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td colspan="3"> </td> <td> </td> <td colspan="3" style="text-align: center">Total future</td> <td> </td> <td colspan="3"> </td> <td> </td> <td colspan="3"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="3"> </td> <td> </td> <td colspan="3" style="text-align: center">minimum lease</td> <td> </td> <td colspan="3" style="text-align: center">Present value</td> <td> </td> <td colspan="3" style="text-align: center">Right of use</td></tr> <tr style="vertical-align: bottom"> <td colspan="3"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">payments</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">discount</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">lease liabilities</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 1%"> </td> <td style="width: 20%">2021</td> <td style="width: 1%"> </td> <td style="width: 5%"> </td> <td style="width: 1%">$</td> <td style="width: 19%; text-align: right">150,103</td> <td style="width: 1%"> </td> <td style="width: 5%"> </td> <td style="width: 1%">$</td> <td style="width: 19%; text-align: right">13,873</td> <td style="width: 1%"> </td> <td style="width: 5%"> </td> <td style="width: 1%">$</td> <td style="width: 19%; text-align: right">136,230</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td>2022</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">146,568</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">6,358</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">140,210</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt">2023</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">40,000</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">989</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">39,011</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">336,671</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">21,220</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">315,451</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

Revenue Recognition - In accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 606, "Revenue from Contracts with Customers", the Company recognizes revenue when obligations under the terms of a contract with the customer are satisfied. Generally, this occurs upon shipment of the CPAP to their customer or when the test is performed.

Cost of Revenues - Costs of services consist of supplies and operating expenses. Supplies are recognized in the period in which a patient receives the supplies.

Right of Use Assets and Lease Liabilities - During the quarter ended March 31, 2019, the Company implemented Accounting Standards Update 2016-02, Leases. Under the new guidance, a lessee must record a liability for lease payments (referred to as the lease liability) and an asset for the right to use the leased asset during the lease term (referred to at the right of use asset) for all leases, regardless of whether they are designated as finance or operating leases. This election requires the lessee to recognize lease expense on a straight-line basis over the lease term. The right of use assets and corresponding right of use liabilities have been recorded using the present value of the leases. See Notes 10 and 11 within the financial statement for additional disclosure on leases. As of June 30, 2020, the lease liabilities associated with future payments due under the leases are as follows: <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 71%">Total present value of future lease payments</td> <td style="width: 10%"> </td> <td style="width: 1%">$</td> <td style="width: 17%; text-align: right">368,870</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1pt">Principal payments made as of the six month period ended June 30, 2020</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(53,419</td> <td style="padding-bottom: 1pt">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt">Total right of use lease liabilities as of June 30, 2020</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">315,451</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

The following is a schedule of future minimum lease payments under the right of use lease agreements together with the present value of the net minimum lease payments as of June 30, 2020: <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 71%">Total future minimum lease payments</td> <td style="width: 10%"> </td> <td style="width: 1%">$</td> <td style="width: 17%; text-align: right">336,671</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1pt">Less present value discount</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">21,220</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Total right of use lease liabilities as of June 30, 2020</td> <td> </td> <td> </td> <td style="text-align: right">315,451</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1pt">Less current portion due within one year</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">136,230</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt">Long-term right of use liabilities</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">179,221</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

Total maturities of lease liabilities as of June 30, 2020 are as follows: <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td colspan="3"> </td> <td> </td> <td colspan="3" style="text-align: center">Total future</td> <td> </td> <td colspan="3"> </td> <td> </td> <td colspan="3"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="3"> </td> <td> </td> <td colspan="3" style="text-align: center">minimum lease</td> <td> </td> <td colspan="3" style="text-align: center">Present value</td> <td> </td> <td colspan="3" style="text-align: center">Right of use</td></tr> <tr style="vertical-align: bottom"> <td colspan="3"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">payments</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">discount</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">lease liabilities</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 1%"> </td> <td style="width: 20%">2021</td> <td style="width: 1%"> </td> <td style="width: 5%"> </td> <td style="width: 1%">$</td> <td style="width: 19%; text-align: right">150,103</td> <td style="width: 1%"> </td> <td style="width: 5%"> </td> <td style="width: 1%">$</td> <td style="width: 19%; text-align: right">13,873</td> <td style="width: 1%"> </td> <td style="width: 5%"> </td> <td style="width: 1%">$</td> <td style="width: 19%; text-align: right">136,230</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td>2022</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">146,568</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">6,358</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">140,210</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt">2023</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">40,000</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">989</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">39,011</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">336,671</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">21,220</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">315,451</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

136230 113911

-23611568

-28401814

-25903239

-27214990

666617

673617

716617

1167514

673617

1167514

28012007

28036007

28719246

35361980

28036007

35361980

-54581873

-55309634

-57837687

-60141072

-55924624

-56672425

-60141072

-26600000

-23611568

-27962791

10434

66661656

67361656

71661656

116751439

67361656

116751439

7075380

5000

450897

10000

6624483

15000

500000

45089783

18251 253239 18251 253239

-614990

-1375039

-727761

-928346

-614990

-747801

-1165262

-1375039

-727761

-928346

-747801

-1165262

2000 43000 14000 430000 16000 473000 200000 4300000

As of June 30, 2020 and December 31, 2019, the balance was as follows: <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">June 30, 2020</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">December 31, 2019</td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="3"> </td> <td> </td> <td colspan="3"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 60%">Notes payable</td> <td style="width: 8%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">10,416,176</td> <td style="width: 1%"> </td> <td style="width: 8%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">12,352,189</td> <td style="width: 1%"> </td></tr> <tr> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td></tr></table>

<table cellspacing="0" cellpadding="0" style="width: 100%"> <tr style="vertical-align: top"> <td style="width: 0px"> </td> <td style="font: 12pt/106% Times New Roman, Times, Serif; width: 0px; padding-bottom: 8pt">2.</td> <td style="font: 12pt/106% Times New Roman, Times, Serif; padding-bottom: 8pt">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</td></tr> </table> Established in 1969, Advanzeon Solutions, Inc., (formerly Comprehensive Care Corp.) (“Advanzeon”, “we”, “Parent”, or the “Company”), through its wholly-owned subsidiary Pharmacy Value Management Solutions, Inc., and its wholly-owned subsidiaries during 2015, and partly in 2016, provided managed care services by acting as the administrator for certain administrative service agreements in the behavioral health and substance abuse fields. We primarily offered these services to commercial, Medicare, Medicaid, Children’s Health Insurance Program (“CHIP”) health plans, as well as self-insured companies. Our managed care operations consisted solely of servicing administrative service agreements. Starting in July of 2015, we implemented our comprehensive sleep apnea program, called “SleepMaster Solutions” ™. SleepMaster Solutions (“SMS”) utilizes an administrative system for the convenient identification/testing and therapy of Obstructive Sleep Apnea (“OSA”). We partnered with a national health care provider by initiating a sleep apnea wellness program whereby we screened, tested and when needed, offered treatment programs for treating this disorder. We also contracted with a union to treat its driver members. Beginning in 2017, our only business was our SMS sleep apnea program. The Company has elected to not adopt the option available under United States generally accepted accounting principles (“GAAP”) to measure any eligible financial instruments or other items at fair market value at this time. Accordingly, the Company measures all of its assets and liabilities on the historical cost basis of accounting, except as otherwise required by GAAP. Inter-company accounts and transactions have been eliminated in consolidation. Certain minor reclassifications of prior period amounts have been made to conform to the current period presentation. Use of Estimates - The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates that affect the reported amounts. Actual results could differ from these estimates. Estimates involved in the determination of an allowance for doubtful accounts receivable are considered by management as particularly susceptible to material change in the next year. Other significant estimates relate to stock-based compensation, warrants and beneficial conversion features. Accounts Receivable - Accounts receivable is carried at its estimated collectible value. Since customer credit is generally extended on a short-term basis, accounts receivable does not bear interest and are uncollateralized. We manage credit risk and determine necessary allowances by evaluating customers’ credit worthiness before extending credit and periodically for collectability, based primarily on customers’ past credit history and current financial conditions and general economic conditions, results of prior collection efforts, the relative strength of our relationship therewith and, in the event of a dispute, its legal position and the estimated cost of proposed collection proceedings. Management has not established a policy for when to charge off uncollectible accounts receivable or to use external collection agencies and makes such decisions on a case-by-case basis. The maximum losses that the Company would incur if a customer failed to pay would be limited to the carrying value of the receivable. Revenue Recognition - In accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 606, "Revenue from Contracts with Customers", the Company recognizes revenue when obligations under the terms of a contract with the customer are satisfied. Generally, this occurs upon shipment of the CPAP to their customer or when the test is performed. Property and Equipment - Property and equipment (Note 4) is stated at cost less accumulated depreciation. Depreciation and amortization are computed using the straight-line method over the estimated useful lives ranging from 2 to 12 years. Leasehold Improvement - Leasehold improvement (Note 5) is stated at cost less accumulated amortization. Depreciation and amortization are computed using the straight-line method over the estimated useful lives ranging from 2 to 12 years. Leasehold improvements are amortized over the shorter of the lease term or the asset’s useful life. Fair Value Measurements - The carrying amounts of cash, accounts receivable and accounts payable approximate their estimated fair value due to the short-term nature of these instruments. Since our other financial liabilities are not traded in an open market, we generally use a present value technique, which is a level 3 input, as defined in GAAP, to measure the estimated fair value of these financial instruments, except for valuing stock options and warrants (see below). The rate used for discounting expected cash flows is a risk-free rate adjusted for systematic and unsystematic risk. The carrying amounts of long-term debt and estimated fair values of the attached warrants at June 30, 2020 and December 31, 2019 are as follows: <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="7" style="border-bottom: black 1pt solid; text-align: center">June 30, 2020</td> <td style="padding-bottom: 1pt"> </td> <td colspan="7" style="border-bottom: black 1pt solid; text-align: center">December 31, 2019</td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="3"> </td> <td> </td> <td colspan="3" style="text-align: center">Estimated</td> <td> </td> <td colspan="3"> </td> <td> </td> <td colspan="3" style="text-align: center">Estimated</td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="3" style="text-align: center"> </td> <td> </td> <td colspan="3" style="text-align: center">Fair Value of</td> <td> </td> <td colspan="3" style="text-align: center"> </td> <td> </td> <td colspan="3" style="text-align: center">Fair Value of</td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="3" style="text-align: center">Carrying</td> <td> </td> <td colspan="3" style="text-align: center">Attached</td> <td> </td> <td colspan="3" style="text-align: center">Carrying</td> <td> </td> <td colspan="3" style="text-align: center">Attached</td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">Amount</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">Warrants</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">Amount</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">Warrants</td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="3"> </td> <td> </td> <td colspan="3"> </td> <td> </td> <td colspan="3"> </td> <td> </td> <td colspan="3"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 48%">Convertible promissory notes</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">5,956,533</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">—  </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">7,564,173</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">—  </td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Short term notes payable</td> <td> </td> <td> </td> <td style="text-align: right">3,215,803</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—  </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">4,788,016</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—  </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1pt">Loan payable related party</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt none"> </td> <td style="text-align: right">102,229</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td> </td> <td style="text-align: right">—  </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td> </td> <td style="text-align: right">342,670</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td> </td> <td style="text-align: right">—  </td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1pt">PPP Loan</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">1,243,840</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">— </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">— </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">— </td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">10,518,405</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">—  </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">12,694,859</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">—  </td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>   During the six-month period ended June 30, 2020, there have been 10 additional convertible notes issued totaling $547,360. During the six-month period ended June 30, 2020, 53 convertible notes totaling $3,727,213 plus accrued interest was converted to stock. Cost of Revenues - Costs of services consist of supplies and operating expenses. Supplies are recognized in the period in which a patient receives the supplies. Right of Use Assets and Lease Liabilities - During the quarter ended March 31, 2019, the Company implemented Accounting Standards Update 2016-02, Leases. Under the new guidance, a lessee must record a liability for lease payments (referred to as the lease liability) and an asset for the right to use the leased asset during the lease term (referred to at the right of use asset) for all leases, regardless of whether they are designated as finance or operating leases. This election requires the lessee to recognize lease expense on a straight-line basis over the lease term. The right of use assets and corresponding right of use liabilities have been recorded using the present value of the leases. See Notes 10 and 11 within the financial statement for additional disclosure on leases. Income Taxes - We are subject to the income tax jurisdictions of the U.S. and multiple state tax jurisdictions. However, our provisions for income taxes for 2020 and 2019 include only state income taxes.  Management has evaluated our tax positions taken or to be taken on income tax returns that remain subject to examination (i.e., tax years 2017 and thereafter federally), and has concluded that there have been no uncertain tax positions (as defined in GAAP) taken that require recognition or disclosure in the consolidated financial statements. In the event of any income tax-related interest or penalties are incurred, they would be included in general and administrative expense. Concentration of Credit Risk - The Company maintains its cash and cash equivalents with a financial institution which management believes to be of high credit quality. Their accounts are insured by the Federal Deposit Insurance Corporation (FDIC) up to $250,000 in coverage. The Company had an uninsured cash balance of $595,340 as of June 30, 2020 and no uninsured cash balances as of December 31, 2019. Stock Options and Warrants - We grant stock options and warrants to our employees, non-employee directors, note holders and certain consultants allowing them to purchase our common stock pursuant to approved terms. The estimated value of the warrants issued with debt instruments is recorded as a discount on notes payable and amortized as interest expense over the term of the notes using the effective interest method.

Fair Value Measurements - The carrying amounts of cash, accounts receivable and accounts payable approximate their estimated fair value due to the short-term nature of these instruments. Since our other financial liabilities are not traded in an open market, we generally use a present value technique, which is a level 3 input, as defined in GAAP, to measure the estimated fair value of these financial instruments, except for valuing stock options and warrants (see below). The rate used for discounting expected cash flows is a risk-free rate adjusted for systematic and unsystematic risk. The carrying amounts of long-term debt and estimated fair values of the attached warrants at June 30, 2020 and December 31, 2019 are as follows: <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="7" style="border-bottom: black 1pt solid; text-align: center">June 30, 2020</td> <td style="padding-bottom: 1pt"> </td> <td colspan="7" style="border-bottom: black 1pt solid; text-align: center">December 31, 2019</td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="3"> </td> <td> </td> <td colspan="3" style="text-align: center">Estimated</td> <td> </td> <td colspan="3"> </td> <td> </td> <td colspan="3" style="text-align: center">Estimated</td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="3" style="text-align: center"> </td> <td> </td> <td colspan="3" style="text-align: center">Fair Value of</td> <td> </td> <td colspan="3" style="text-align: center"> </td> <td> </td> <td colspan="3" style="text-align: center">Fair Value of</td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="3" style="text-align: center">Carrying</td> <td> </td> <td colspan="3" style="text-align: center">Attached</td> <td> </td> <td colspan="3" style="text-align: center">Carrying</td> <td> </td> <td colspan="3" style="text-align: center">Attached</td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">Amount</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">Warrants</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">Amount</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">Warrants</td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="3"> </td> <td> </td> <td colspan="3"> </td> <td> </td> <td colspan="3"> </td> <td> </td> <td colspan="3"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 48%">Convertible promissory notes</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">5,956,533</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">—  </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">7,564,173</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">—  </td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Short term notes payable</td> <td> </td> <td> </td> <td style="text-align: right">3,215,803</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—  </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">4,788,016</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—  </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1pt">Loan payable related party</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt none"> </td> <td style="text-align: right">102,229</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td> </td> <td style="text-align: right">—  </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td> </td> <td style="text-align: right">342,670</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td> </td> <td style="text-align: right">—  </td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1pt">PPP Loan</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">1,243,840</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">— </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">— </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">— </td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">10,518,405</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">—  </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">12,694,859</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">—  </td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>   During the six-month period ended June 30, 2020, there have been 10 additional convertible notes issued totaling $547,360. During the six-month period ended June 30, 2020, 53 convertible notes totaling $3,727,213 plus accrued interest was converted to stock. Cost of Revenues - Costs of services consist of supplies and operating expenses. Supplies are recognized in the period in which a patient receives the supplies.

The carrying amounts of long-term debt and estimated fair values of the attached warrants at June 30, 2020 and December 31, 2019 are as follows: <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="7" style="border-bottom: black 1pt solid; text-align: center">June 30, 2020</td> <td style="padding-bottom: 1pt"> </td> <td colspan="7" style="border-bottom: black 1pt solid; text-align: center">December 31, 2019</td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="3"> </td> <td> </td> <td colspan="3" style="text-align: center">Estimated</td> <td> </td> <td colspan="3"> </td> <td> </td> <td colspan="3" style="text-align: center">Estimated</td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="3" style="text-align: center"> </td> <td> </td> <td colspan="3" style="text-align: center">Fair Value of</td> <td> </td> <td colspan="3" style="text-align: center"> </td> <td> </td> <td colspan="3" style="text-align: center">Fair Value of</td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="3" style="text-align: center">Carrying</td> <td> </td> <td colspan="3" style="text-align: center">Attached</td> <td> </td> <td colspan="3" style="text-align: center">Carrying</td> <td> </td> <td colspan="3" style="text-align: center">Attached</td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">Amount</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">Warrants</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">Amount</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">Warrants</td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="3"> </td> <td> </td> <td colspan="3"> </td> <td> </td> <td colspan="3"> </td> <td> </td> <td colspan="3"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 48%">Convertible promissory notes</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">5,956,533</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">—  </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">7,564,173</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">—  </td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Short term notes payable</td> <td> </td> <td> </td> <td style="text-align: right">3,215,803</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—  </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">4,788,016</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">—  </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1pt">Loan payable related party</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt none"> </td> <td style="text-align: right">102,229</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td> </td> <td style="text-align: right">—  </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td> </td> <td style="text-align: right">342,670</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td> </td> <td style="text-align: right">—  </td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1pt">PPP Loan</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">1,243,840</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">— </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">— </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">— </td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">10,518,405</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">—  </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">12,694,859</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">—  </td> <td style="padding-bottom: 2.5pt"> </td></tr></table>

EX-101.SCH 8 chcr-20200630.xsd XBRL SCHEMA FILE 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Consolidated Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Consolidated Balance Sheets (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Consolidated Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - CONSOLIDATED STATEMENT OF STOCKHOLDERS’ EQUITY (DEFICIENCY) (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - Description of The Company's Business and Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Current Assets link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Property and Equipment link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Leasehold Improvement link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Related Party Loans Payable link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Debt link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Contingent Liability link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Other Accrued Liabilities link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Right of Use Assets link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Right of Use Lease Liabilities link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Common Stock link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Legal Proceedings link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Current Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Property and Equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Leasehold Improvement (Tables) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Related Party Loans Payable (Tables) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Debt (Tables) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Contingent Liability (Tables) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Other Accrued Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Right of Use Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Right of Use Lease Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - Summary of Significant Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - Current Assets (Details) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - Current Assets (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - Property and Equipment (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - Leasehold Improvement (Details) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - Leasehold Improvement (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - Related Party Loans Payable (Details) link:presentationLink link:calculationLink link:definitionLink 00000041 - Disclosure - Debt (Details) link:presentationLink link:calculationLink link:definitionLink 00000042 - Disclosure - Debt (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000043 - Disclosure - Debt (Details 2) link:presentationLink link:calculationLink link:definitionLink 00000044 - Disclosure - Debt (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000045 - Disclosure - Contingent Liability (Details) link:presentationLink link:calculationLink link:definitionLink 00000046 - Disclosure - Contingent Liability (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000047 - Disclosure - Other Accrued Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 00000048 - Disclosure - Right of Use Assets (Details) link:presentationLink link:calculationLink link:definitionLink 00000049 - Disclosure - Right of Use Assets (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000050 - Disclosure - Right of Use Lease Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 00000051 - Disclosure - Right of Use Lease Liabilities (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000052 - Disclosure - Right of Use Lease Liabilities (Details 2) link:presentationLink link:calculationLink link:definitionLink 00000053 - Disclosure - Common Stock (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000054 - Disclosure - Subsequent Events (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 9 chcr-20200630_cal.xml XBRL CALCULATION FILE EX-101.DEF 10 chcr-20200630_def.xml XBRL DEFINITION FILE EX-101.LAB 11 chcr-20200630_lab.xml XBRL LABEL FILE Class of Stock [Axis] Series C Convertible Preferred [Member] Series D Convertible Preferred [Member] Remaining Preferred stock [Member] Long-term Debt, Type [Axis] Convertible Promissory Notes [Member] Short Term Notes Payable [Member] Loans Payable Related Party [Member] Asset Class [Axis] Property and equipment [Member] Range [Axis] Minimum [Member] Maximum [Member] Property, Plant and Equipment, Type [Axis] Leasehold Improvements [Member] Consolidated Entities [Axis] Advanzeon Parent [Member] Pharmacy Value Management Solutions Inc.[Member] Debt Instrument [Axis] Short Term One Note [Member] Loss Contingency Nature [Axis] Son of Former Note Holder [Member] Collateral [Axis] Automobiles [Member] Office [Member] Award Date [Axis] 2021 [Member] 2022 [Member] Equity Components [Axis] Common Stock PPP Loan [Member] Counterparty Name [Axis] Mechanics Bank [Member] 2023 [Member] Subsequent Event Type [Axis] Subsequent Event [Member] Convertible-promissory notes [Member] Class of Warrant or Right [Axis] Warrant [Member] Board Of Director Board Of Director Board Of Director Existing note holders [Member] Existing note holders [Member] Existing note holders [Member] Existing note holders [Member] Existing note holders [Member] Existing note holders [Member] Existing note holders [Member] Existing note holders [Member] Existing note holders [Member] Existing note holders [Member] Existing note holders [Member] Existing note holders [Member] Existing note holders [Member] Existing note holders [Member] Existing note holders [Member] Existing note holders [Member] Existing note holders [Member] Existing note holders [Member] Series C Convertible Preferred Stock Additional Paid-In Capital Accumulated Deficit Document and Entity Information [Abstract] Entity Registrant Name Entity Central Index Key Amendment Flag Amendment Description Current Fiscal Year End Date Document Type Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Entity Current Reporting Status Entity File Number Entity Filer Category Entity Shell Company Entity Small Business Entity Emerging Growth Company Entity Incorporation, State or Country Code Entity Interactive Data Current Entity Common Stock, Shares Outstanding Statement [Table] Statement [Line Items] ASSETS CURRENT ASSETS Cash Restricted cash Accounts receivable Current portion of right of use asset Other current assets Total current assets PROPERTY, PLANT, AND EQUIPMENT Property and equipment, net Leasehold improvements, net Total property, plant, and equipment RIGHT OF USE ASSET, NET OF CURRENT PORTION TOTAL ASSETS LIABILITIES AND STOCKHOLDERS' DEFICIENCY CURRENT LIABILITIES Related party loans payable Account payable Debt Contingent liability Current portion of lease liability Other accrued expenses Total current liabilities LEASE LIABILITY, NET OF CURRENT PORTION TOTAL LIABILITIES STOCKHOLDERS' DEFICIENCY Preferred stock, value Common stock, $0.01 par value; 1,000,000,000 shares authorized; 13,201,582 shares reserved 116,751,439 and 71,661,656 shares issued and outstanding as of June 30, 2020 and December 31, 2019, respectively Additional paid in capital Accumulated deficit Total stockholders' deficiency TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIENCY Preferred stock, par value (in dollars per share) Preferred stock, authorized Preferred stock, issued Preferred stock, outstanding Common stock, par value (in dollars per share) Common stock, authorized Common stock, issued Common stock, outstanding Common stock, share reserved Consolidated Statements Of Operations Revenues: Obstructive sleep apnea (OSA) Total revenues Costs and expenses: Costs of revenues General and administrative Depreciation and amortization Total costs and expenses Loss from operations Other income (expense): Interest expense Interest income Legal settlement Forgivable SBA EIBL loan advance Total other expense Net loss PER SHARE INFORMATION Net Loss Per Common Share Weighted Average Number of Common Shares Outstanding Balance Balance, shares Stock Issued for Services Stock Issued for Services (in shares) Sale of warrants Sale of stock Sale of stock, shares Net loss Balance Balance, shares Statement of Cash Flows [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES Net loss Adjustments to reconcile net loss to net cash used in operating activities: Stock issued for services Amortization of right of use assets Net changes in assets and liabilities: Accounts receivable Other current assets Payments on lease liabilities Accounts payable Other accrued expenses Net cash used in operating activities CASH FLOWS FROM INVESTING ACTIVITIES Purchase of property, plant, and equipment Net cash used in investing activities CASH FLOWS FROM FINANCING ACTIVITIES Proceeds from promissory notes Proceeds from PPP loan Payments on debt Sale of stock Net cash provided by financing activities Net increase (decrease) in cash CASH - Beginning of Year CASH AND RESTRICTED CASH - END OF PERIOD Supplemental disclosures of cash flow information: Cash paid during the period for: Interest Cash paid during the period for: Income taxes Recording of right of use assets under lease agreements (ASU 2016-02) Schedule of non-cash investing transactions: Convertible promissory note and accrued interest converted to common stock Organization, Consolidation and Presentation of Financial Statements [Abstract] DESCRIPTION OF THE COMPANY'S BUSINESS AND BASIS OF PRESENTATION Accounting Policies [Abstract] SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Other Current Assets CURRENT ASSETS Property, Plant and Equipment [Abstract] EX-101.PRE 12 chcr-20200630_pre.xml XBRL PRESENTATION FILE XML 13 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Jun. 30, 2020	Aug. 10, 2020
Document and Entity Information [Abstract]
Entity Registrant Name	Advanzeon Solutions, Inc.
Entity Central Index Key	0000022872
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Type	10-Q
Document Period End Date	Jun. 30, 2020
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2020
Entity Current Reporting Status	Yes
Entity File Number	1-9927
Entity Filer Category	Non-accelerated Filer
Entity Shell Company	false
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Incorporation, State or Country Code	DE
Entity Interactive Data Current	Yes
Entity Common Stock, Shares Outstanding		117,516,838

XML 14 R2.htm IDEA: XBRL DOCUMENT

Consolidated Balance Sheets (Unaudited) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
CURRENT ASSETS
Cash	$ 145,915	$ 69,327
Restricted cash	845,340
Accounts receivable	40,990	29,769
Current portion of right of use asset	136,230	113,911
Other current assets	657,025	826,597
Total current assets	1,825,500	1,039,604
PROPERTY, PLANT, AND EQUIPMENT
Property and equipment, net	5,683	1,239
Leasehold improvements, net
Total property, plant, and equipment	5,683	1,239
RIGHT OF USE ASSET, NET OF CURRENT PORTION	179,221	146,880
TOTAL ASSETS	2,010,404	1,187,723
CURRENT LIABILITIES
Related party loans payable	102,229	342,670
Account payable	403,265	99,441
Debt	10,416,176	12,352,189
Contingent liability	642,659	642,659
Current portion of lease liability	136,230	113,911
Other accrued expenses	13,742,192	15,891,787
Total current liabilities	25,442,751	29,442,657
LEASE LIABILITY, NET OF CURRENT PORTION	179,221	146,880
TOTAL LIABILITIES	25,621,972	29,589,537
STOCKHOLDERS' DEFICIENCY
Preferred stock, value
Common stock, $0.01 par value; 1,000,000,000 shares authorized; 13,201,582 shares reserved 116,751,439 and 71,661,656 shares issued and outstanding as of June 30, 2020 and December 31, 2019, respectively	1,167,514	716,617
Additional paid in capital	35,361,980	28,719,246
Accumulated deficit	(60,141,072)	(57,837,687)
Total stockholders' deficiency	(23,611,568)	(28,401,814)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIENCY	2,010,404	1,187,723
Series C Convertible Preferred [Member]
STOCKHOLDERS' DEFICIENCY
Preferred stock, value	10	10
Series D Convertible Preferred [Member]
STOCKHOLDERS' DEFICIENCY
Preferred stock, value
Remaining Preferred stock [Member]
STOCKHOLDERS' DEFICIENCY
Preferred stock, value

XML 15 R3.htm IDEA: XBRL DOCUMENT

Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Jun. 30, 2020	Dec. 31, 2019
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, authorized	1,000,000	1,000,000
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, authorized	1,000,000,000	1,000,000,000
Common stock, issued	116,751,439	71,661,656
Common stock, outstanding	116,751,439	71,661,656
Common stock, share reserved	13,201,582
Series C Convertible Preferred [Member]
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, authorized	14,400	14,400
Preferred stock, issued	10,434	10,434
Preferred stock, outstanding	10,434	10,434
Series D Convertible Preferred [Member]
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, authorized	7,000	7,000
Preferred stock, issued	250	250
Preferred stock, outstanding	250	250
Remaining Preferred stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, authorized	978,600	978,600

XML 16 R4.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Revenues:
Obstructive sleep apnea (OSA)	$ 103,444	$ 90,453	$ 230,992	$ 158,376
Total revenues	103,444	90,453	230,992	158,376
Costs and expenses:
Costs of revenues	65,000	66,157	129,909	107,817
General and administrative	715,397	416,039	1,311,462	841,843
Depreciation and amortization	312	235	623	440
Total costs and expenses	780,709	482,431	1,441,994	950,100
Loss from operations	(677,265)	(391,978)	(1,211,002)	(791,724)
Other income (expense):
Interest expense	(707,774)	(341,178)	(1,102,403)	(669,193)
Interest income		5,994	20	5,994
Legal settlement		112,172		112,172
Forgivable SBA EIBL loan advance	10,000		10,000
Total other expense	(697,774)	(223,012)	(1,092,383)	(551,027)
Net loss	$ (1,375,039)	$ (614,990)	$ (2,303,385)	$ (1,342,751)
PER SHARE INFORMATION
Net Loss Per Common Share	$ (0.01)	$ (0.01)	$ (0.02)	$ (0.02)
Weighted Average Number of Common Shares Outstanding	79,534,495	67,361,656	75,598,076	67,027,954

XML 17 R5.htm IDEA: XBRL DOCUMENT

CONSOLIDATED STATEMENT OF STOCKHOLDERS’ EQUITY (DEFICIENCY) (Unaudited) - USD ($)	Series C Convertible Preferred Stock	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Total
Balance at Dec. 31, 2018	$ 10	$ 666,617	$ 28,012,007	$ (54,581,873)	$ (25,903,239)
Balance, shares at Dec. 31, 2018	10,434	66,661,656
Stock Issued for Services		$ 2,000	14,000		16,000
Stock Issued for Services (in shares)		200,000
Sale of stock		$ 5,000	10,000		15,000
Sale of stock, shares		500,000
Net loss				(727,761)	(727,761)
Balance at Mar. 31, 2019	$ 10	$ 673,617	28,036,007	(55,309,634)	(26,600,000)
Balance, shares at Mar. 31, 2019	10,434	67,361,656
Stock Issued for Services
Stock Issued for Services (in shares)
Sale of stock
Sale of stock, shares
Net loss				(614,990)	(614,990)
Balance at Jun. 30, 2019	$ 10	$ 673,617	28,036,007	(55,924,624)	(27,214,990)
Balance, shares at Jun. 30, 2019	10,434	67,361,656
Stock Issued for Services
Stock Issued for Services (in shares)
Sale of stock
Sale of stock, shares
Net loss				(747,801)	(747,801)
Balance at Sep. 30, 2019	$ 10	$ 673,617	28,036,007	(56,672,425)	(27,962,791)
Balance, shares at Sep. 30, 2019	10,434	67,361,656
Stock Issued for Services		$ 43,000	430,000		473,000
Stock Issued for Services (in shares)		4,300,000
Sale of warrants			253,239		253,239
Sale of stock
Net loss				(1,165,262)	(1,165,262)
Balance at Dec. 31, 2019	$ 10	$ 716,617	28,719,246	(57,837,687)	(28,401,814)
Balance, shares at Dec. 31, 2019	10,434	71,661,656
Stock Issued for Services
Stock Issued for Services (in shares)
Sale of warrants
Sale of stock
Sale of stock, shares
Net loss				(928,346)	(928,346)
Balance at Mar. 31, 2020	$ 10	$ 1,167,514	35,361,980	(60,141,072)	(23,611,568)
Balance, shares at Mar. 31, 2020	10,434	116,751,439
Sale of warrants			18,251		18,251
Sale of stock		$ 450,897	6,624,483		7,075,380
Sale of stock, shares		45,089,783
Net loss				(1,375,039)	(1,375,039)
Balance at Jun. 30, 2020	$ 10	$ 1,167,514	$ 35,361,980	$ (60,141,072)	$ (23,611,568)
Balance, shares at Jun. 30, 2020	10,434	116,751,439

- Definition

The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=116874947&loc=SL4591551-111686

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3000-108585

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4K
-URI http://asc.fasb.org/extlink&oid=116874947&loc=SL4591552-111686

+ Details

XML 18 R6.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (2,303,385)	$ (1,342,751)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	623	440
Stock issued for services		16,000
Amortization of right of use assets	54,660	25,579
Net changes in assets and liabilities:
Accounts receivable	(11,221)	(2,756)
Other current assets	169,572	(712,065)
Payments on lease liabilities	(54,660)	(25,579)
Accounts payable	51,383	210,951
Other accrued expenses	1,215,572	742,356
Net cash used in operating activities	(877,456)	(1,087,825)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of property, plant, and equipment	(5,067)	(1,549)
Net cash used in investing activities	(5,067)	(1,549)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from promissory notes	559,360	1,070,250
Proceeds from PPP loan	1,243,840
Payments on debt	(17,000)
Sale of stock	18,251	15,000
Net cash provided by financing activities	1,804,451	1,085,250
Net increase (decrease) in cash	921,928	(4,124)
CASH - Beginning of Year	69,327	25,036
CASH AND RESTRICTED CASH - END OF PERIOD	991,255	20,912
Supplemental disclosures of cash flow information:
Cash paid during the period for: Interest
Cash paid during the period for: Income taxes
Recording of right of use assets under lease agreements (ASU 2016-02)		119,640
Schedule of non-cash investing transactions:
Convertible promissory note and accrued interest converted to common stock	$ 7,075,380

XML 19 R7.htm IDEA: XBRL DOCUMENT

Description of The Company's Business and Basis of Presentation

6 Months Ended

Jun. 30, 2020

Organization, Consolidation and Presentation of Financial Statements [Abstract]

DESCRIPTION OF THE COMPANY'S BUSINESS AND BASIS OF PRESENTATION

DESCRIPTION OF THE COMPANY’S BUSINESS AND BASIS OF PRESENTATION

XML 20 R8.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies

6 Months Ended

Jun. 30, 2020

Accounting Policies [Abstract]

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Inter-company accounts and transactions have been eliminated in consolidation. Certain minor reclassifications of prior period amounts have been made to conform to the current period presentation.

The carrying amounts of long-term debt and estimated fair values of the attached warrants at June 30, 2020 and December 31, 2019 are as follows:

	June 30, 2020				December 31, 2019
			Estimated				Estimated
			Fair Value of				Fair Value of
	Carrying		Attached		Carrying		Attached
	Amount		Warrants		Amount		Warrants

Convertible promissory notes	$	5,956,533	$	—	$	7,564,173	$	—
Short term notes payable		3,215,803		—		4,788,016		—
Loan payable related party		102,229		—		342,670		—
PPP Loan		1,243,840		—		—		—
	$	10,518,405	$	—	$	12,694,859	$	—

Cost of Revenues - Costs of services consist of supplies and operating expenses. Supplies are recognized in the period in which a patient receives the supplies.

XML 21 R9.htm IDEA: XBRL DOCUMENT

Current Assets

6 Months Ended

Jun. 30, 2020

Other Current Assets

CURRENT ASSETS

Cash and restricted cash consists of the following at June 30, 2020 and December 31, 2019:

	June 30, 2020		December 31, 2019

Cash	$	145,915	$	69,327
Restricted Cash		845,340		—

Total cash and restricted cash shown in the
consolidated statement of cash flows	$	991,255	$	69,327

Other current assets consists of the following at June 30, 2020 and December 31, 2019:

	June 30, 2020		December 31, 2019

Loans to others	$	34,406	$	42,676
Security and lease deposits		3,500		3,500
Capitalized portion of lease		1,237		1,808
Prepaid expenses		288,487		452,953
Miscellaneous receivable		329,395		325,660

Other current asset	$	657,025	$	826,597

XML 22 R10.htm IDEA: XBRL DOCUMENT

Property and Equipment

6 Months Ended

Jun. 30, 2020

PROPERTY, PLANT, AND EQUIPMENT

PROPERTY AND EQUIPMENT

Property and equipment, net, consists of the following at June 30, 2020 and December 31, 2019:

	June 30, 2020			December 31, 2019

Property and equipment	$	6,616		$	1,549
Less accumulated depreciation		(933	)		(310	)
Property and equipment - net	$	5,683		$	1,239

Depreciation expense for the six-month periods ended June 30, 2020 and 2019 is $623 and $141, respectively. A laptop was acquired in January of 2020.

XML 23 R11.htm IDEA: XBRL DOCUMENT

Leasehold Improvement

6 Months Ended

Jun. 30, 2020

Leases [Abstract]

LEASEHOLD IMPROVEMENT

Leasehold improvement, net, consists of the following at June 30, 2020 and December 31, 2019:

	June 30, 2020			December 31, 2019

Leasehold improvements	$	2,992		$	2,992
Less accumulated amortization		(2,992	)		(2,992	)
Leasehold improvements - net	$	—		$	—

Amortization expense for the six-month periods ended June 30, 2020 and 2019 is $0 and $299, respectively.

XML 24 R12.htm IDEA: XBRL DOCUMENT

Related Party Loans Payable

6 Months Ended

Jun. 30, 2020

RELATED PARTY LOANS PAYABLE

As of June 30, 2020 and December 31, 2019, there are the following related party notes payable:

	June 30, 2020		December 31, 2019

Related party loans payable	$	102,229	$	342,670

XML 25 R13.htm IDEA: XBRL DOCUMENT

Debt

6 Months Ended

Jun. 30, 2020

Notes Payable [Abstract]

Debt

DEBT

As of June 30, 2020 and December 31, 2019, the balance was as follows:

	June 30, 2020		December 31, 2019

Notes payable	$	10,416,176	$	12,352,189

Break-out of debt between the parent company and our subsidiary PVMS is as follows:

	June 30, 2020		December 31, 2019

Advanzeon parent	$	3,381,163	$	5,010,016
PVMS		7,035,013		7,342,173
	$	10,416,176	$	12,352,189

At Advanzeon, the total notes issued year-to-date and their dollar values were as follows:

	June 30, 2020		December 31, 2019

Number of notes issued		2		—

Dollar value	$	165,360	$	—

All debts issued during the six-month period ended June 30, 2020 are short-term in nature and have a stated interest rate of 10%.

At PVMS, the total of notes issued year-to-date and their dollar values were as follows:

	June 30, 2020		December 31, 2019

Number of notes issued		8		51

Dollar value	$	382,000	$	2,289,250

All debt is short-term in nature, one-year maturity date. All debt issued has a stated interest rate of 12%.

XML 26 R14.htm IDEA: XBRL DOCUMENT

Contingent Liability

6 Months Ended

Jun. 30, 2020

Contingent Liability

CONTINGENT LIABILITY

Contingent liability consisted of 3 items:

Interest payable in the amount of $171,247 to the same person listed in (1). This interest is related to the lawsuit referenced in (1).

Advanzeon won a decision on a court case against Universal Healthcare. The attorney's fees relating to this matter total $21,412. This fee will be paid out of the proceeds of the case when collected.

As of June 30, 2020 and December 31, 2019, the balance of this indebtedness is as follows:

	June 30, 2020		December 31, 2019

Disputed note payable	$	450,000	$	450,000
Disputed interest payable		171,247		171,247
Pending attorney fees		21,412		21,412

Total contingent liability	$	642,659	$	642,659

XML 27 R15.htm IDEA: XBRL DOCUMENT

Other Accrued Liabilities

6 Months Ended

Jun. 30, 2020

Other Accrued Liabilities

OTHER ACCRUED LIABILITIES

As of June 30, 2020 and December 31, 2019, the balance of other accrued liabilities is as follows:

	June 30, 2020		December 31, 2019

Management compensation	$	8,907,258	$	8,873,802
Accrued interest non-related party		4,760,728		5,956,368
Board of Director fees		37,500		1,050,000
State fees		—		2,800
Payroll liabilities		14,047		—
Other accrued liabilities		22,659		8,817
Total other accrued debt	$	13,742,192	$	15,891,787

XML 28 R16.htm IDEA: XBRL DOCUMENT

Right of Use Assets

6 Months Ended

Jun. 30, 2020

Notes to Financial Statements

RIGHT OF USE ASSETS

10.

RIGHT OF USE ASSETS

As of June 30, 2020, the right of use assets associated with future operating leases are as follows:

Total present value of right of use assets
under lease agreements	$	368,870

Amortization of right of use assets		(53,419	)

Total right of use assets as of June 30, 2020	$	315,451

Total amortization expense related to the right of use assets under the lease agreements was $54,660 and $25,579 for the six-month periods ended June 30, 2020 and 2019, respectively.

XML 29 R17.htm IDEA: XBRL DOCUMENT

Right of Use Lease Liabilities

6 Months Ended

Jun. 30, 2020

Notes to Financial Statements

RIGHT OF USE LEASE LIABILITIES

11.

RIGHT OF USE LEASE LIABILITIES

As disclosed in Note 10, the Company entered into two leases for office space prior to the quarter ended June 30, 2020 that are classified as right of use assets and lease liabilities.

As of June 30, 2020, the lease liabilities associated with future payments due under the leases are as follows:

Total present value of future lease payments	$	368,870

Principal payments made as of the six month period ended June 30, 2020		(53,419	)

Total right of use lease liabilities as of June 30, 2020	$	315,451

The following is a schedule of future minimum lease payments under the right of use lease agreements together with the present value of the net minimum lease payments as of June 30, 2020:

Total future minimum lease payments	$	336,671

Less present value discount		21,220

Total right of use lease liabilities as of June 30, 2020		315,451

Less current portion due within one year		136,230

Long-term right of use liabilities	$	179,221

Total maturities of lease liabilities as of June 30, 2020 are as follows:

	Total future
	minimum lease		Present value		Right of use
	payments		discount		lease liabilities
2021	$	150,103	$	13,873	$	136,230
2022		146,568		6,358		140,210
2023		40,000		989		39,011
	$	336,671	$	21,220	$	315,451

XML 30 R18.htm IDEA: XBRL DOCUMENT

Common Stock

6 Months Ended

Jun. 30, 2020

Common Stock Abstract

COMMON STOCK

12.

COMMON STOCK

During the six-month period ended June 30, 2020, the Company issued 45,089,783 shares of its common stock as follows:

During the six-month period ended June 30, 2019, the Company issued 700,000 shares of its common stock as follows:

XML 31 R19.htm IDEA: XBRL DOCUMENT

Legal Proceedings

6 Months Ended

Jun. 30, 2020

Legal Proceedings

LEGAL PROCEEDINGS

13.

LEGAL PROCEEDINGS

Except as disclosed above and in Item 1, all of the legal proceedings for the six-month period ended June 30, 2020, are disclosed in our annual report on Form10-K filed on April 9, 2020.

XML 32 R20.htm IDEA: XBRL DOCUMENT

Subsequent Events

6 Months Ended

Jun. 30, 2020

Subsequent Events [Abstract]

SUBSEQUENT EVENTS

14.

SUBSEQUENT EVENTS

Issuance of debt and warrants

Stock issued for conversion of debt and accrued interest

The Company issued 765,399 shares of common stock for the conversion of debt and accrued interest. The total debt and accrued interest converted was $84,194 or $0.11 per share.

XML 33 R21.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Policies)

6 Months Ended

Jun. 30, 2020

Accounting Policies [Abstract]

Use of Estimates

Accounts Receivable

Revenue recognition

Property and Equipment

Leasehold Improvement

Fair Value Measurements

The carrying amounts of long-term debt and estimated fair values of the attached warrants at June 30, 2020 and December 31, 2019 are as follows:

	June 30, 2020				December 31, 2019
			Estimated				Estimated
			Fair Value of				Fair Value of
	Carrying		Attached		Carrying		Attached
	Amount		Warrants		Amount		Warrants

Convertible promissory notes	$	5,956,533	$	—	$	7,564,173	$	—
Short term notes payable		3,215,803		—		4,788,016		—
Loan payable related party		102,229		—		342,670		—
PPP Loan		1,243,840		—		—		—
	$	10,518,405	$	—	$	12,694,859	$	—

Cost of Revenues - Costs of services consist of supplies and operating expenses. Supplies are recognized in the period in which a patient receives the supplies.

Cost of Revenues

Cost of Revenues - Costs of services consist of supplies and operating expenses. Supplies are recognized in the period in which a patient receives the supplies.

Right of Use Assets and Lease Liabilities

Income Taxes

Concentration of Credit Risk

Stock Options and Warrants

XML 34 R22.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Tables)

6 Months Ended

Jun. 30, 2020

Accounting Policies [Abstract]

Schedule of carrying and estimated fair values of financial instruments

The carrying amounts of long-term debt and estimated fair values of the attached warrants at June 30, 2020 and December 31, 2019 are as follows:

	June 30, 2020				December 31, 2019
			Estimated				Estimated
			Fair Value of				Fair Value of
	Carrying		Attached		Carrying		Attached
	Amount		Warrants		Amount		Warrants

Convertible promissory notes	$	5,956,533	$	—	$	7,564,173	$	—
Short term notes payable		3,215,803		—		4,788,016		—
Loan payable related party		102,229		—		342,670		—
PPP Loan		1,243,840		—		—		—
	$	10,518,405	$	—	$	12,694,859	$	—

XML 35 R23.htm IDEA: XBRL DOCUMENT

Current Assets (Tables)

6 Months Ended

Jun. 30, 2020

Other Current Assets

Schedule of Cash and restricted cash

Cash and restricted cash consists of the following at June 30, 2020 and December 31, 2019:

	June 30, 2020		December 31, 2019

Cash	$	145,915	$	69,327
Restricted Cash		845,340		—

Total cash and restricted cash shown in the
consolidated statement of cash flows	$	991,255	$	69,327

Schedule of other current assets

Other current assets consists of the following at June 30, 2020 and December 31, 2019:

	June 30, 2020		December 31, 2019

Loans to others	$	34,406	$	42,676
Security and lease deposits		3,500		3,500
Capitalized portion of lease		1,237		1,808
Prepaid expenses		288,487		452,953
Miscellaneous receivable		329,395		325,660

Other current asset	$	657,025	$	826,597

XML 36 R24.htm IDEA: XBRL DOCUMENT

Property and Equipment (Tables)

6 Months Ended

Jun. 30, 2020

PROPERTY, PLANT, AND EQUIPMENT

Schedule of property and equipment, net

Property and equipment, net, consists of the following at June 30, 2020 and December 31, 2019:

	June 30, 2020			December 31, 2019

Property and equipment	$	6,616		$	1,549
Less accumulated depreciation		(933	)		(310	)
Property and equipment - net	$	5,683		$	1,239

XML 37 R25.htm IDEA: XBRL DOCUMENT

Leasehold Improvement (Tables)

6 Months Ended

Jun. 30, 2020

Leases [Abstract]

Schedule of leasehold improvement, net

Leasehold improvement, net, consists of the following at June 30, 2020 and December 31, 2019:

	June 30, 2020			December 31, 2019

Leasehold improvements	$	2,992		$	2,992
Less accumulated amortization		(2,992	)		(2,992	)
Leasehold improvements - net	$	—		$	—

XML 38 R26.htm IDEA: XBRL DOCUMENT

Related Party Loans Payable (Tables)

6 Months Ended

Jun. 30, 2020

Schedule of related party notes payable

As of June 30, 2020 and December 31, 2019, there are the following related party notes payable:

	June 30, 2020		December 31, 2019

Related party loans payable	$	102,229	$	342,670

XML 39 R27.htm IDEA: XBRL DOCUMENT

Debt (Tables)

6 Months Ended

Jun. 30, 2020

Schedule of notes payable

As of June 30, 2020 and December 31, 2019, the balance was as follows:

	June 30, 2020		December 31, 2019

Notes payable	$	10,416,176	$	12,352,189

Schedule of break-out of debt

Break-out of debt between the parent company and our subsidiary PVMS is as follows:

	June 30, 2020		December 31, 2019

Advanzeon parent	$	3,381,163	$	5,010,016
PVMS		7,035,013		7,342,173
	$	10,416,176	$	12,352,189

Advanzeon Parent [Member]

Schedule of notes issued

At Advanzeon, the total notes issued year-to-date and their dollar values were as follows:

	June 30, 2020		December 31, 2019

Number of notes issued		2		—

Dollar value	$	165,360	$	—

Pharmacy Value Management Solutions Inc.[Member]

Schedule of notes issued

At PVMS, the total of notes issued year-to-date and their dollar values were as follows:

	June 30, 2020		December 31, 2019

Number of notes issued		8		51

Dollar value	$	382,000	$	2,289,250

XML 40 R28.htm IDEA: XBRL DOCUMENT

Contingent Liability (Tables)

6 Months Ended

Jun. 30, 2020

Contingent Liability

Schedule of contingent liability

As of June 30, 2020 and December 31, 2019, the balance of this indebtedness is as follows:

	June 30, 2020		December 31, 2019

Disputed note payable	$	450,000	$	450,000
Disputed interest payable		171,247		171,247
Pending attorney fees		21,412		21,412

Total contingent liability	$	642,659	$	642,659

- Definition

Tabular disclosure of the loss contingencies that were reported in the period or disclosed as of the balance sheet date.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=118942415&loc=d3e14472-108349

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=118942415&loc=d3e14326-108349

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=118942415&loc=d3e14453-108349

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=118942415&loc=d3e14615-108349

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 460
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=118943654&loc=d3e12021-110248

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=118942415&loc=d3e14394-108349

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=118942415&loc=d3e14435-108349

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=118942415&loc=d3e14557-108349

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 460
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=118943654&loc=d3e12053-110248

+ Details

XML 41 R29.htm IDEA: XBRL DOCUMENT

Other Accrued Liabilities (Tables)

6 Months Ended

Jun. 30, 2020

Other Accrued Liabilities

Schedule of other accrued liabilities

As of June 30, 2020 and December 31, 2019, the balance of other accrued liabilities is as follows:

	June 30, 2020		December 31, 2019

Management compensation	$	8,907,258	$	8,873,802
Accrued interest non-related party		4,760,728		5,956,368
Board of Director fees		37,500		1,050,000
State fees		—		2,800
Payroll liabilities		14,047		—
Other accrued liabilities		22,659		8,817
Total other accrued debt	$	13,742,192	$	15,891,787

XML 42 R30.htm IDEA: XBRL DOCUMENT

Right of Use Assets (Tables)

6 Months Ended

Jun. 30, 2020

Notes to Financial Statements

Schedule of right of use assets associated with future operating leases

As of June 30, 2020, the right of use assets associated with future operating leases are as follows:

Total present value of right of use assets
under lease agreements	$	368,870

Amortization of right of use assets		(53,419	)

Total right of use assets as of June 30, 2020	$	315,451

XML 43 R31.htm IDEA: XBRL DOCUMENT

Right of Use Lease Liabilities (Tables)

6 Months Ended

Jun. 30, 2020

Notes to Financial Statements

Schedule of lease liabilities associated with future payments due under the leases

As of June 30, 2020, the lease liabilities associated with future payments due under the leases are as follows:

Total present value of future lease payments	$	368,870

Principal payments made as of the six month period ended June 30, 2020		(53,419	)

Total right of use lease liabilities as of June 30, 2020	$	315,451

Schedule of future minimum lease payments under the right of use lease agreements

The following is a schedule of future minimum lease payments under the right of use lease agreements together with the present value of the net minimum lease payments as of June 30, 2020:

Total future minimum lease payments	$	336,671

Less present value discount		21,220

Total right of use lease liabilities as of June 30, 2020		315,451

Less current portion due within one year		136,230

Long-term right of use liabilities	$	179,221

Schedule of maturities of lease liabilities

Total maturities of lease liabilities as of June 30, 2020 are as follows:

	Total future
	minimum lease		Present value		Right of use
	payments		discount		lease liabilities
2021	$	150,103	$	13,873	$	136,230
2022		146,568		6,358		140,210
2023		40,000		989		39,011
	$	336,671	$	21,220	$	315,451

XML 44 R32.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Details) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Schedule of carrying and estimated fair values of financial instruments
Carrying Amount	$ 10,518,405	$ 12,694,859
Estimated Fair Value of Attached Warrants
Convertible Promissory Notes [Member]
Schedule of carrying and estimated fair values of financial instruments
Carrying Amount	5,956,533	7,564,173
Estimated Fair Value of Attached Warrants
Short Term Notes Payable [Member]
Schedule of carrying and estimated fair values of financial instruments
Carrying Amount	3,215,803	4,788,016
Estimated Fair Value of Attached Warrants
Loans Payable Related Party [Member]
Schedule of carrying and estimated fair values of financial instruments
Carrying Amount	102,229	342,670
Estimated Fair Value of Attached Warrants
PPP Loan [Member]
Schedule of carrying and estimated fair values of financial instruments
Carrying Amount	1,243,840
Estimated Fair Value of Attached Warrants

XML 45 R33.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Details Narrative)	6 Months Ended
	Jun. 30, 2020 USD ($) Number	Dec. 31, 2019 USD ($)
Convertible notes	$ 547,360
Convertible notes plus accured interest	3,727,213
Amount insured by FDIC	250,000
Uninsured cash balance	$ 595,340	$ 0
Short Term One Note [Member]
Number of additional notes \| Number	10
Number of convertible notes \| Number	53
Property and equipment [Member] \| Minimum [Member]
Useful Life	2 years
Property and equipment [Member] \| Maximum [Member]
Useful Life	12 years

XML 46 R34.htm IDEA: XBRL DOCUMENT

Current Assets (Details) - USD ($)	Jun. 30, 2020	Dec. 31, 2019	Jun. 30, 2019	Dec. 31, 2018
Current Assets
Cash	$ 145,915	$ 69,327
Restricted Cash	845,340
Total cash and restricted cash shown in the consolidated statement of cash flows	$ 991,255	$ 69,327	$ 20,912	$ 25,036

XML 47 R35.htm IDEA: XBRL DOCUMENT

Current Assets (Details 1) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Other Current Assets
Loans to others	$ 34,406	$ 42,676
Security deposit	3,500	3,500
Capitalized portion of lease	1,237	1,808
Prepaid expenses	288,487	452,953
Miscellaneous receivable	329,395	325,660
Other current asset	$ 657,025	$ 826,597

XML 48 R36.htm IDEA: XBRL DOCUMENT

Property and Equipment (Details) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
PROPERTY, PLANT, AND EQUIPMENT
Property and equipment	$ 6,616	$ 1,549
Less accumulated depreciation	(933)	(310)
Property and equipment - net	$ 5,683	$ 1,239

XML 49 R37.htm IDEA: XBRL DOCUMENT

Property and Equipment (Details Narrative) - USD ($)	6 Months Ended
Property and Equipment (Details Narrative) - USD ($)	Jun. 30, 2020	Jun. 30, 2019
PROPERTY, PLANT, AND EQUIPMENT
Depreciation expense	$ 623	$ 141

XML 50 R38.htm IDEA: XBRL DOCUMENT

Leasehold Improvement (Details) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Leasehold improvement
Leasehold Improvements [Member]
Leasehold improvement	2,992	2,992
Less accumulated amortization	(2,992)	(2,992)
Leasehold improvement - net

XML 51 R39.htm IDEA: XBRL DOCUMENT

Leasehold Improvement (Details Narrative) - USD ($)	6 Months Ended
Leasehold Improvement (Details Narrative) - USD ($)	Jun. 30, 2020	Jun. 30, 2019
Leases [Abstract]
Amortization expense	$ 0	$ 299

XML 52 R40.htm IDEA: XBRL DOCUMENT

Related Party Loans Payable (Details) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Related Party Transactions [Abstract]
Related party loans payable	$ 102,229	$ 342,670

XML 53 R41.htm IDEA: XBRL DOCUMENT

Debt (Details) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Notes Payable [Abstract]
Notes payable	$ 10,416,176	$ 12,352,189

XML 54 R42.htm IDEA: XBRL DOCUMENT

Debt (Details 1) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Notes payable	$ 10,416,176	$ 12,352,189
Advanzeon Parent [Member]
Notes payable	3,381,163	5,010,016
Pharmacy Value Management Solutions Inc.[Member]
Notes payable	$ 7,035,013	$ 7,342,173

XML 55 R43.htm IDEA: XBRL DOCUMENT

Debt (Details 2) - USD ($)	6 Months Ended	12 Months Ended
Debt (Details 2) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Advanzeon Parent [Member]
Number of notes issued	2
Dollar value	$ 165,360
Pharmacy Value Management Solutions Inc.[Member]
Number of notes issued	8	51
Dollar value	$ 382,000	$ 2,289,250

XML 56 R44.htm IDEA: XBRL DOCUMENT

Debt (Details Narrative)	6 Months Ended
Debt (Details Narrative)	Jun. 30, 2020 USD ($) Number shares
Maturity date	One-year
Description of interest rate	All debt issued has a stated interest rate of 12%
Stated interest rate	10.00%
Convertible notes plus accured interest	$ 3,727,213
Notes converted in shares \| shares	39,652,283
Pharmacy Value Management Solutions Inc.[Member] \| Mechanics Bank [Member]
Frozen account balance	$ 845,340
Short Term One Note [Member]
Stated interest rate	12.00%
Number of additional notes \| Number	10
Debt converted into stock	$ 547,360
Number of convertible notes \| Number	53
PPP Loan [Member] \| Pharmacy Value Management Solutions Inc.[Member] \| Mechanics Bank [Member]
Loan received	$ 1,243,840

XML 57 R45.htm IDEA: XBRL DOCUMENT

Contingent Liability (Details) - USD ($)	6 Months Ended	12 Months Ended
Contingent Liability (Details) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Contingent Liability
Disputed note payable	$ 450,000	$ 450,000
Disputed interest payable	171,247	171,247
Pending attorney fees	21,412	21,412
Total contingent liability	$ 642,659	$ 642,659

XML 58 R46.htm IDEA: XBRL DOCUMENT

Contingent Liability (Details Narrative) - USD ($)	6 Months Ended	12 Months Ended
Contingent Liability (Details Narrative) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Disputed interest payable	$ 171,247	$ 171,247
Attorney fees	21,412	$ 21,412
Son of Former Note Holder [Member]
Contingent liability	450,000
Disputed interest payable	171,247
Attorney fees	$ 21,412

XML 59 R47.htm IDEA: XBRL DOCUMENT

Other Accrued Liabilities (Details) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Other Accrued Liabilities
Management compensation	$ 8,907,258	$ 8,873,802
Accrued interest non-related party	4,760,728	5,956,368
Board of Director fees	37,500	1,050,000
State fees		2,800
Payroll liabilities	14,047
Accrued wages and related	22,659	8,817
Total other accrued debt	$ 13,742,192	$ 15,891,787

XML 60 R48.htm IDEA: XBRL DOCUMENT

Right of Use Assets (Details)	6 Months Ended
Right of Use Assets (Details)	Jun. 30, 2020 USD ($)
Right Of Use Assets
Total present value of right of use assets under lease agreements	$ 368,870
Amortization of right of use assets	(53,419)
Total right of use assets	$ 315,451

XML 61 R49.htm IDEA: XBRL DOCUMENT

Right of Use Assets (Details Narrative) - USD ($)	6 Months Ended
Right of Use Assets (Details Narrative) - USD ($)	Jun. 30, 2020	Jun. 30, 2019
Lease, description	The Company entered into two leases, one for office space and one automobile lease that are classified as right of use assets and lease liabilities. The Company pays the lease payments on a residential unit in California that is used as an office/residential unit for certain of its marketing personnel. The lease is on a month-to month basis. The Company has occupied this unit for the past approximately 1-1/2 year period and intends to do so for the foreseeable future. The lease for the Company’s office space expire in June 2022.The lease for the automobile expires in June 2021.As the implicit interest rate is not readily identifiable in the leases, the Company calculated the present value of the leases using the average commercial real estate interest rate of 5.50% at the commencement of the office leases and the interest of 2.99% for the automobile lease. Applying the commercial rate, the Company calculated the present value of $339,833 for the office leases and $29,037 for the automobile leasing that are being amortized over the life of the leases.
Total amortization expenses	$ 54,660	$ 25,579
Automobiles [Member]
Present value of lease	$ 29,037
Interest rate	2.99%
Office [Member]
Present value of lease	$ 339,833
Interest rate	5.50%

XML 62 R50.htm IDEA: XBRL DOCUMENT

Right of Use Lease Liabilities (Details)	Jun. 30, 2020 USD ($)
Right Of Use Lease Liabilities
Total present value of future lease payments	$ 368,870
Principal payments made	(53,419)
Total right of use lease liabilities	$ 315,451

XML 63 R51.htm IDEA: XBRL DOCUMENT

Right of Use Lease Liabilities (Details 1) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Right Of Use Lease Liabilities
Total future minimum lease payments	$ 336,671
Less present value discount	21,220
Total right of use lease liabilities	315,451
Less current portion due within one year	136,230	$ 113,911
Long-term right of use liabilities	$ 179,221	$ 146,880

XML 64 R52.htm IDEA: XBRL DOCUMENT

Right of Use Lease Liabilities (Details 2)	Jun. 30, 2020 USD ($)
Total future minimum lease payments	$ 336,671
Present value discount	21,220
Right of use lease liabilities	315,451
2021 [Member]
Total future minimum lease payments	150,103
Present value discount	13,873
Right of use lease liabilities	136,230
2022 [Member]
Total future minimum lease payments	146,568
Present value discount	6,358
Right of use lease liabilities	140,210
2023 [Member]
Total future minimum lease payments	40,000
Present value discount	989
Right of use lease liabilities	$ 39,011

XML 65 R53.htm IDEA: XBRL DOCUMENT

Common Stock (Details Narrative) - USD ($)						1 Months Ended										6 Months Ended
Common Stock (Details Narrative) - USD ($)	Jun. 12, 2020	Jun. 05, 2020	Jun. 01, 2020	May 15, 2020	Apr. 02, 2020	Jun. 18, 2020	May 29, 2020	May 28, 2020	May 26, 2020	May 25, 2020	May 21, 2020	May 18, 2020	Apr. 21, 2020	Mar. 29, 2019	Mar. 21, 2019	Jun. 30, 2019
Board Of Director
Share price					$ 0.20
Stock issued for services, Shares					3,262,500
Stock issued for services, value					$ 652,500
Board Of Director
Share price					$ 0.20
Stock issued for services, Shares					1,087,500
Stock issued for services, value					$ 217,500
Board Of Director
Share price					$ 0.20
Stock issued for services, Shares					1,087,500
Stock issued for services, value					$ 217,500
Existing note holders [Member]
Share price													$ 0.20
Stock issued for debt conversion, Shares													14,584,350
Stock issued for debt conversion, Value													$ 2,916,869
Existing note holders [Member]
Share price													$ 0.20
Stock issued for debt conversion, Shares													1,327,252
Stock issued for debt conversion, Value													$ 265,450
Existing note holders [Member]
Share price													$ 0.20
Stock issued for debt conversion, Shares													2,156,515
Stock issued for debt conversion, Value													$ 431,303
Existing note holders [Member]
Share price				$ 0.11
Stock issued for debt conversion, Shares				1,263,745
Stock issued for debt conversion, Value				$ 139,012
Existing note holders [Member]
Share price				$ 0.11
Stock issued for debt conversion, Shares				4,284,565
Stock issued for debt conversion, Value				$ 471,302
Existing note holders [Member]
Share price				$ 0.11
Stock issued for debt conversion, Shares				7,210,168
Stock issued for debt conversion, Value				$ 793,118
Existing note holders [Member]
Share price												$ 0.11
Stock issued for debt conversion, Shares												700,751
Stock issued for debt conversion, Value												$ 77,083
Existing note holders [Member]
Share price											$ 0.11
Stock issued for debt conversion, Shares											502,434
Stock issued for debt conversion, Value											$ 55,268
Existing note holders [Member]
Share price										$ 0.11
Stock issued for debt conversion, Shares										319,627
Stock issued for debt conversion, Value										$ 35,159
Existing note holders [Member]
Share price										$ 0.11
Stock issued for debt conversion, Shares										333,824
Stock issued for debt conversion, Value										$ 36,721
Existing note holders [Member]
Share price									$ 0.11
Stock issued for debt conversion, Shares									781,206
Stock issued for debt conversion, Value									$ 85,933
Existing note holders [Member]
Share price								$ 0.11
Stock issued for debt conversion, Shares								884,555
Stock issued for debt conversion, Value								$ 97,301
Existing note holders [Member]
Share price							$ 0.11
Stock issued for debt conversion, Shares							937,116
Stock issued for debt conversion, Value							$ 103,083
Existing note holders [Member]
Share price			$ 0.11
Stock issued for debt conversion, Shares			1,024,189
Stock issued for debt conversion, Value			$ 112,661
Existing note holders [Member]
Share price		$ 0.11
Stock issued for debt conversion, Shares		668,797
Stock issued for debt conversion, Value		$ 73,568
Existing note holders [Member]
Share price		$ 0.11
Stock issued for debt conversion, Shares		603,987
Stock issued for debt conversion, Value		$ 66,439
Existing note holders [Member]
Share price	$ 0.11
Stock issued for debt conversion, Shares	1,564,245
Stock issued for debt conversion, Value	$ 172,067
Existing note holders [Member]
Share price						$ 0.11
Stock issued for debt conversion, Shares						504,957
Stock issued for debt conversion, Value						$ 55,545
Common Stock
Number of shares issued														500,000	200,000	700,000
Share price															$ 0.08
Stock issued for partial payment of legal fees, value															$ 16,000
Warrants to purchase shares														500,000
Value of common stock issued														$ 15,000
Warrants issued price														$ 0.03
Stock issued for services, Shares																200,000
Stock issued for services, value																$ 2,000

XML 66 R54.htm IDEA: XBRL DOCUMENT

Subsequent Events (Details Narrative) - USD ($)	1 Months Ended	6 Months Ended
Subsequent Events (Details Narrative) - USD ($)	Jul. 30, 2020	Jun. 30, 2020
Interest rate		10.00%
Conversion of Stock, Amount Converted		39,652,283
Subsequent Event [Member]
Interest rate	11.00%
Conversion of Stock, Amount Converted	84,194
Conversion of Stock, shares issued	765,399
Subsequent Event [Member] \| Warrant [Member]
Number of warrant issued	300,000
Exercise price of warrants (in dollars per share)	$ 0.25
Subsequent Event [Member] \| Convertible-promissory notes [Member]
Face amount	$ 56,180
Interest rate	22.00%

EXCEL 67 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( %J&$U$'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " !:AA-1=S4HZ^\ K @ $0 &1O8U!R;W!S+V-O&ULS9)1 M2\,P$,>_BN2]O;3%X4+7%\4G!<&!XEM(;EM8DX;DI-VW-XU;A^@'\#%W__SN M=W"M\D(- 5_"X#&0P7@SV=Y%H?R&'8B\ (CJ@%;&,B5<:NZ&8"6E9]B#E^HH M]P@UYRNP2%)+DC #"[\06==J)51 24,XX[5:\/XS]!FF%6"/%AU%J,H*6#=/ M]*>I;^$*F&&$P<;O NJ%F*M_8G,'V#DY1;.DQG$LQR;GT@X5O#\_O>9U"^,B M2:&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M M3A^%$5B-;'EDD81_OTV23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R M> +]O6N[!3+ MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,! M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2 MBW A(5M>5 TR M6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T1G*=D 4. #?$ MT4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7K;YH] M5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J-2S%UGB5P/&M MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZKR2.FJW"$2M"/F(9 M-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.$9)>-T(^8LZ+ MD!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]072N0/)J<_Z3(T M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+ M.7\N?<^E[[GT/:'2MSAD6R4)RU3393>* M$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.WF)&Y M"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&&F,_# M0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O& RN0 MHGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/55OR ML+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SC MYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5YYNTB42%(JP# 4A M%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF M8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.' MYA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,?-2K6J5D*Q$_ M2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]! MU4#E/]O4#6CV#30,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04 M" !:AA-11"MR>-X# !7#@ & 'AL+W=O_0N/K@"V9K^P ,X0D[6YGTVSHQ^QT>B%L@3VQ+2K)(>FO M[Y%L;+)C#K1<@#]T7CTZ.GJ1IGNIGG4BA"&O>5;HF9<8L_OH^SI*1,YU7^Y$ M 6\V4N7<_5V M(S*YGWG4.SQX2K>)L0_\^73'MV(ES&^[1P5W?J,2I[DH="H+HL1FYBWHQR4+ M;(!K\7LJ]OKHFMBAK*5\MC>?XID76"*1B)F9)[G_2=0#&EJ]2&;:?9-]U78P M\$A4:B/S.A@(\K2H?OEKG8BC #8Z$<#J /9= #W50U@'A&Z@%9D;UBTW?#Y5 M!LD%E!]0;A@I^+HL^ M"8,KP@(6=/ L\?!%N>T3VAG^#B=L,AR<_BK8L25PKLA[')F"%8HP9KA \9)BEV$W6?\6T7#!Z_X9D6",>X MX1BC.LM2*4>1Z@C2\TUP99<&@67;.9&X6J]'62^D"->DX9J@2DT=__JVZP3! MPVG0^XI07#<4UY=1/ J5RAC-#*YTL(D?/GPXL])IT)IDQD\JDQ9:L##0W:>9( ]EOA:J$P87H;WK:S;&>%I/IQ>9NN519 G%OI6JTRW/ MZ#S(HL>C"+9&"D3B2A C;!V=7F3IJP2V660I\QTON@%QF7,62ELOI[@9'X!R M#D WI8;7NKNDMKU/X=!MK9/<;=N((U0U9;>VCX_ MV$.=&M%(>.F5[ MD'J94SH>TM$DG$S]EV,L_VCK;FO(G6@TB>SD5+OXYFES:EJXLX+?-J^.7%^X M+4%-,K&!T* _AOY5=8JI;HSGR(4Z^IBO.!?J^#J/TJK42 M8O.VTTG]%5^S]"+>\ B^6<;)F@GXF-QWTDW"V2)W6H<=8AAV9\V"J-6]S/\W M2;J7<2;"(.*3!*79>LV2Q_<\C!^N6KBU_\)&3)>'XXO^UX,Q)$#-AL< M2.% SG6@A0/-$]TIR],:,,&ZETG\@!)I#='D13XVN3=D$T1R&FOT&P*R-*5:E1V7G;N)7?3MHM-R\/696=[G'W= MS/8H<0Y6)YK,@R93JVG*4Y$$OIQ4OT'>+H!U=%_7M*AI5.1I[R.+S-MTPWQ^ MU8(JDO)DRUM=I!E4ZY" I4V@Y_MQ%L$B3+C/@RV["[DJ":N6A&EX7C6'NA7Q M'-M3#[%]4&CKISU+$AX)M(F3O"#%2Y3(FB$OLI0CEJ9JQ6/$$"LM.>ZXQ58ET:G>W+<<@U<5;-W.);7D-J]<]B'2U M(N>Q8.$9(MWZ$+G$LHSJ4"KL#.K9AJF6Z1UD>MI*,IF.)\/I_$L;3:Y[-_,V MZMT,T/"/V]'D,Q08S2; 1EF=#>U(3!( =B(>$8L6B'_+@@T@5+11I%Y:1;3C M3"W;I97A4%AA0ANV SXB"=9JO>: TU4<+E"PWB3QEDNI:;-6;;2S*DN1SL\' M.LVX) DF9ZS333%';;0!?,+DG,R5,G5RUC35K3335-(*ZW$U'?WV<8[&'P#H MPQT$V^AFF/]GC\;)>#H?C6^4TFE=E.,1@JOB%7:F[;I&@_P2;%A/MOEXWKM6 MPKL06.<:- Z&>;39"X5U0XQ=QR&T06*)+FR=U6%C^6BH:S-P"1RL M)\Z4AWF;MF&R(H0QBU*X?FQB(U80Q""$>-6!J-M1D]A.TU25J,%ZUA0,UVJL M \0T*""DJK%NYWFFV0!#7((&ZTDSX'?J':I"AHEM[-A590I+0BV"W::=6N(% M>_H.(XY$$-U+!H8!NPO"0#PJQ7IU6)L2PU6I/[0[;:A+2A$]I12M4"AAH)=- M%!A2-4(J.TTG1$I@$3VP=KT0\_TD@UW%O\/1..7*1J,(="K5,0GV2%6LPM)R M/>RX#3T1.3JWG$.;?5>T']J@07$='L0R3>)8U4JMLH2M!>NB27&)&J)'S?6P M!XS9E\$O3^$,.9,S*CL-9TC)&7(.9QI+>*%2 1O+AF7AU-:%PM*#A6'1IE$N M<4/TN)G-Q_W?/XZO!\/I["4:##^,^J/A3?^+[JQ<,H?HF3-)^)+#BEN@5,3^ MUS;:LC!3EG)]H"?T<\\0Z#39$EA$#ZQ^O%Y#^2HR?6%<&%C"=I?S.X3;AF'L M?U"Z8G![Q#*QBI/@7[X ]J&7J-MN63_;2%P\>LOV#;>[7YC;+=A&[9-ZN6M MHH/;M@T_EKWW"M(T._61=G$F4@$7@ 0X$T&1/3;XE$7\\) E#SN @_/Z#@K< M_ME)6ZK9\/RY6:BNR'7*@EC06NV=%(8.AB2:UG+)8Z+G<6^Q""1"9%O- CA) M1,AGFP *GU)OG;W4HC;VW!I#ZI;$=:!\FW:#Y)+21$]IZ'*R=;;KS!9\&?B! MLJ,@=?B^L0UL8J->*Q2FEN-2QVZ"""U13?6HWD$D7^'RJ,:3]&6AFD>^6ZJ,LE:EK&MC%#4=M6L*:ZF%=J\?Y:?N\VES^F2@,-2> M#&B)<*I'^(PGP&O41]#:;>',&$!;C,H2^_?G?,?^HWLH>?14DCXW%FA)1ZJG MX_E8H(IC5G5WZFU.)998I/HGB,58#WYBK$M*4OO9Q[JD$M53Z0ECK0WT! 0_ M0Z#39$L 4#T IER^>Y*(JZ1]UH2519OJ']W]CPDSRQIK_NBAW;D3I@_TA E[ MAD"[9#M'KY+D>[S/++D/HA3.Q$/$ZOUQQ M!F"1!O#],H[%_H-\875X0=G]#U!+ P04 " !:AA-1&.:@E*$# !J$ M& 'AL+W=OC$C;0=, M@"2K)%(GHZJMM%(THVTO5GOAP$FPQN#4-LEN?WUM8" $ D$[[5S,\/&>X^>< MY/B59W'BXE7& I]2U@JEU:LU.&C; M+0YD#R^@/A\V0M_959:()I!*RE,D8+>T?L$?UVX>D"O^I'"29]?(E++E_-7< M_!XM+<<0 8-0F11$_SG"&A@SF33'WV52JUK3!)Y?OV7_-2]>%[,E$M:<_44C M%2^MF84BV)&,J6=^^@W*@GR3+^1,YK_1J= &VTB0FGQV6JSX6J[I75OTC2Q_0Q/F 7,=U.L+7_>%/$.IP;,+Q MO!ENZ_JK)KA5$]P\GWYL!&[^5=6N)D$_E M> %!0:(UTAOY$82B6P:HW@^^?()D"^)KSR:)G=HJG/]^FRS7&-HG!V7-&L[L M#K_G5EEF:WQNGM<:X$%9D[;V)3S2F*Y/<)FIN8EX$^^2=$C6)*T="(^TH($) MQEWFTH$[)&OBUA:$^SVH')NG'QB;VC-POVF\S]CXMXW-D*Q90VTCN-]'QHY- MATNT;6](U62MC03W.\F8H6G;@^NW,/M%3F+:#=*#VBYJHM<7@ M?H]Y!G,>U%SH OJ6.7%K>W'_!WMQ;[.705FSAMI>W'>U%[?M&_/I+&A-RK"N MX+7/#H+F%/Z)B#U-)6*PTX'.PU1G$,7!MKA1_)"?#;=K%QUA 4 .<5 8 >&PO M=V]R:W-H965T&ULK5A=<^(V%/TK&J8/V9DFZ,.?&<(, ;:; MSF[(A-WNLX(5\*QM44N0M+^^US8Q( N%MOL"V)Q[K\ZQ='6LP8LL?ZB5$!J] MYEFA;GHKK=?7_;Y:K$3.U9599ESC5")W50GO4IQD$_YVG1 M&P[J>P_E<" W.DL+\5 BM%@S9=B+O2W M]4,)5_TV2Y+FHE"I+% IGF]Z(W(]I75 C?@C%2_JX#>JJ#Q)^:.ZN$MN>K@: MDIH*77PK M^"9) ?,!7:)O\PFZ^.7#H*]A %6:_F)7[+8I1D\48^B++/1*H6F1B,02/W'' M!X[X/A!OV=,W]K?4F?#W37&%&/X544RQ93SCL\-);*/S_ZI/_W/U(S%8.Q58 MG8^=R//H\N+,:>SXY1DRZ*,AS']!@VM=3T(Q8&+>R(NM]2 M]YW4OTK-,^BAC9@VKDV\_Q[7+LS&M8NRP8L$B5?8 MNI1[\H1MUM"I8),5.I!+Q+!#*/ QQH:&%E1 _-#0L(LB-(YQ;&AH@>$P(J%= MPZAE&SG9_B8*Z+-9K2)/H,6GL'1XM7)LM*/.&$+BL]A@-.["/!)@9C":=&&$ M$>(%YNSIXB*/1!ZS,X];YK&3^42 MUFDO'$,%?U_(? M7/V2['=NPIS*WA5:E$+IMPEE5959F.$P#,U]QP9D'B%=52U T)1ZV%Q,-F00 MP),ZT4'(WF<0M]%HF3?"6HD[,U1O8M=JS1?BI@?M2(ER*WI#9#.#NT2'+/S. M\IE84!2;>KR3Z5B,O?,@;NOQ62RAO2BA=5;;>*L:SA3_1@V+I8 U%5)3CY]4 MWGU$F.>Q)R987"_ND"BQFH.L_ MW)7/)S\YK][T)]0[%G'OV8C;M#5;FZR;G*L+=4W491#;NI %2,':FAO^Q 8D M.*8LZG0A"]+WH6&=<'!D;^&(V\/="PTS1MEWLZCSFG%)6.AWW-C8A@R(!T[4 MI&P!@C2,1;Y)V5KFS<2._>SA^DCFG\:/4[1W?W'V>.7T=>[V;WK MG7SODJC;)55JUE[A >;26.8YV,/YBI?6";7+%1TRQ%?8<#_C\V"3$S#3);P+ M.V:^=TC4[9"^U^=:(D&C+1BDI4#WF_P)1(!WH4,=%)IMM-+@(--B:16EZV+" MV(=WS-BT4!9D$+* !'Y@2F/)Z?LQ6-+ 5,>6$U99[)L[7/_@X"H7Y;(^,51@ MD#>%;@XNVKOMJ>2H/HLS[M^2ZS&QW)^0ZVESYKA/WQR!?N'0] N%,O$,I?!5 M",,MFU/%YD++=7UL]B2UEGG][TX_$5A*FV'@!)]U_ MOP(38Y"X@*/.I+'C>P_2D+(ND530AAF%-5D&X'IV?%G^[2^9QG=YN;1+R;[%&6 MX8JOTS!>HX0_G(T^X8\^,_.$(N+OD+^D!Z]1WI7[./Z1O[E%4FBQ:LPO7N=_"S).(@@=HM M":1,((T$3%L2:)E &PFD[0JL3&#-A+8^F&6"V;=)5IE@%=SOR"J8=H,L.#]- MXA>4Y-$"+7]1#%>1+0@.U_G,FF>)^#04>=GY[/IJ?OWETOUTZ[EH?BM^??6N M;M&U+]Y?D)'R)YEF\^*% G<&HLWBU$O.W+=N%LS\M1;_$_ \B=!.$R_'E&LV" M39@%D0++Z\!:++:K;10(GI#+'\)%F"E ?!CD-I:N/1$#OA]ULA]U4N"P%IR+ M( K6"XZ"3+1E\0%1_!X1 SNJ8=LA6052?I]Z/L?&Z>3Y< SD$$O\PW8]S)7# MB&-@<0]L!'IRX-ADIH,=F]8C?44D,:<&)72ZCZPQ1/<,T3X,O4?I4Y"(>=F' MJ1VB66.*4=8@2XXJR+),2]UBMF\Q UMSC^DF6/"SD2A7J<#AHW.D^O8Q>4@-HS$]7";SPJ0H3U.3?,75K,.KU<@U M]^2:QY&+3L)U.4>4-ST0=@#1IM2KG.BV;EG[;EEPMP)QDXT?4-IR?[P TPF,"\%XCL3DV":V;>%&R>F.JU$^W5,^[5N2OP;) MOM!,54,P[2[)#KI0O(U07DZ0+R-0#5A[*2S1C6 MS4?+ !AWR+"^':C>]TH08U@1=VH%.']('S4!N;J /%U O@:@^O!5[@!WV(.^ MR@3&&3*,;P>J][42ZQA6ZY!\@5.'=$\3D*L+R,.R21A;F$VG#7'@]PBL,U_Y M"0P;B@,5\\=V+2JS 51FV11(,D81H]0Q6%;S+4)&$2F4S)0PBS25C"J4V 0B MJO()*"BG339@L]I521@[KD#*5+<"P+Q@F970Y!5U KBX@3Q>0KP&H/I25 MW<"PWSA>RH"X0X;U[4#UQ<_*1Q#81W1*&3A_0!]U ;FZ@#Q=0+X&H/KP58:* M=!BJOE(&QADRC)H=!SE8J(<=!R1EX-0AW=,$Y.H"\DJ@^BH+LQVCN1K3([#. M?.5W2*\=@+PRS_D&KLPE%+Q)(LN;H6NC7!>02V1X0L[9A6LXM31?TNR]8Y[]R(Z3#C73*.%T.1!>0JPO( MTP7D:P"J#U_E0 CL0$!IH\MDZ )R=0%Y1+%!@D5%(Q9I%NT>D?7##94#HKUV M4IK'&I2UNH0"Q8TBQL:*(R!4WF8ACHWSY9?&[4<1.39MA]J6TP#U5:'$809V M,&LAJO(:%/8:'>= U(3A7N)&$59PUBIN:.4:Z)'[%,KFZK(1NH!<74">+B!? M U!]* _.(75LNQPKH&#<(YI<&0+:;ZL!TD4PQ)!)IPG(U07DZ0+R-0#51[ R M1[3#''4I*SA_R/#IVD71!>3I O(U -6'KS)==,"Q+FB!#,89,HQO!ZKWM3)A M%#9AD(J$4X=T3Y?YT@7D4=E4C:?$H4T=Y?<(K#-?V2\*VR_UB25B*$?"Z:$A M%3'8LDW,FB)2/H)%36KAJ=-<'U%$CBT#,VS83;&M"B4"%)N6T\)4Y71HK[-= M+>>66AB3Q;]21"K"=J2U^6M6F036;YL$JN,PQ)"3Q+IV2ICBP)=#S,;"L:?K M>G[G]>KL5\Z##=CE4%*O:W>C!*HM2IJ&,VV:-R8;%LLBC#FTR:VNDUZ**]J& M;5*G9>V.50Z)=3BDOB42QAG"LKQ3L6/Y@+YZ9RJ/P&"/ -5 .'5(^W6=RM(% MY#'%I@:FMFDTUS+]/I%U[@^>NNBU^]$XP*&^IY=08!54Q2BKH"*PI0HJ(MNJ MH"H4KH*L,A4,-A7PD9<6QN1]"5455(6U5,')P;-R^;.3HA _ANL41?Q!Y!H? M; &2[!Y'W+W)XDWQ^-Q]G&7QJGCYQ(,E3_( \?E#'&>O;_(G\O8/A9[_#U!+ M P04 " !:AA-1,!MA-I0& L&0 & 'AL+W=OF78,QJ]>QJ=Y_5YO1)JN]ZQ9A!ST4N]%EO9V8.;+>J[@6W^K)>,%$YI+ M@11;GO4F^&0:AG9!*?&5LR>]\XRL*?=2?K=?9ME9+["(6,Y28U50^'AD4Y;G M5A/@^%$K[6WWM MWGW]JORJ-!V/NJ693F7_CF5F=]88]E+$EW>3F5C[]P6J# M8JLOE;DN_Z*G2C89]%"ZT486]6) 4'!1?=+GVA$["T"/>P&I%Y#]!5''@K!> M4'JN7R$KS;J@AHY/E7Q"RDJ#-OM0^J9<#=9P88]Q813\RF&=&4^ET#+G&34L M0PL#'W!&1B.Y1%.J5^@*SEFCHR^";C(.,A_0,?JRN$!'OWTX[1L 8-7TTWJS M\VHSTK'9 'V6PJPTNA09RUZO[P/P+7KR$_TY\2K\>Z<'+ M\<@#)]PZ,RSUA5W.G"S^0%=_W7Q;H*O;F\_H9GYY.[F;7?^.)M.[V=?9W>QR MX=DFVFX3E=M$'=M<0W;G4FO7 50K!^5*F\*/XV,2!F$XC$_[C[N><0CB,")) MC+>"K\#%6W"QUP>3[!^(VBJ(C(1,3Z5(>&UT1!V7" H2XH: M+AZJO.:&,WWB<=5@BV;@==4%@^*6-J-;,.&T:MK#$T6 0 M['F^+47B.!FY$8^VB$?>B+7IE*ZH>&#:AF*%L0R6G--[GK\9C#AHBFW@=TZ: MRHW-# A*QA_I?(<3L!?FC5DQ!>RC%*2Q MY]!J-:\C:!0G9!]G6^XXP208Q!U(28.4>)'.Z4O-5P+E#.A\]\R6,,-1>#PL!!8TY?.\P_;V8##X7X=IQ D];I_P,$FB'4@U=(<@ M#H;)D'2%;\-.>/"NAF%V_?5R<7C#@!MZP7Y^F6\4E#A(#RC$:V5=9%X^HG5. MA?E8ECKV8\/7-I6PGUCV3_=J=CVYGAY\NJ2A%>*GE;F2*6.91DLE"WN^!7024KT@ M(8W;,Z3-''$\"EMET"&'@R0@<4>70!J.(7Z.>8UY/I]#\IZP!$^".'&R2Z?T%++BA<,-ZL!<3! M5,,@BMKH'8+!,.X.^8:JR-M4Q46JRC[E*&/5TP=;T:Q93M1M[AD1/"+#?= . MCHH@2SH@-P1%_/>GLH0=HW/VP(6P3H;P^)M1Y<3JN#N-0K)?;1UBX-NPHQ$@ M#<41/\654"?7%^@6*/1V-KV[O$ U_$MX>W.%X#8^N[EP0F\SUVB$H=_;Q]Z6 M(P$(=F!O&(X,O4RQV*S7>3EYH3G*N$[AHKR![+;N+B-^F8-*+JJQ'=RL?-<1 MTA 4&?E=5B83Y1G*-LJ>+O1]"'H#+LM+Z F:"<, AKN>>76_XQKZ"Q2]GM8T MO!GZ>?, ^U-9,&3HL[NH^/6_PP>_0-%K'S0\'/IY^):E4F5U:CLNZV@C,K@, M5)F*99N* M\X04QV6F-;VE451H6DZ;O=?_<&<\Z"?8J03ERG"X]NUW:=5PJKYQ\3KM4%HM M@%=&PI>B@/ZBDYWKS7='>DF0Q.%PO\/PHWQ'L/5WYLX%4P_E.%ZC\H);#7&W M;[R\O6=X5[D%+;@%VE) MSIR9.7,A)SMCO[@,T<-#KK0[BS+OBT_]ODLRS(7KF0(UG6R,S86GI=WV76%1 MI$$I5_W18/"NGPNIH^DD[*WL=&)*KZ3&E057YKFP^SDJLSN+AE&S<2NWF>>- M_G12B"W&Z.^+E:55OT5)98[:2:/!XN8LF@T_S4]8/@C\(7'G'GT#1[(VY@LO MENE9-&"'4&'B&4'0WS<\1Z48B-SX6F-&K4E6?/S=H%^&V"F6M7!X;M2?,O79 M6?0A@A0WHE3^UNP^8QW/6\9+C'+A%W:U["""I'3>Y+4R>9!+7?V+AYJ'ERB, M:H51\+LR%+R\$%Y,)];LP+(TH?%'"#5HDW-2O',Q+1^+.@= IS(63CF56%AUJ+UAGTO?D!$/UD]K@O#(X>L;@ M.[@RVF<.%CK%]$?]/CG?1C!J(IB/C@+^6NH>C ==& U&@R-XXY:1<< ;/X-W M8[="R^\AO"Z1H9U1,A55#1$/C\-G.BZE%CJ10D%,FT@%ZQW\/5L[;ZGD_CGB MT4GKT4GPZ.2Y'"WB\]OEZFYY0'G-U>KV?5?KV*8W\?+ZT4!FSS.IV$2^N[V:L\U2.CAL<]N!YFS__]&$T?'_Z$LNAG)*604QATY+E M6K(Z4B>J3!$\28LD,24S2,S.TF]"?T>B.3:J9+Y=%Y8Z"6F0)+/+C%)[,#M- MT*Y<.YE*FBS=5H!256#H^\.Q1 >_4-NHZD#M.S0'T%J"\ 8RM"@IT62)W>%@ M1X/3NB7":G@*W7J[=?#_!SNL=[H-0ND:&6.;/5/:>O-UC^(*!DTA=5U8N= T M%IFB;DM-<$/J;:?4HDSEV[XL?(NR83>$K6^9I#NB[#O,XL8$N+D MPYN<>Q\*M-*D058#\AP( BQ.+M$\#8;HXK&AR]PQL$X#5N'0-,!V&@1)=K$7 M*O%)INKBHWK1'3;!LQZ&@S>_@[#84!2.0P)L2A!(0YK"J/S]6DI;8Y'3+02; M3@UHXQL3(1FU2"I=HHPK";Z!2#OK?5/^E&$R37JR4"2Q14U4*#[%HG:&4>YU MJ( P=ZJ.R8F,1/38!9X+;CS#<)U#\H76):E9 M+(SU0*EO6/FM3<6&(B"1/0I;4]\4!AP*8R,5'4,>--F4LJ:ZE3HB3,@(,UXK=QH0VH5*K#X?2>&MG]1UQ64E$KW)#JH/?^;02V>CQ4"V^*<&&OC:?K/WQF M]-Y"RP)TOC'&-PLVT+[@IO\!4$L#!!0 ( %J&$U&^IGMBI@@ ( 2 8 M >&PO=V]R:W-H965T&ULC5AK;]NX$OVN7T'X%A7W_/D)+LM&EWOU@2Q1G.X\R9 ML2YWQMZY0@C/'DJEW>M.X?WV9:_GLD*4W'7-5FB\61M;R:7N7%V&M86]NC255U*+A66N*DMN]V^$,KO7G4&G6?@L-X6GA=[5 MY99OQ%+XK]N%Q5.OU9++4F@GC696K%]WIH.7;\:T/VSX78J=.[IGY,G*F#MZ MF.>O.WTR2"B1>=+ <;D7,Z$4*8(9?]8Z.^V1)'A\WVA_%WR'+RONQ,RH;S+W MQ>O.>8?E8LTKY3^;W0=1^S,A?9E1+ORR7=P['G585CEOREH8%I12QRM_J.-P M)'#>_XG L!88!KOC0<'*M]SSJTMK=LS2;FBCF^!JD(9Q4E-2EM[BK82L,61LE,"G?9\SB/I'I9K?M-U#W\B>Y3=F.T M+QR[UKG('\OW8&=K[+ Q]LWPEPI_JW27C?HI&_:'_5_H&[7.CX*^T4_T/>$E M^\]TY;P%6/[[BP/&[0'C<,#X9]']>G,S_?P'NWW'EO/WG^;OYK/IIR]L.IO= M?OWT9?[I/5O!Z]25K_8B>]7%A#7OETUEOE"-"_I)*[W]=L7:>(+:ZI-P:1W;%<8 MI?8G9J?A@:M63N:2@+LH.(HSV[/?N:H$N^$:7 +6\$<^L>@3U_DO5%'R\\H2 M&(;]P21L3[;<>L0 $OZ&XUBH8WU@1S'VDL5ZP07/DB^$%F M>ZY)8E4YP=92J-QUV3JY=9<.Q"VLVEI"4>_(X33*N%';7 MCB]IRPV'@?8 N3H2M&=\/GP%&Y[:U09O>;-L8X=72OZ%-/$?0;*'?)FLZ[)! M8.X%X@>L Y/@,2)O4MSSPD44ZI!\R[?!Z5NBMBKTP6@0FP;/&C-NE]/&C(@D MQ$T'!.TDX8[IH)ZKI$YP2%5=$Y;0#VN]Y/'L1\$C &CA7!-%%"$40P(I@MDS!V>DI74:ERHJ;!,9_I"HHBE,Q;V!!>X!RE@9\& T H>0D>9/L M@&E:10*?PDJ7?2D$JWF-%=@8!^E\UJ_L8.1,B*3,&3MO*"C<@#7H' I$%^ MRGC>07W)XW8;$-O_(B,"+3!G,U+JM_8,=]1@NL^ M&E,6H4 @1JG;?:CKVB&8HXS>G""Z)>;@E4_H"%%;F$>T!)B$O:$;>L\SFD!V M4,9#%CP868MVJ MFOH5+5(1L-*#5P04CFN%4ZPI_(MS+Y+',#_N3Z]:*]BXY M<@[F/'I*9HUST\;"'U:2:?";?6M,_^XYF1$;H\]0)A#24CK0T)ZJ' %XQB;I MQ>0TG8Q&N ]==?@*=V?IY'2<#LZ.5I-E82SJBL(:A;=\'_([2H=H6N?]4:M@ MG)Z=GZ>83%KACP9MHQ&P0H4@$(_OV: _3(?#BU9X-!ZFIV?]5G2Q6+ @/DB' MXU%Z/FY??7]-GD%9.AFC)Z0O]!\2@]&YXA#2/,-I4C-K%5H FD"]!GU ]J^4CRH+'L#JQ! M) ;8U26*LJ5_B[1"E3UMN3 6)OMXQ(B874TIV!?^@(>C\39T$ZHOWHPNGC^P MK7$R\IGG=P@==4>#*++Z4E5$:.1J2H/4VAH%X]3JPT: M73,3/W* /8$>=Q)V4G9(5:Q2%0)TTAM7D._ XPA@P1.V$S\7<>P(NIQE0J3U9A M/7H/6^KN':+VW60G'J#."0(*HJ%]G'W)DAF42@^\N#M, 0 3N]W&^)":AGV> M^J_:._HJ@&%_$[Y]4$) 6_$#0;O:?EZ9QJ\*A^WQV\P-MQB&'%-B#=%^]VS2 M839^[X@/WFS#-X:5\=Z4X18C(M! &_!^;5!(]0,=T'YTNOH_4$L#!!0 ( M %J&$U%]:B-I(@, .0& 8 >&PO=V]R:W-H965T&UL MK55-;^,V$+WK5PS4Q9Z$2*8^+*>V@22;HELT;6!GNV=:&EO$2J26I.-L?WV' ME*/8;9)3+^+7O#=O'L'1_*#T-],@6GCJ6FD686-M?QG'IFJPX^9"]2CI9*MT MQRTM]2XVO49>>U#7QBQ)BKCC0H;+N=^[U\NYVMM62+S78/9=Q_6/:VS581%. MPN>-E=@UUFW$RWG/=[A&^Z6_U[2*1Y9:="B-4!(T;A?AU>3R.G/Q/N O@0=S M,@=7R4:I;V[QN5Z$B1.$+5;6,7 :'O$&V]81D8SO1\YP3.F I_-G]E]\[53+ MAAN\4>U74=MF$98AU+CE^]:NU.%7/-:3.[Y*M<9_X3#$,LI8[8U5W1%,ZT[( M8>1/1Q]. &7R!H = VN7IN<5+D)Z3 ;U(X;+] +.>>&&FP:XK&&%QFI16:R' MO?% OQQ4;J]2]&",-:"V0*7#5K7T\(3&F M40<)0CK5@:M"M:+F[MA8&CIW?523C]U2288RSV:3B.4O&F"X[>IXV]S?]JDE MP9DE\']9\KOBTH!5H%Q^IRS-HBPI:)*QJ)@6P1I)E+ _?(86J8]0[^B5$20K MC?(D&;YD;B_()O$WU=TK[3L753T@J-AT2M\R*8-[C3T7-> 3]6>#!EA91EDY MA2QGT2Q/@SMA*FIV7*+:&W*[0O'(-RW5P>S7Q2>?I4.]\?W6.[Z4=FM"X.[;PJZ%SO80/_?^.ZYT@%UO<$C2Y MF.8AZ*&G#@NK>M_'-LI25_33AGY#J%T G6^5LL\+EV#\L2W_ 5!+ P04 M" !:AA-1]&P6([@" #Y!0 &0 'AL+W=O[W]W?SEU_+=6;7B$:V.29T -O94QQ[?LZ66'.=$L6*.AD(57. M#"W5TM>%0I8ZISSSHR#H^CGCPAOVW=Y4#?NR-!D7.%6@RSQGZGV,F5P/O-#; M;BZFBE5]34IZCT%P*4+@8>*/P>MRV]L[@.\>UWIN# M53*7\LTN[M*!%]B$,,/$6 *CX3?>8)99$*7Q:\OTZI#6<7^^HW]VVDG+G&F\ MD=D/GIK5P+OR(,4%*S,SD^LON-73L;Q$9MI]85W9QA0Q*;61^=:9UCD7U<@V MVWO8<[@*CCA$6X?(Y5T%,L.&?277H*PUT>S$277>E!P7]E&>C:)33GYF M.%7TOLJ\ Q,I3'Z5O* ;-WW?$-M:^,F6,ZXXT1%.%QZE,"L-$Y%B^M'?IYSJ MQ*)=8N/H)/"^%"V(@R9$012O&1Z-_#!J'P\,9=)O= ML$MCV.RT>XT'U)J*+2GS,F,&4ZH1:A<)9ZX*SWMQ#!=P'HQ T=QCS+:X^"&VI*V,I63J_GF,K=_8(. 7*8:T/Z(!Y1;+< UG'6CV&V< MA6V2J% 7Z%I$]MZ"$62L,+* -;-B*#-%,"[@GHF2FA?0+5MBZ]"/X^^58XYJ MZ9J.IA_YE53?&1JR86&#!?D&K0^=3Q05:.I%I2C*^ZY M--0JW'1%O1F5-:#SA91FM[ !ZFX__ -02P,$% @ 6H8342 /^X*6 @ MQ 4 !D !X;"]W;W)K&UL?511;]HP$'[G5YRR M:MHD2D*@7>D B:Y,[516U&[=P[0'DQS$:FQGME/H?OW.#J14!5[B._N[S_== M?-=?*OUH,D0+*Y%+,P@R:XOS,#1)AH*9EBI0TLE<:<$LN7H1FD(C2WV0R,,X MBDY#P;@,AGV_-]7#OBIMSB5.-9A2"*:?+S!7RT'0#C8;=WR16;<1#OL%6^ ] MVI_%5),7UBPI%R@-5Q(TS@?!J'U^T75X#WC@N#1;-C@E,Z4>G7.=#H+()80Y M)M8Q,%J>\ OFN2.B-/ZN.8/Z2A>X;6_8OWKMI&7&#'Y1^2^>VFP0G 60XIR5 MN;U3RRM!\0^ M[^HBG^4ELVS8UVH)VJ&)S1E>JH^FY+AT/^7>:CKE%&>'-TB2,I6G<"T*K9Z0 M"F[[H25J!PB3-C^_'5[&ULC551;]HP$'[G5YRB/2(2 M J4M B0H3-O4;HBR3=6T!Y-4%2L.5!(W9.)AVA[.^B_\0R$<$Q2<[(Q510TF!067UZWLX =Q$[P#B&A![W54BKW+. M+)N,M-J#=M'$Y@Q?JD>3."[=1WFTFDXYX>QDA8)93&')M#W O6+2D'U@&X&C MT%("%Q8F-=FL(HO?(1O @Y(V-["0*:;G^)"$->KBH[I9?)'PRTYVH!>U(8[B MZ )?KZFVY_EZ_U7M6E.US+\. [^F&V,U>;\OY.DW>?H^3_^]/(O[Z7HQA^5T MM7Z"^V_3KX]D/TUG]XNW;O4BF6O+H2E9@N. ^LZ@?L%@,NC A22PSA'N5%$R M>8"<&6J?!.GUIY!QR63"Y;:5:57 Y/4>M1D%E0&]@1%H#WUBEM]9('%!K5Q M86JG8::83ITSY\1ME38=E]0@<)GR%Y[NF## -%*+$'\*5L$&24?U 4KZ !Q- MBW;/DLK4^5P[%MQ0I$1CH* ^<.B4FT0H0WB#Q$!,XM"!J1=%3P6;I^*)YE2S MT]SJ==UN][;MN$F14^6R9DK03**[.)-U *DL&K)]%PQ;Y\Q'5CBRME9G8.%; MJ ;#!^A&<3N.;\GJ]>/VX#J"M]Y7>-+!!>JMGU,&$K63MFKF9K<9A=-J OP+ MK^;H ]-;3A($9@2-.M=7 >AJ-E6.5:6?!QME:;IX,Z=QCMH%T'FFJ/[:<0F: M/XC)7U!+ P04 " !:AA-1'&Y,!V<% T# &0 'AL+W=O#PKGZS7ALLP(K84>Z1D4K6VTJX>C5[,:V-BAR;U25XR2*9N-*2#6XNO!S M:W-UH1M72H5K [:I*F$.*RSU_G(0#XX3'^2N<#PQOKJHQ0YOT7VJUX;>QCU* M+BM45FH%!K>7@V7\9C7A_7[#9XE[>S(&9K+1^HY?WN>7@X@#PA(SQPB"'O?X M%LN2@2B,?SK,0>^2#4_'1_1?/'?BLA$6W^KR3YF[XG*P&$".6]&4[H/>_XH= MGRGC9;JT_C_LV[W)= !98YVN.F.*H)*J?8HO71Y.#!;1,P9)9Y#XN%M'/LIK MX<35A=%[,+R;T'C@J7IK"DXJ/I1;9VA5DIV[NL:-NQ@[0N+W<=99K5JKY!FK M&=QHY0H+[U2.^4/[,470AY$R%!?K;ZI*ZR+X)'@(%H'+3\ZX[_ M*XBC8*"'3ZAZ-D^1T6!M=26NU.8#RT3CM1,G>7DTG\S"=12/X M^ AMFCX#$3R&2,-Y,@^3N#? G%8A/0MG1"U9I& +8=!G.],5$0/JI>QN!'\H M6-9&EI"D)Z3@K:YJH0X__;!(XOFY#?8%Y?H >J$V38;*W-)JA7"FG KD1W@ MLR@;A!NA2+Q(IASKSWM&W& )#DE[7$HM7(K*2*.DZ:%X[7 1\=U1Q%V M,LO&GV7G_YAQ MR$HA*]\,&RPEWJ,-?##2M;A*_] N)-_7/HW,J*&N^ MNND0O]+#[Q%]:_-!+R;3,)U00ZPTK?D\42Q!?T14R6 1[[CT=XW,O:&O"=YR M6PD*DKS[SR4DBB;+;,VM?W42 :CIK M>\SG63?FI*U:SO+[1&Z9WPOU%8ECBT_2EH;I(@[C64KC:1B1[$7Q+/#@\S!* M>2JE43HA^9NGP;/""$L'/7S;*UY[.BDC46I(&P\HS-#I80^%Z/D_/@^@2?HYY-64UIU&V )9T/GT%OFS\A\\&I MS#_^(G&]%=JXH4-3<94L721A%G#?^8)R%R33J,\>E^%0"0M *AQQZ4/&$= =@ J-3 M2^^Q\%KY;)*2'T=/W47&)S>Y"LW.WU=)&KGOVDM=/]M?B9?M3?#;]O8^?2/, M3BIJ8]R2:32:TPW4M'?4]L7IVM\+-]K1+=,/"[K6H^$-M+[5E,'NA1WT/Q2N M_@502P,$% @ 6H8345M#PUS^ P @0@ !D !X;"]W;W)K&ULG5;;;N,V$'WW5PP$ VT!P[K8N6Q@&XB=;=>+;#;8]6[1 M1TH:6VPH4B6I:-VO[Y"ZQ&F3//3%),69PSEGAD,O&J4?3(%HX4K50M15< MXKT&4Y.WMO$UC8T[FX)BD2CVXQ39?!I$+" 5FUB$P&AYQ@T(X( KCKPXS M&(YTCJ?S'OU7SYVXI,S@1HG?>6Z+97 90(Y[5@O[134?L.-SYO R)8S_A::U M3>C$K#96E9TSK4LNVY']Z'0X<;B,7G%(.H?$Q]T>Y*.\89:M%EHUH)TUH;F) MI^J]*3@N75*^6DV[G/SL:J.DY?* TL(M9RD7W!X7H25DMQ]F'03F' M3X13&'@O<\R?^X<4T1!6TH>U3MX$_%C+*['_3? 8[ M'V#G'G;^&NSGN]WV[K?W=SNXW5ZOM[?;W1\OJ?/N%6?:IY=Z&9G([,EU-*/TYX],_HT$VSA2+J/OQQ3 I)HC-.0BF9/X*JA2_(<]#^ MHQMNJMH)[BN_3^D8^FLSS)XL^;\+H$]W-X[N4>9.NE[35M%6LFX8[;R.V4NW M?0SG\V1R?O;N9/92,PM/GH42]<$_?L:E7=KVA1B^#N_K=?NL/)FWC_,GI@]4 M("!P3Z[1].(L -T^>.W"JLH_,JDB3J6?%O0? ;4SH/V](OFZA3M@^->Q^@=0 M2P,$% @ 6H8349#09EGI @ )@8 !D !X;"]W;W)K&ULI951;]HP$,??\RE.V;0GKW$<0D('2-!V&E.K56VW/9OD &N) MS6Q3UF\_VX&LG49?]D)\]MW/][_DCO%>Z1]F@VCA5]M(,XDWUF[/D\14&VRY M.5-;E.YDI73+K3/U.C%;C;P.06V3,$J'2KIV.ULXV0>*O![-J6 MZZ,O7>(_VZ_96.ROI*;5H41JA)&A<3>)9>CX? M>/_@\$W@WCQ;@U>R5.J'-Q;U)*8^(6RPLI[ W>,1+[!I/,BE\?/ C/LK?>#S M]9'^,6AW6I;Y4N#@[_6(WJ&%657J'-5P+OA2-L +-.+$.[YV2ZH":=RAV C6$ M&R7MQL"5K+%^&9^XM/KUFO- B_[/ZTOV(.> M/0CLP2GVPZ>K.YA=7-Q]O;J$Z\5LOKA>/"RN[O]5QU=1O@W/S997.(E=GQG4 MCQA/1V=P\@J8&5 K<.7"OES 90V76&&[1!UEJ=]-1P1<"=Q7W'!9H8]1H23\ M4)+F3TE &. &5JIQ;6O.HY?P(QB.X.B&2]?#KELM5*IU(\/PT'5OH20C6A"6 MEV%=%ADI*8N.;T%(BTZD!:GD>XT-MVYSR[5]@@$IAI04K(2^VJ-=A0AE7Q)VT71OWN_T0G'6]_\>]FZ W7*^%--#@RH72LR*/ M07=3J3.LVH9)L%36S96PW+A!CMH[N/.54O9H^ OZOX;I;U!+ P04 " !: MAA-12U]?2H@$ !A"@ &0 'AL+W=OON$.SG7:&8&,@@91DAJ1)=SNS;69)VF=A7T"SLN25Y!#ZZWLE MV8Z30%[ LG7//>=^2?.=TM_-%M'"QMK2TOXMAD6RR8&:@2)7U9*UTP M2TN]B4VID>7>J!!QFB1G<<&X[%W-_;M[?357E15F M\PQ.R4JI[V[Q);_L)8X0"LRL0V#T]X0W*(0#(AH_:LQ>Z](9=I\;]#NOG;2L MF,$;)?[EN=U>]J8]R''-*F&_J=UGK/5,'%ZFA/&_L M[1TD/LLI85=3&Q*#@ M,ORSYSH.'8/I,8.T-D@][^#(L_R=678UUVH'VNTF-/?@I7IK(L>E2\K2:OK* MR^2R 6L.C05@8@];,8TO [G.N@1=AZ2#%B)J(#JY#@:F M:S$<+$*J>%$*GOETN,(B>9ITN8A)1<\TY3F)# E8F VFV@[VM%1VR]< [:6^75_U!+ P04 " !: MAA-1(9:+N^T# !'"0 &0 'AL+W=OKO"0FZG?NSO M%N[Y>F/L0CB;5&R-#VB>JJ6B6=BAY+Q$H;D4H' U]>?QY57?VCN#?SEN]<$8 M;"3/4OZPDT4^]2,K" O,C$5@]'K!:RP*"T0R?K:8?D=I'0_'._1;%SO%\LPT M7LOB/YZ;S=0?^9#CBM6%N9?;K]C&,[!XF2RT>\*VL4V),:NUD67K3/.2B^;- M7ML\'#B,HD\A!&@601$ET!B_M DX=7OH)WC_2H 8CX98+)C+."G@P MS" UFM%G\/L=?M_A]S]+Z.*OKX_P_1:>'F[@[F9NGXOYU>)N\;BX>3B5T+-X M]E!>ZHIE./7IU&E4+^C/XK@'YXE@KB'G.BNDQARX !LWQ)1'LT&XEF7%Q)M' M,:-R^Y00LY50V [00(>=>F+%,P3'#97BM&2-R/MGS13Y =H2 Q4(NP+1/C/ M%$)6,*WYBI,%TZ!V;593@]$&&@U,Y)[C@V+?<3TKG.R.4!O1SM8[L+5 DBIH MB&/+S096M:F)NF)OKIJ0UP@UB51[?^W$,1MB01\D?>D]2D,]X'(K#+RP@IQ( M0(O5".P0OT Z' 6CB\A;*D[=4UG7W6;)<@=-WI9/\U)^I"=%OT8@C3%@Z _B.&16)NXN%@#)W.P7_&\+M#;AT1?$5[6 MY?O0]HDZH8&M%39'A)I@C62EFI1;^P^YLXN"+I0C)J]C.A'$K@SG)5*DZ3 8 M7L3>'6K]CM=VNZQIFL1!DD2_GL\VFPU'5BME.2JIW"UB6\H&3B=*DM,;,@4Q MB4K2R+N38OT''8SR'>L!WQ>(+\8DCVKEY-&U4JMFBZP_Z/-.Z3O=P$WFO./, M+8\R='^@:E^-+F\?V8DNMI('41!'J1VEU/O-H F9+!*(^\-@,!S!,$@'(YI% M01*[K11H'$41C$=C2,=!%,=>5T-":2IUT,"GOK_AP>56HEJ[*YP*8S4W]URW MVOTES)O+<6_>_&)\8VK-A:9(5^0:]2X&?E.JW<3(REV5S]+0Q>N&&_K3064- M:'\EZ2O:3BQ!]^\T^Q]02P,$% @ 6H8344Z4:GP>!0 9!H !D !X M;"]W;W)K&UL[9E;4^,V%,??\RDT*=.^J(DL6[Y0 M8 ;8[?0R%&;9ML_"5F(-MN5*"H%OWR,YR6;98"!#!S_TA=BRSM'Y_8]N2$=+ MI6]-*81%]W75F.-Q:6U[.)V:O!0U-Q/5B@:^S)2NN857/9^:5@M>>*.ZFE)" MXFG-93,^.?)E5_KD2"UL)1MQI9%9U#77#V>B4LOC<3!>%WR2\]*Z@NG)46&V[$N:K^EH4M MC\?I&!5BQA>5_:26OX@5#W/^/*JWAN!DXY)R;35\E6!G3\Y5 M78,XUU;EMT=3"QY=^31?69]UUO0)ZQA=J,:6!GUL"E%\;3^%2#;AT'4X9[37 MX6^+9H)"@A$EE/3X"S=XH?<7O@ /G=X8JZ$;]/B--GXC[S=ZRN_EQ<7E'^CZ M\^7Y[[MDZ[<.Z 1M>T ?%EHVD#1F(8I1Q#!),YRD(3(EU\(@-4/2&I1W&ABO 3=HIBH8BN8073;HM-6R M0B3H\1MB&E/,".ES:Q7BZ$9Q7;C/A=0PZ)1&M:AOA$;+4B$_#@$$:N:JN1/: M;JI]_UU*@^0GB$R >]X4R/ *9@BH:SEH-Q\=Q,R',$&?G42^R26@="$B;M$! MF5#B).NBG+P0+@#-DO>&@^__P^V H[UP$69IA$/V')VXE\:ZT=4H*U"IJD)H M\Q18JU4-#2A <-4-:JL%@.6Y]M$"X*)IN2Q&LK$"&K4;4G1 <1;$.(VSMV?% M(4TP9?2Y1#8[:?\3V)CAB+U]6BD.6(Q9P(:#&H6@/PE?AWK!'U# >G-*XQ G MT8! @S##Q*U-/:!!\%K0"%,8IRP>$&B4N(R^-2B,T(#@($Z' YID(0Z"= _0 MM ^4$)RPX'TPT1ISM(69P$K7/T!W4O;.1(Q0'(71<)+)&$P9>^22]G7:,,AP M3)/AY#)DL +T+Z%[4(8A3ND[Y7(G98P3&NQ!&?>-RQ06%1(/AS)E. OW&9=] MLT_J5A/V3JO)+LHL@<5DGUQF/919F,#,/:!4G_2)>0F:YDK3M)O^B.5-?4MB'X/@ABQSQ!IT4AW<$\KZH'["JO!,NV!!L] MR@)[D6#;?='77/5%UZV67&L.E%W1-X*)>Z%S::#[2K.N:Z#OH78!P7'X\&T( M6WK^\"B8F=( S#I@I^+:9:?=BJKH^J?;$X [@$\Z0] S='J.NGZ\Z]AZNG7R M7PL]]_<;QO<'VUT";$HW5RBGW-2_P,3,DD86.DNSN-[L6J MUM\CW"AK5>T?2\%!15&ULG91+4]LP M$(#O_(H=GR%V'K2423(#(05::#.DI6?%WM@JLN1*ZR3\^ZYD8$4./1BZ['[ M[4.[.]X:^^ *1()=J;2;1 51=1K'+BVP%*YG*M1\LS:V%,1;F\>NLBBRH%2J M>) D'^)22!U-Q^%L8:=C4Y.2&A<67%V6PCZ>HS+;2=2/G@[N9%Z0/XBGXTKD MN$3Z62TL[^*.DLD2M9-&@\7U)#KKGYZ/O'P0N)>X=7MK$&LC'GPF^ML$B7> M(528DB<(_FUPADIY$+OQIV5&G4FON+]^HG\.L7,L*^%P9M0OF5$QB4XBR' M M:D5W9GN%;3S'GI<:Y<(7MHULGX73VI$I6V7VH)2Z^8M=FX<]A9/D#85!JS ( M?C>&@I<7@L1T;,T6K)=FFE^$4(,V.R>U?Y0E6;Z5K$?3&\R%@H4U*6(F=>[& M,3'67\9IBSAO$(,W$!_@UF@J',QUAME+_9C=Z7P://ET/G@7^*76/1@FAS!( M!LD[O&$7XS#PAO\7XPOFJ&.. G/T%G-^>78#B[OOL_G\XOK;Y?*UO+V+\.UV MZBJ1XB3B?G)H-QA-^\,>_,.&'P7"S)25T(_ LAMI:J<>N2DJ8PDSH$+0 ;&0 MDB1S$>I]A;1%U'!G"-,"KE H*E)A\1"N==H#H3-8%((K.WV$>Z%JA%NAN1&Y MY0B61M4>XUIIAT0*L]X+5RS^YN8*]O$@LV)-K5Q $-K2!3,IUX?4-3H@ R+/ M.5K'O<@1@_DNQ8I .,BD2Y5Q;$2LS 8#3^J#:\(2^H<@E *S MAA![>.;J^9F!9U:X<7)W5/H:A0JM-!F@KU3@.L.NSAAE<<^:U&!JR^9TS=0F MT\!I];.@GQQ]/5A+SH<_.:NL5/"IP?3@M>**]QJT1)N',>0X+[6FIE>[TV[2 MG34-_BS>C,E;87.I.5NX9M6D]_$X MN,GF9#I@KMOC+$PR,L"Y[6:+T WZ\- M%T2[\0:Z^3_]"U!+ P04 " !:AA-14V+(F+0# #W!P &0 'AL+W=O M)#F2(VE&4I2I M.Y..&]GI0R8/$+D2,08!!@ E^^^[ "E:J2_3%Q*7W;/G[ *+Z5'I>U,@6G@H MA32SH+"VNHHBDQ58,A.J"B7M[)0NF:6IWD>FTLAR[U2**(WCRZAD7 ;SJ5^[ MT?.IJJW@$F\TF+HLF7Y&Z+63 .(,<=JX7]JHY_8*MGY/ R M)8S_PK&Q32SAS&\2L.:>N0>MY-(,_R$[-L/M7J M"-I9$YH;>*G>F\AQZ8JRL9IV.?G9^:;>&OQ9H[2P/M#73"-+L&XSREJ(90.1 MO@)Q"5^4M(6!MC?KP_K=QFL8? MGU3W&M5^/?G8!UL@K%19,?D(>&"B9A9SNI9=EK#)DBVTJO>$7^_I($(R:2K2 M .3DY 8&8<%,@+&T6GKG(VH$=F!#&U)B'\*G67.Z!DUU+ M@&YH@[M3@AJ%VWU.R&/RG,9\QS&_@FO"\WE0.[J*6PM,YG!D6C-G?E9W"N_ MMTQX\Z;?.0G]WGDV"F9:CG QNNPGX]@A9TH>4%M..GZOM"K)0NE'D,JB"6$A MA#/R.7$4J%/45$/@TF4K\90<+FNRD].&)1V44$W3'KFFZ3MOQ0W4TF!&[I2C ME9(TTHZ]K[(+P/^C]]=:GK$?Q'$_CN.G7#"7&ZH':FJU@ ^H,TZEJS3//(>+ M.$Q'),9Z1$M]U\4XQ>L#(Y4=6,%RDD/' \E*4_T/"(_(-)"PD@ZM5=G]B0F] M&VT"?1]OB?><7CK'NCY/R.V9F-;]P^6H/YA,J&*,3'J^&F5)0,8'<>B.\/,( M\%*$T(>PRM)9?=7H5&]T1\G Q7C83R9#)Y22E"2]"G5#)X27ND=TUHQ+U'O_ MY!@"K:5M^G*WVKUJBZ:9/YDW3^(7IO=<&A"X(]&ULM5C;:$B[\9A..@60JKVV8E?FYBS$UVZ7"J<&+!E40CS>(ZYOC]M1^W-PHV< M+QPO=,].EF*.M^@^+2>&WKHU2B8+5%9J!09GI^UQ='P>]5C [_@L\=YN/0.; M,M7ZCE^NLM-VR(PPQ]0QA*"?%5Y@GC,2\?BZ!FW7.EEP^WF#_MX;3\9,A<4+ MG7^1F5N&]+2.EVLA8E!(57U M*Q[6CM@2&(4'!.*U0.QY5XH\RW?"B;,3H^_!\&Y"XP=OJI\8;W>=P(^'NI.I"$ <1A'#;@);4?$H^7 M',#;9_"?XZEUAN+FKP8%O5I!SROH'5#PR2([^=(Z2;&$=I\/7X*P0ZI?D^HW M0JZMMG"#*C&@$XHYU;).<=%484LY5.NU?RM0U-0,9^Z%I\%KE,L@QF#K1C,[W6$ M(9P3U!LSN"D$TW%IMW2ZT<>#=6@DO MQ2-7!DB"..H'HS"I 7K!<#0*PFA0"W_00M4"!G/OA*7@5(G".(CCHUHXZ<7! M8!C6HI/)!+QX%,2])!CUZD_/?UNO""SH1Z.@%_9W[(D(\J@7C/I'6\OO2L.> MY BP\N%MP>T,*'VEIGCAIN9CH+4YSX!WTH$OQ IABDB$*"ZRS-<@D4.ZY>C* M0>3JDE"<=B)G3:_ZO6&0#,+.=ZKF4&I5JOO)'OPGX"08QD,ZA@26>4GAFZ:& M-4M%QT6A3X%M-_*>$- 4DMYUX$+31PJ[=56UT% +HO!I D;J\%SU+W#12/$ M_CKPG]ANC4M1M21^LB1N MU':E4ET@?!0/!\A^OSA<"T4C/-=9"G@+R!73)ZTN#3CQ $MM?>3;EA-WE S: M<%Q-$=:OBJ+/X_%F@ZXTBB)V0965RC?=+>C6,/V;!GF6P@=!@[#P0_UKV<%. MX*4>41C+E7/HG>;33\PHI&&&&1J1YX]O E_>%U5\IWG)N>.U/$]6I:%4*24 MZ]XQ %Z3-(W]Y Y.&?AU/)Z\69NQ)DR=W.P,+FQN)FV::VY'+8;D9D1H-&IF M5:,ABU0JJ3)81PN^977@JMK)$>P#0ZC'+4>]W93&.G-)#UW71,Y!XOL-;2Z- MPZ(95YUIKZ][Q7A,9N5;RU,N7)7(UP5GL- 7_+&LCIV]LVF3>]G^ M&+"*:W?K0E>@F?MK*POJ;E>OUE?C<74A?-I>W:NOA9E+4IGCC$3#SI"& M>5-=5:L7IY?^>CC5CBZ;_G%!UWLTO(&^SS2UC_4+*ZC_87#V#U!+ P04 M" !:AA-1D2Y\32T# #M!@ &0 'AL+W=OM7#-2@: %U]6W+6]N =Y.@#1+ B-/D4/1 2R.;"$6J)+W. M_OL.*5OU)KN^2.1PWILW(\YH?E3ZJ]DC6OC6"6D6X=[:_C:.3;W'CID;U:.D MDU;ICEG:ZEUL>HVL\:!.Q%F23.*.<1DNY]ZVULNY.EC!):XUF$/7,?UXAT(= M%V$:G@T?^6YOG2%>SGNVPPW:O_JUIET\LC2\0VFXDJ"Q782K]/:NX3/' MH[E8@\MDJ]17M_FS682)$X0":^L8&+T>\!Z%<$0DX]\39SB&=,#+]9G]K<^= M\II)"ZNZ5@=IN=S!6@E>V%6A^G<>6 CMX M7)^"W U!LA>"3."#DG9OX(ULL'F*CTGPJ#H[J[[+KA*^.\@;R),(LB1+KO#E M8Q5RSY>_P/=OK6]*S&14A-:U _ M8+C\M,<+%9U+W<<42NY^LZ@[NM=;&US59XF#6_;H.@GR*$O+J$KRD:"(IE45)>ED M!+]73(X C<(7H6?:/D*:9%&6S49P7F319)J,T/5Z#1Z>1EF11U4Q'GW_#EX1 M652F550DY9-\4J*<%5%5SB[,S_5#?#&".M0[/V@-^+8:IM%H'6?Y:AAA_[L/ M/X(/3._HSH/ EJ#)S;0,00_#==A8U?N!ME66QJ-?[NE_A-HYT'FKJ,RGC0LP M_N&6_P%02P,$% @ 6H834:M/FF0V P @@< !D !X;"]W;W)K&ULK57;;MLX$'W75Q#JHF@!(9*IB^6L;2!)6[1%@P9) MNOM,2V.+"$6J)!6G^_4[I!S%P=K&/O1%O&CF\,R8M2,.5 M)!K6B_!B'K=F;$Q?)2JD'M_A2+\+$$0(!E74(#(='N (A'!#2 M^+G##,/^_!G]DX\=8UDQ U=*_,UKVRS",B0UK%DO[*W:?H9=/)Y@I83Q M7[(=;--I2*K>6-7NG)%!R^4PLJ=='O8E$N;,:_W+TL\NK7FN0EEP8 ]:0=_=L)<"\G\<6P9U)7.V M+@<@>@2H(-=*VL:0C[*&^K5_C*1&9O29V24]"?BUEV6:A)A7N' MLGD2U5W%<].Q"A8AWC4#^A'"Y3%X4BF\) ;E0PX8)5DK@9>-RTW +,$\PIA' M[_X!*FA7F(QTXG8GL_/@M=%_# )_]!]DDN71;)+CK)A%*9T&MR],O$F)!FF6 MD+=O2CJA?P;WRC(QD#Q$W#1J*PF7CG7@HE""U\S]-A:'UBF%,7G;-89D\.39 M;!+1_(4#.2%B/HJ8_V\1E:^3:E1#PLX/<#T/OB!:_$([]+O&^* M24.L&D)S.4RS*$L*G&0T*J9%< =(BMM?_@0!V.6PLW7*<*251GF2#%\L@XZC MH/P?5*A3VO=53-G@@;*D4_R621G<:.@8KPD\X>MAP!!:EE%63DF6TVB6I\$U M-Q6V8B9!]0;KH@+^Z%H/22FJ.LMQS*.B2((#.7/2Y],HH:X(2EI$^>QP%<1[ M?;$%O?'=WV6\EW9HD>/N^,!<#'WUQ7QXG:Z9WG#,HH UNB9G4Y1?#QU_6%C5 M^2Z[4A9[MI\V^$B"=@;X?ZV4?5ZX \9G=_DO4$L#!!0 ( %J&$U%VY]-_ MA@( 'D% 9 >&PO=V]R:W-H965T!"%83)\CE9NBUO-W!/%]GQAX$HT') MUOB(YJF<*8J"AB7-"Q0ZEP(4KH;>N-6?M&V^2_B5XT;O[<%VLI3RV0:WZ= + MK2#DF!C+P&AYQ6ODW!*1C)4M,#]_8[]J^N=>EDRC=>2_\Y3DPV]*P]2 M7+&*F[G0_YA-YXL_/LSNQ@\+'\8/-S#]^70[ MNY\^+$X4:#<%VJY ^TB!1S).6G$$N8)R?[RX&Z\/ LU'HSU);/W9UR5+<.B1 M 36J5_0.+_"P@@^))/=HH\](BLD05I*3"W.Q!F: !HO-8!W\!A,LEJ@@;MG3 M5J]_=ICT7\+9Q^7A$W3];JM+:\OOM'MG=Z@U.3"IBHHS@RD9AUI(=Z+ M8[B \[@5PL4QRL^V)2+L^-VKV!%'<0\^NJ]@SPX%JK4SO:9A5,+4SFA.FW=E M7-OI7WK]*-TSMJ-KH=6!DZ&UL?53;;M- $'WO5XP,0E0*M>.DI0E)I*8%442E MJN7R@'C8V./8ZE[,[K@I?#VSZ\1-HR=*Q$)'I34;AJ5 M1/4XCEU6HA+NR-2H^:0P5@EBURYC5UL4>0A2,DZ3Y"16HM+1;!+VKNUL8AJ2 ME<9K"ZY12MC?"VO6'_$'KG7A;"X;F1WZNDZ( UUMXE"E1>"Q&QBS0JL1S.; M-T*K(9J+J[2_E%NR?%IQ',T^([=4&IG#I:JMN4<>.,'K+V(AT1U.8N(<'AEG M:[YYRY?NX#N!*Z.I=/!>YY@_C8^YMJ[ =%/@/-U+^*G11S!(>I F:;*';] U M/ A\@WT-._AQMG!D^9_XN8=SV'$. ^=P!^HZT;^S=!#S+#:G'D?"%4(A1&LNHJO3P0!#Q)["8) M0N=P@1FJ!5H8]/UN?S0^> KZ#W#P;'8'+R'MC4;I9F685(HC"&H?V3_YVJF6+3=XI\3/(K7YG-TP2#'CM;!KM?^,;3U7CB]1PO@O M[)O8<<@@J8U590NF#,I"-BM_:?MP KAY"Q"U@,CGW0CY+.^YY?%,JSUH%TUL MSO"E>C0E5TCWIVRLIM."<#9>H^ 64UAQ;0_P37%IR#[PK4!X_^@6\V$66%)R M\4'2LBX;UN@-U@D\*&ES Q]EBNDY/J ,NS2C8YK+Z"+AUUH.8!3V(0JC\ +? MJ"M[Y/E&_U7VHZ:RN;\F!GXMML9J\GY?T!EW.F.O,WY#9T-#E-;42Y71%6XT M*Z\IE45#MF_U:QV^2.QF=6HJGN"7DISVSIF/K'!D[:W/P,)?IA8,[V 81OTH MNB5K-([ZD^L07FMP<'*72]0[/[$&$E5+VUSK;K=[%!;-+/P+;UZ4!ZYW!:4@ M,"-H.+B^8J";*6TU1]3PN2RXFCI[K:M[SU/I M'DNF;D6%G%:V0I9,DRAWGJHDLLP:E847^G[LE2SGSFQBYU9R-A&U+G*.*PFJ M+DLF#PLL1#-U N,8]A*;C> M*_B99YB]M/?(E^1SDK!>(K0 M, 7TVXJ""D#=#UX"G(SA9#SX_=Q+^ X"WQT&L1N,8R.$;C0*W2"YZ\G-L,O- M\*MSLZ&*?KJAJC5"1H?BM?STPIGKXUY5+,6I0_>#0OF,SFQQB0L;U TBMSFJ MF$2N!ZDH*\8/-INB-E?&1N593I<$K!Z7:\C?EL%Y]LSXOT@UW^)3WB(W2@(W MB",:CUR?6+N""$[]\E81#^-'@XPS>U9]0)T@,\VEV6C%/C*@V':U'4ILTH^,#3VZ]@-.FV3/XW1GN1 MKC)JJN"A.A- JTOA44U5$P&W2OK-E_4$L#!!0 ( %J&$U'VQ,(]@@( (D% 9 M >&PO=V]R:W-H965T*F$-(N@M+:>A:')2JR8&:D:)9T42E?,DJNWH:DULMR#*A$F430-*\9E ML)S[O;5>SE5C!9>XUF":JF)ZOT*A=HL@#@X;]WQ;6K<1+N!_SBN#,G-KA*-DH].>=;O@@B)P@%9M8Q,%J> M\0:%<$0DXT_'&?0I'?#4/K!_\;53+1MF\$:)WSRWY2*X#"#'@C7"WJO=5^SJ MF3B^3 GCO[!K8\?C ++&6%5U8%)0<=FN[*7KPPG@,GH'D'2 Q.MN$WF5M\RR MY5RK'6@736S.\*5Z-(GCTEW*@]5TR@EGES=*6BZW*"W\X&S#!;=[^/C(-@+- MIWEH*84+#+..;M72)>_03>&."$L#GV6.^6M\2-)Z?88;5!#>/8[<97PX$MD7Y7P63F1=F2 M&^!T*1N+N41#C@%FH%""YM+,!J])_R$+.G ME'*:)L/IY.K$>NLNPY/QJ%!O_2-@B+.1MIV4?K=_9Z[;\3J&MX_4'=-;+@T( M+ @:C2XF >AV\%O'JMH/VT91394W2WHK4;L .B\4M:]S7(+^]5W^!5!+ P04 M " !:AA-12T=_8MT" >!@ &0 'AL+W=OO(+QAV #M+,MQ[-R2 )?>AF[8H8=>VSTK-I,(E:5, M4IK>OR]E)][=L 382RQ2Y,?O8TQZ?K3NL]\A!OC::>,7Z2Z$_6V6^6:'G?0W M=H^&;C;6=3*0Z;:9WSN4;9_4Z4QP/LTZJ4RZG/>^1[> M5ZCM<9'FZ=GQ7FUW(3JRY7POM_B$X>/^T9&5C2BMZM!X90TXW"S2N_QV-8GQ M?< GA4?_X@Q1R=K:S]'XO5VD/!)"C4V(")(>7_ -:AV!B,;?)\QT+!D37Y[/ MZ+_UVDG+6GI\8_5?J@V[15JGT.)&'G1X;X]O\:2GC'B-U;[_A>,06U!P<_#! M=J=D8M I,SSEUU,?7B34_$*"."6(GO=0J&=Y+X-6+X+.W1PUS3N@"W\J>1::144>OCQ@UQK]#_-LT!U8G36G#!7 M Z:X@#F%!VO"SL.OIL7V=7Y&_$:2XDQR):X"_G$P-U!P!H(+?@6O&$47/5[Q M?T5?P9Z,V),>>W(!^XG&ICUH!+L!V]>1ISKZ4IVA!5=AXVS>^KUL<)'2\'ET M7S!=WOE8A;J#8W= FA;NL<%NC2XI\NC-9PR(";V]6IKF.C-0'J2'C=4TKOXV M>0U^!H8SLF-;)RDK71N+WRM$\6P<;)+)%Q4K. M(6>\Y(QSGCP% AKN?OBN%KGX!035Y)1]LD/I?#6QQ'4AF7K!J(E@^$]$H63W+6557\%^O5?9B9CMTVWXS>6KB MP81A?$?ON/SNAIG_)WS8G _2;97QH'%#J?RF*E-PPS8:C&#W_098VT#[I#_N M:(&CBP%TO[$VG(U88/PD++\!4$L#!!0 ( %J&$U']BX-D@@( *T% 9 M >&PO=V]R:W-H965TO!^>]^;-VYV=[;1Y ML3DBP5LIE9T'.5$U#4.;Y%@*>Z4K5/PGTZ84Q$NS#6UE4*0>5,HPCJ+KL!2% M"A8SO_=@%C-=DRP4/ABP=5D*\W.%4N_FP2#8;SP6VYS<1KB856*+:Z3GZL'P M*NQ8TJ)$90NMP& V#Y:#Z6KDXGW MP)W]F .KI*-UB]N\3F=!Y$3A!(3<@R" MAU>\12D=$]\[5S+1EB\U?)[D5(^#R8!I)B)6M*CWGW" MMIZQXTNTM/X+NR;V)@X@J2WIL@6S@K)0S2C>6A\. )/H!"!N ;'7W23R*C\( M$HN9T3LP+IK9W,27ZM$LKE#N4-9D^&_!.%KX4P"=P;-%6%J+9.'B26PDVLM9 M2)S!Q85)R[9JV.(3;-=PKQ7E%CZJ%-._\2$KZ^3%>WFK^"SAEUI=P3#J0QS% MT1F^85?NT/,-3_!]U8062,-=H81*"B%A38*0KQG9,_RCCG_D^4G=J*Y'@ M/.#FM&A>,5@LK4O/'F+G81\HQT9:[[^D@3 . IF6W-!VVGO2Q"[ZI(K@5\+"B_&P/QJ\A\LV\W&; M_RG<91F,^Z/Q (Z=?YOR>HG$!_#_3?$O;A4O0O="+WU!+ P04 M " !:AA-1[K^B&*X# X"@ &0 'AL+W=OZ$_*ZVB!J>JK)6,W^K=7,5AFJUQ8JI M"]%@35_60E9,4U=N0M5(9(4-JLHPB:(\K!BO_?G4CBWD?"I:7?(:%Q)46U5, M/M]@*78S/_;W W=\L]5F()Q/&[;!>]3?FH6D7MBC%+S"6G%1@\3US+^.KVYR M,]].^)/C3AVUP:QD*<1WT_FMF/F1$80EKK1!8/3WB)^Q+ T0R?B[P_1[2A-X MW-ZC?[%KI[4LF<+/HOR+%WH[\\<^%+AF;:GOQ.Y7[-:3&;R5*)7]A5TW-_)A MU2HMJBZ8%%2\=O_LJP*2+B"QNAV15?DSTVP^E6('TLPF--.P2[71)([7 MIBCW6M)73G%Z;JL 8@W?%,(M,O/+V9*77'-4\/&!+4M4GZ:A)C(3$JXZX!L' MG+P!G,-74>NM@E_J HO3^)!$]DJ3O=*;Y"S@[VU] 6D40!(ET1F\M%]Y:O'2 M-_#^$)H6J 5\X36K5YR5<*^91G*<5F?P1SW^R.*/WL"_I_U3M"6:Y)8VL>51 M8IE2@C@U%E1PO85UJUN)T+!GRP]%B]!2YB3H+;IX-52$LQK,CKY2#5OAS*FP M7&IZQ ^0YN-@?!EY"\FI*HT)W7^L6&&A*=KP*?X$E3$9-"BY* "-U4Y7!A^S M-!C%$_C4Z9![P[<*!^OR*CE&4YP%HRR&,[;(>EMD[[9%EP+:UKQJJY>I."1V M0#/;2!RRJG/%60G#KG@@'ES=HE(O> NN5J*E;A('21+]>ZMT1G$D4F(25221MZMJ#<_:935"]8CO@\07TY(WED;YKT- M\W?;D.ZV5CJ.H;-JR&!GP=\PF,WI#[B\H:0.'RBNW-YIN1Q]Z/]L^C:O08.T]V;ZBN3 M&UXK6NF:0J.+2SH8I'NGN(X6C7T;+(6FEX9M;NEIA]),H.]K0;=DUS$$_6-Q M_@]02P,$% @ 6H8343_S+M&? P _0\ !D !X;"]W;W)K&ULQ9==C]HX%(;_BA7M12OM3F+G@S "I"FSU6ZU747#MKVH M]L*$$[":V*SM0.??KYUD$A@@!='1W$"<^+P^[_$3#AYMA?RF5@ :?2]RKL;. M2NOUK>NJ= 4%53=B#=P\R80LJ#9#N7356@)=5$%%[A+/B]R",NY,1M6]1$Y& MHM0YXY!(I,JBH/+Q'>1B.W:P\W3C@2U7VMYP)Z,U7<(,]*=U(LW(;546K "N MF.!(0C9V[O#ME'@VH)KQF<%6[5PC:V4NQ#<[^',Q=CR;$>20:BM!S=<&II#G M5LGD\5\CZK1KVL#=ZR?U]Y5Y8V9.%4Q%_H4M]&KLQ Y:0$;+7#^([1_0& JM M7BIR57VB;3UW0!R4EDJ+H@DV&12,U]_T>U.(G0 N>:CH92;%%TLXV:O:BJDT5;=PP;K=QIJ5YRDR4: MW:6I*+EF?(D2D;.4@4)O[D%3EJNWZ#?T:7:/WOSR=N1JDX-5N3$ M>A]*?H-\[U=$/.(="9_VA]]#:L*Q#\*6_ECE:T%HDK OIZ;"?9"' =>.'(WNS4\,I%$PR .A^W$O1R# M-L>@-\??VZ*\MT7Y;(MB:W*G-;6%1%^,"7I0CSK[7FG[:W6KUC2%L6-^CA3( M#3@3= R0ZW7VO(>M][!_?P3?@-1L;F!)I"B84L*\-W\+;;CX^A&*.]:) MVG6B5R9RT&8RN);(6B#< 2T1^VWH>]WF@XD;AK*)B\')/]VA= ^1.$]OUW;0SW][&_!.4=C ^0 M5[5(J-2/9Z'9]2(O36'7$7!_2SB'PN$AA23P MS7_(YQCV+G7Y/I&NY1#OY3CMU[Z TY\@5/MW=\YF]F#\D&PO=V]R:W-H965TOO*]U5:8$G4F=@B M-S.YD"71IBLWOMI*))D#EQ!;@5 MGRGNU$$;K"MK(;[;SKMLZ@56$3),M:4@YG.'5+!5/N'W;UVF'L05HI+4VVU<:6EFJ<'IV:K>/A YK.B&TYRFA&NX2%-1<4WY!I:"T92B@N<+ MU(0R!==$2F*C_V+B:Z/!,OEI8^^RMA>=L#>$*\%UH> USS#['>\;[:T#T:,# MEU$OX?N*GT$/WMQ795KE!WBYOU<"TP-5VBYPG'#U2,Q;F,< M.]K!"=JYX'$?&23S8VZ]3ZGC9 M"86C5N&H5^&J$%+#)Y0E?.0(UV;;X.L5VI3^UI.-YRW]>2]]?3CL@2=91NU= M2EB3&S_AY,FY/#_:C?"$G^-6R/B)0M*C+.U3,CY2DIS(R3#8WX)!KY:E-(51 MZ@<@/ /\4=&M*56Z#;O1&ULC579;MLP$/P50NA# K36[<2!+""Q M4[0%"@1)TSXSTLHB0I$JN;;2OR])*8(='_"+>V:I&N^'G64M7\ 3XW#XHL_)'E9(U(#23 M@BBHYMYM>'.?6KP#_&;0Z:TYL96\2/EJ%]_+N1?8A(!#@5:!FF$#"^#<"IDT M_@Z:WAC2$K?G[^I?7>VFEA>J82'Y'U9B/?>N/5)"1=<<'V7W#89Z7(*%Y-K] MDF[ !AXIUAIE,Y!-!@T3_4C?!A^V"&%RA! -A.A<0CP0XG,)R4!(SB6D \&5 M[O>U.^.6%&F>*=D19=%&S4Z<^XYM_&+"_D^>4)E39GB8+]9*@4!RJS6@)A=+ M0,JXOB1?R//3DEQ\NLQ\-'$LVB\&S;M>,SJB^6,M)B0./I,HB((#],5I^A(* M0P\M/9P=H"_/CGZ0?G]^].M=NF^\'0V.1H,CIQ>?9? )P7@4C)U@Z8H:U :\G)PP-1T+2$\6\$LBY:0PN1,J M2M, QWKZS1#(V]8%GUV,JT7GW(@73/^=DLC-*/ M%[0/V[V@_AO81T6!4=M%W1] I4$\_7#9_E;[L(_#3ZI63&C"H3*\8')E9%3? M)IC^Y:6W>*% 68,XK*?%]89O4^.KE_P%02P,$% @ 6H83 M41)9-1^M @ >@< !D !X;"]W;W)K&ULC95= M;]HP%(;_BA7MHI6V)CB?5 &I!4W;M&JHJ-NU20Y@U8DSVX&VOWZVDV9 ML- M\<=YWSS'YIRD>RZ>Y19 H9>"E7+B;)6J;EU79ELHB+SA%91Z9\U%092>BHTK M*P$DMZ*"N=CS(K<@M'2FJ5U;B&G*:\5H"0N!9%T41+S> ^/[B3-RWA<>Z6:K MS(([32NR@26HIVHA],SM7'):0"DI+Y& ]<2Y&]W.$A-O WY2V,N#,3*9K#A_ M-I.O^<3Q#! PR)1Q(/JQ@QDP9HPTQN_6T^E>:82'XW?WSS9WGIJ_2;3+R;M:[WC2L^X_JM M+F^0[WU$V,/>@'QV63Z'3,M'1CX:'\M=G5^7).Z2Q-;//^/W0VU!H.-4+]CZ MG:UO;8,SMM\Y*252'''C+X>.J3&(K($IJ-W4#P(O2MW=X6GTHP($K!94O>H_=<4E54-XC4-XB!=ZW@G=/X*.X,(.+KP(-R,55831-\A1 MQ86M:+Y&#'1%#H&&/881]N,3T(&@Q$N&0:,.-+H(NA!0$9HC>-%]4\+@)4>] M]^(D"9)3O'Y8$.)QZ \#QAU@?!'P@R')3@*Q_$)HWO0 M&JJ&STKJZ M<%V5K:"@ZE144.+.0LB":@SETE65!)I;4,'=P/,&;D%9Z22Q74ME$HM:[,&/+E38+;A)7= EWH.=5*C%R.Y:<%5 J)DHB83%T M1O[%.#+Y-N$W@XW:F1/CY$&(1Q-6T^F. M-,#=^9;]F_6.7AZH@K'@?UBN5T/GS"$Y+&C-]4QLOD/KQPK,!%?V2S9-;C]T M2%8K+8H6C H*5C8C?6[KL /P^^\ @A80?!80MH#0&FV465L3JFD22[$ATF0C MFYG8VE@TNF&E^8MW6N(N0YQ.4HD70NH70LN<3)]J5N$OTN1H IHRKH[)"9G? M30;E9RWW9< ?OCT2>(%W #[^&#Z!#.&^@?OGK^$N MNNRL!IW5P/*%[UF=_4RGL_N_/9)>CV[O>V1T.R'37_.K]&9Z>__! 6%W0&@/ MZ'^FEK"MY:&Z-3P#RV/Z;)T,!OX@=M>[U=E/\J/^>9?T2F*_D]C_4.(U*(6M MD]5%S:F&'&\\-G_&J.FI0TH;NFA'Q,EY&+Y1>B I]+W#2J-.:?0?Q<3K6,+! MDD9[U8H&9V^%[B?Y0?BVI.Y.-YF7[(;*)2L5X;! F'?Z%5ED\SHT@1:5;; ' MH;%=[72%#RI(DX#["R'T-C ]VSW1R3]02P,$% @ 6H8345=5HL1! @ M!04 !D !X;"]W;W)K&ULC51;;YLP%/XK%MI# M*V6! ,VVBB#E-JW5DK%<-NW1@9-@U=C4-DG[[V<;PK(NB?8"/L?G^\[%_AP= MN'B2.8!"+P5EV7!18:5/L7%D*P)D%%=3U/:_O M%I@P)XZL+Q%QQ"M%"8-$(%D5!1:O(Z#\,'!ZSM&Q(+M<&8<;1R7>P1+4NDR$ MMMR6)2,%,$DX0P*V V?8NQ^')MX&_"!PD"=K9#K9 \ (@ M: "!;;2NS+8UP0K'D> ')$RT9C,+.QN+UMT09DYQJ83>)1JGXD3H"R'4*\(L M0]/GBI3ZB!2ZF8#"A$HTQT)@,^E;]!ZMEQ-T\^XV4++DUQ\2V9+E:_.BCY.IRO.F@XGZ#I]_5#,IO.5U<2A&V"T"8(+R28@-9H M2K"]^O"B-2SAW#'4+'W+8@2\C_M^$+G[T]'\&],+>VU,79Y[NT2E&C;@_3'ARX"59MS&P3NOWZV88PHM&D5?<"OO8] MQ^=1E6A=SC%62 2=J( K(S4.JT("21V( M,QSX_A1S0G,O#MW<2L:A*#6C.:PD4B7G1/ZZ!B:JR!MZAXD[NLNTG,K).-$ \VN$DCS[>" M@$&B+0,QKSTL@#%+9&3\;#B]=DL+[(X/[!^==^-E0Q0L!/M&4YU%WGL/I; E M)=-WHOH$C9^)Y4L$4^Z)JCIW''@H*946O $;!9SF]9L\-G7H (;C)P!! PB> M"Q@U@)$S6BMSMI9$DSB4HD+29ALV.W"U<6CCAN;V%-=:FE5J<#K^ J8&F6 I MNN&%%'LP)Z31Q1(TH4Q=HBMTOUZBBS>7(=9F.PO"24-]75,'3U!_+O,!&OEO M4> '?@]\<1J^A,3 AQ8^G!W#L3'9.@U:IX'C&Y]U2O\Z[7-UDL;>JKDJ2 *1 M9ZZ- KD'+T9]]E[/<^1SU/H,J(A180+J>EO8EM'G]+)/R*N M>J2>RSK2.FVU3E]>37/OIW>).[[%]_Y;('>\Z9,^,9I[72SZ8$L&0ON#3CH+2VN@U#DY<@J.FI"B2>K)46 MU**I-Z&I--#"@P0/XR@:AH(R&62IWUOH+%5;RYF$A29F*P35/Z? 53T.^L%A MXY%M2NLVPBRMZ :68)^JA48K[%@*)D :IB31L!X'D_[M;.#\O<,7!K4Y6A.7 MR4JI9V?<%>,@X MM!I/&>)L]@FP!J7B!;D3E58[P!NRY&H.EC)NR&>J-76%OB9OR--R3JY>7:>A MQ< .'N9MD&D3)#X39$@>E+2E(>]E <7?^! %=ZKC@^II?)'P?BM[)(E>DSB* MHQ-Z9O\-[X\NR$FZ(B:>+[E41$.^35;&:FS,[QZ&<$_-,V#\$#UADE#.*R1,NJ]Q8G0S9 UAE65[].5LMCU M?EGBNP3:.>#Y6BE[,%R [J7+?@-02P,$% @ 6H8342(3=(,# @ < 0 M !D !X;"]W;W)K&ULC511;],P$/XK5L3#)D&= M.%T'4QII:X4 #:EJ&3P@'MSDVEASXF!?U_7?!=N["4 M\8&E5#4T3IF&6=A,H^OD:I;Z^E#P7<'>G<3,.UD;<^^3S^4TBGU#H*% SR#I M\0 ST-H341N_>\YHD/3 T_C(_C%X)R]KZ6!F] ]58C6-WD>LA(W<:5R:_2?H M_5QXOL)H%W[9OJL=4W&Q M=19LS27*/+-FSZRO)C8?A-D$-+E1C?\75VCI5A$.\R5HB5"RA;1X8+=&-H[B M@UQK8&=S0*FT.V?OV-UJSL[>G&<<2=1#>=$+W'0"XAF!+[MFQ-+X+1.QB)^ MSUZ&SZ$@>.+AR8>_X9RL#G[%X%<$OO15?K]9\BO#0CGV\WKMT%+VZP6==-!) M@\[X/SIMT-%AKFTWUZ=FV)%- IE_\1[R)!9"D..'TUG]6Y:.Q>0R'LJZ7OG) M/OAW\:NT6T4-:-@0,!Y=7D3,=OO=)6C:L")K@[1P(:SHDP#6%]#]QA@\)G[K MAH],_@=02P,$% @ 6H834?NP"+GT 0 0@0 !D !X;"]W;W)K&ULC91=;YLP%(;_BH5VT4I;#"9)/P1(;:)IF]0I:M3U M8MJ%(8=@U6!FGX3VW\\V%&52$O4&?.SS/ISWV";IE'XQ%0"2UUHV)@TJQ/:6 M4E-44',S42TT=J54NN9H0[VEIM7 -UY42\K"<$YK+IH@2_S<2F>)VJ$4#:PT M,;NZYOKM'J3JTB *WB<>Q;9"-T&SI.5;6 ,^M2MM(SI2-J*&Q@C5$ UE&MQ% MMXO8Y?N$7P(Z3(LT2KCFB7;6EN MX'OCU=:-:-PNKE';56%UF"TA1W*Q!.1"FDORA3RME^3BTV5"T=)=#BT&TGU/ M8B=(/W;-A,3A9\)"%AZ1+\[+EU!8>>3DT[J[1/HO":32/KN8)W1^V MY$@BBVX3\ ML+*7'+1+L.NELB:&P)VC\;>1_0-02P,$% @ 6H8343P)7757 @ ^ 4 M !D !X;"]W;W)K&ULI5113]LP$/XK5K0'D+8F M3M(44!H)6DUC4J>*"O8P[<%-KTV$8V>VTP*_?F_KO("*Z8&L0>#)6JJ*&0S5QM>U K9RI(K[81 D M?L5*X66IVYNK+)6-X:6 N2*ZJ2JF'J^ R]W8H][SQDVY*8S=\+.T9AM8@+FM MYPHCOU=9E14(74I!%*S'WB6]F"06[P!W)>STWII8)TLI[VUPO1I[@4T(..3& M*C!\;6$"G%LA3.-?I^GU5UKB_OI9_;OSCEZ63,-$\M_ERA1C[\PC*UBSAIL; MN?L!G9^AU41:.:7;C:.#:Z*87]B@NC\+1$GLFFL#3D9 J&E5P3 M>DJ^D=O%E)Q\.4U]@_H6Y>>=UE6K%;ZC];,1 Q(%7TD8A,$!^N0X?0HYTJFE MT_.7=!]=]=;"WEKH].)W]'Y) YK4[)$M.1QRT](31[=_^S:C04P3.DI2?[N? M]P%@& U#>G;> U]D&/491DV!;7Y%KD@P^4).FO3#Y7DN3-=QX%$;I]79(#N"@.Z2AZ51)_KR_M3)PQ MM2G1%X#Y6J*%+K#=WP_[[#]0 M2P,$% @ 6H8341&C?$JL @ H < !D !X;"]W;W)K&ULK571;ILP%/T5"^VAE;8 )B&T(DA-LFF=E"EJU.YAVH,#-P'5 MV,PV2;NOGVTHRY(4;=I>@FWN.3[GWG!OO.?B4>8 "CV5E,F)DRM57;NN3',H MB1SP"IA^L^&B)$IOQ=:5E0"265!)7>QYH5N2@CE);,^6(HEYK6C!8"F0K,N2 MB.@%L /@:$KP""%A!8HXTR:VM.%$EBP?=(F&C- M9A8V-Q:MW13,5'&EA'Y;:)Q*YK!6Z&(.BA14(GR)WJ'[U1Q=O+F,7:7Y392; MMES3A@N_PA6B!6 M]LX)ZH?/(=5PW\#]JQXY09?LP/(-7^&[R7:$_0#][UT2 4RAKPLHUR"^]7 / M.^YA+_?GVC AOD&,*Y"HD+(^6X1IPS.R/.8CWR4X=G>'6>F]R?25:UF1%":. M;AP2Q ZDOO>2OU)=$M2P=_4/-Q=^7X/]5\?%+SZ"AK MIQ$COPOY35W4J8O^J9S123F#2 ^?XW*>AF$<7>&1=Z3./6B")8BMG0T2I;QF MJNF'W6DW?FYLUW5_A3>S:T'$MM#EHK#14&\PUFD1S3QH-HI7MJ6NN=(-VBYS M/4)!F #]?L-U/=J-N: ;RLE/4$L#!!0 ( %J&$U&I+/3$G0, $,+ 9 M >&PO=V]R:W-H965TJ#R89B+6.S=D.=$_]XVL[;* BN'TXW0N)8\\WWXQG M/F9\D.I1%X@&OI1 MITDRB$O*1#0=^V]+-1W+RG F<*E 5V5)U=,,N3Q,(A(]?WC/MH5Q'^+I>$>W MN$+S8;=4=A4W*#DK46@F!2C<3*([-!G[^!"64OYZ!9O\TF4 M.$;(,3,.@MK''N^1?QS!(T:G\[P_/T9_8T/W@:SIAKO)?^;Y::81*,( MX-O!RCH8R MKN&!*D5=FEZ-8V/1W9DX.R+-:J3T"M( %E*80L-KD6/^O7UL6374TF=JLS0( M^$F"*M0!%]TF^JYWT;OB8D%-I9AY@IP: M; LY;/Y.X&]/2%6 2:]AT@M"S5%GBNU\IJ!;XM MGC *23I)\B) 9]#0&02![J78HS)LS1&$-*AAQRN;ABRKU!G--H8U\, #.ZW; M3[O#=)B2[CC>MS :-HR&048/GD56\_(4H"YO^ IM=5Z3J3'[YV1N!OTT'5UA M,VK8C()LEM9C2;,G^$AYA;"@PDJS%6$#*\DK5YT:WHJL\VF!KA$_6Y(+S HJ M6*9A1L4C/.\$+NNF(7,3)/-&R7_1"7@5UBD MS7/F;ISR8ZM\A7JSE6!Z49'D6OI/ZDS"^NK_G,Y;PTBK5S)[;&70O2B"?F_8 M'5QC<5)F$I;F4T:R"_4(IJ1WD9+^E?8D)SDE825<+I?PIZ0"SCKP?VE:G%A:.:A'G.9K,R'>U7/1 MZ7@]7BZHVC*;!XX;:YITAC;-JI[8ZH61.S\EK:6Q,Y=_+>R4B\H=L/L;:2_\ MN' .FKEY^@U02P,$% @ 6H8349;QRK"% @ & < !D !X;"]W;W)K M&ULE95=3]LP%(;_BA7M J2-?#1-!DHC0;MI0T.J M8&S7;G+:6#AV9I]2^N]G.R&44M*M%XWMG/?U 9>;B1=ZSP.W;%6A'?#SK*$KN .\;^;*]/S>I60U",VD( J6 M$^\RO)BF-MX%_&*PT3MM8C-92/E@.]_+B1=8(.!0H'6@YO$(4^#<&AF,/YVG MUT]IA;OM9_>O+G>3RX)JF$K^FY583;S/'BEA2=<<;^7F&W3YC*U?(;EV_V33 MQL9FQF*M4=:=V/1K)MHG?>K684=@? X+HDX0[0N2=P2C3C!RB;9D+JT919IG M2FZ(LM'&S3; M-G:V\7N83#=KA)((B4 :NJ4+#H>VK[5)G(W]V!_S>!R87^8_[B[*T;!7E..> M<@2K--A")*)6!+E@#Z M$&7R9OHHC,-H#_)8U"O&M&=,!QE_2J2<%"\'BA\^4"UH^F9'DSA*QN=[I$?# M6E1_I_C4H%:N)FL#LQ;8UJ%^M"_[EZ[:^2_A[9UQ0]6*"4TX+(TT.$O-,JFV M#K<=E(TK90MI-J-VS&PO=V]R:W-H965T^Y>) %@$*/)65RX11*5>>N*],"2BS/> 5,S^1W8K4AB7BM*&-P*).NRQ.)P"93O%X[O' ?N MR+909L!-X@IO80WJOKH5NN=V+!DI@4G"&1*0+YP+_WPY-_$VX"N!O>RUD7&R MX?S!=#YE"\($W)&@\H3"T MU@U59*G,'=TE_LP/PEGL[OH._ACV1&G8*0U'E5XHQ06# \H!Y)"Z!C[MI0W\ MT ^>B0M?B'L:]43;M-,V'=6VUE6!Y\C<;A#HABM 5YQFNOW]&LH-B!\C6Q5U M2:+1)+W[0H_W96@=HA?K$$X]_1NV..NRS_[?09F]D#!V N:=A/F_G8#Y7^VM MVRM9>KNVMI)+E/*:J:9Z=:/=8W%A:Z3[.[QY::ZQV!(F$85<0[VSF;8LFNK= M=!2O; '<<*V]M,U"/W@@3(">S[D^*VW').B>T.074$L#!!0 ( %J&$U'2 MG4NXZ@( (X( 9 >&PO=V]R:W-H965T -+D,_U@JN1W;D4I(1*$%8A#NNI=>_>S5)=;PI^$]B+HVNDDZP8>]&# M;\74Z46'E\?W+^8["K+"@N8,?J'%'([ MM1(+%;#&.RJ?V/XKM'E"[9U062A?"98XFS"V1YQ7:W<](7IC5&K-*32O^)2M_4-C M[UVP_[ZK;I'O?$:>XSD#\MFX? ZYDKM:[J:G,=7/!^Q)6:]FJ"2Y2S4JTR@?5$'>I98Q09([W,7K,D=6(O3";VZW%S!NJ2 MV$\(K=&<<+4%,([6 MCY(O\#MGE")Z:54T$>)^WP(GB,^Z._JJ#P4]R9!T&9(/S>R]6HD"X:I [;0> M2I+TF^A%87J6I%^5)&X\W.JTPTQ',7\QB2EB9C/"+7(!*SE$F?;V ->/ \]- MO3/0@<(P2=TX.8>UCTX+?5(_8KXAE4 4UDKJW,8J+&].OV8@66T.D!63ZC@R MEUOUAP&X+E#/UXS)PT"?2=U?D.P?4$L#!!0 ( %J&$U$X *C 1P( 'X% M 9 >&PO=V]R:W-H965T_=NS//V4&J M)UT!('FNN=#3H$+R0VMB.UE+^62#S^4TB*P@X%"@9:#F MLX<[X-P2&1D_6\Z@*VF!_?61_:/KW?2RIAKN)/_!2JRFP20@)6QHP_%1'CY! MVT]B^0K)M?LE!Y^;I@$I&HVR;L%&0(S="EYD (K33Z($LI_\:&1UNF+C_KF\47"+XT8D%'TEL11 M'*V6]^3JS?4%VE'7]LC1CBZV_;7?]@76<<F&/4S;LQ\%.% [=96 9@_^DL-?CZ^9.I*6HOM\U$ZF=Q$6;@_(37I MI"87I$N-)DYZ8=\EH/'Q_6DS:B4E?,;=72DC_G\&ULK5?;;N,V M$/V5@9LM=H'$DN7[UC'@."VZ1=,&FZ9]*/I 2R.;"$6J)!7'_?H.J4N4V%&W M:%\L4>(Y<^;,D*(7>Z4?S [1PE,FI+GL[:S-/P:!B7>8,=-7.4IZDRJ=,4M# MO0U,KI$E'I2)( K#29 Q+GO+A7]VJY<+55C!)=YJ,$66,7VX0J'VE[U!KW[P MF6]WUCT(EHN<;?$.[7U^JVD4-"P)SU :KB1H3"][J\'']2!T #_C5XY[T[H' ME\I&J0ZP2&CN^6 GC?V%?SAV'/8@+8U56@4E!QF5Y M94^5$2W ["U 5 &B5X#!Z W L (,?:*E,I_6-;-LN=!J#]K-)C9WX[WQ:,J& M2U?&.ZOI+2><7?JZ@4KAWB"LC$%KX/TU6L:%@9^8ULS9_ $NX/[N&MZ??5@$ MEL(ZL?$FN>N.4]YU,WQRPYAK;*Z8!:81 M8L&,X2DG2F9 UP4O: XK"^XX2I#@C"BXY6CZT!:5LX,ARIJI6(BUG MPQ,:C%J:C\W!SA%H-WE 2V7 M6\A1&R4EBE):J817&C+78Q?DF+]Q2YN_2F%'H54<%[ESPNZ.&T/* XPN!@$$1R0:1>;J\0[175!F9 ;"A(%1C4,=$6#R#94@[2PA<:V MT'I6)>?KKV;18/J->5E-?,HYE8RRIRY%U^!1_YBB5>L28-J(07]5EHIGN>"Q M+X?K*$J/5K-W3"JZITV?4Y)E 5+N91--4V3JN)9>B)F("T$$26F7RU5:>&2B M0%>K9QP5VI7+*WU$35\#B%66H8Y=G2FN !+CI;P01B3C_CA\!]0N#NQ!,D;7 M:76$RJTJD"N'S[3FH5E1?SY_=\HJC^G#*L_%H=;7UD42_EW&9\/A_'PV'#;! MCL6=1?/S<#A]2TXIHUJG&W1#EBEM^5\44Y%WI:L\?>5POV/;&C7;UJA[RU&6 MLJ[",?]-I6:B#S2:4_M723;Q9.YL\+@-.I:O&- ._WV"V0?U'AP&3AG;227O[NI[>VU.Y3XZSFE-53V/\?_)U?N0KK2A:4*>-'83/9YKP MOUG[#WB_"YUR(F@=M&C?V/KSIZ%=I)"V/+\T3YLS[LJ?[%X]OW)G7W^ >Z8I M#\XW3&^Y-&1:2I1A?TIK0Y=GT7)@5>Z/&ULC91M;],P$,>_BA7Q8DC0/'=E2B/150@0B&JE\-I- M+HTUQP[VI=F^/;:31M5H)][$3W?_^]WE[*R7ZE'7 $B>&B[TTJL1VSO?UT4- M#=4SV8(P)Y54#46S5 =?MPIHZ9P:[D=!,/<;RH279VYOH_),=LB9@(TBNFL: MJIY7P&6_]$+OM/' #C7:#3_/6GJ +>"NW2BS\B>5DC4@-)."**B6WL?P;I5: M>V?PBT&OS^;$9K*7\M$NOI1++[! P*% JT#-<(1[X-P*&8P_HZ8WA;2.Y_.3 M^B>7N\EE3S7<2_Z;E5@OO85'2JAHQ_%!]I]AS,Q#F<.47C%(1H=(L<]!'*4:XHTSY3LB;+61LU.7*K.V\ Q87_* M%I4Y9<8/<_<7B*S(3@/Y!M1^&=TSSI"!)C=K0,JX?IOY:*)9'[\8E5>#_ UJ?JL%- N(O8TF?3F*@O5650GSMU>R6.>3Q?+&Z#S#]> MH$HFJN15JHUBHF"M)1MCFRXHX1+ ()2> ;Q/XR3\J/]"D_Y8C3),T?$'CG[6P?0V^4W5@0IL8E7$,9K=&1PTW;%B@;%U7[R6: M.^*FM7F40%D#%O2C3,Y?_!5!+ P04 " !:AA-1((MY'I," #- M!@ &0 'AL+W=O<<_$EZ;AX MDB6 0L\5J^72*95JKEU79B541%[P!FJ]4W!1$:6G8NO*1@#)+:ABKN]YD5L1 M6CMI8M?N1)KP5C%:PYU LJTJ(EYN@/%NZ6!GOW!/MZ4R"VZ:-&0+#Z >FSNA M9^X8):<5U)+R&@DHELY'?+V*S7E[X">%3AZ,D5&RX?S)3+[D2\QIFT3]3U9\/ 05DK%:\&L&90T;I_D^?!AP, 7LP _ '@OQ40#(# M"NV965EKHDB:"-XA84[K:&9@O;%HK8;6IHH/2NA=JG$JM65#O$"/$M M$/.D M9$,9510D.EN#(I1)A,_1!_3XL$9G[\X35^G,!N]F0Y:;/HL_D^5K6U^@P'N/ M?,_W)N"KT_ U9!J.#1Q?_0MWM=Y1M#^*]FV\X*3H[S.B3R0(Q@2!3;"82?"# M*\)0T:I6@*D:K=H*,9NH(2_Z$B@Y96(?-+)!S?7;I4$013%.W-T$F<5(9G&2 MS"U(B?05ESHMVA'6 LJIS'A;JRD2?;#P@(2/?5.U*0[AR"%\@R%B_[&UVHC> M#C;G>T\F/"(3X' 1SC@2C6RB_SN2M4(81QHN;$/)M2\=526M$:\!O0 14XRB M(T8XB/S@KS_]!QT=E1+CX K/$(]'XO%IXKS>?E @JE=6GC8Q/N827_D^?D5Y MXM@BNKQ\77GWH-F81O^-B"VMI:YGH8'>1:R]$7WS[">*-[;_;+C2W+[:K:"G*ICL8;"O%D(F5-MIG+IJ[4$.G=!.?=)$"1^ M3EGA9:E[-I%9*DK-60$3B529YU3>G0(7V[&'O8<'EVRYTO:!GZ5KNH0KT-?K MB30SOT&9LQP*Q42!)"S&WF=\"_V9SO1I[0P_-84%+ MKB_%]BO4!<46;R:XTK=9&H8=FI=(BKX,-@YP5U9W>UANQ%T!P1P"I XCC M725R+,^IIEDJQ19)N]J@V8$KU44;@*>,*D8^IKTT^&^7/:NS3"IMT8'\OBV,4!I\0"4AP?76.CCX\ M0?$-VX8R:2@3!QMUP/X4FG*T*'4IP6X)R\L<<4=]3>_,B=&JC6L%FCA0>U8W M61@FR0"G_J:%3-B0"7O)3"0HDQ%M*"\!S9F:B;+0;?DKG'@O/\&$!.WIHR9] MU)N^D:\TU5=[P'?RM=&(#FB$.([BCFV(&QYQ+P^C,$9_+B"?@OS;HW'2X"7O MH7%R4!R. QR$[<4-&C*#-])X<)@_' XZT@^;],,WUGC80B,A8<=9&S4\1O_3 MF#Q'8QSLO"=X#Y5KU$?U14F<#-OKPWM>B-](Z!IHGT(2QET$=LZ&^ZWMY5+7 M@(_WPGR,'5KCG:_A?F,S:H?/4GMG5;C?JUZK]J%C18'Y=12XL4";'PL0%QP-3B*R: ME6JBQ=HU"%.A3;OAABO3X(&T"\S[A1#Z86)[CJ9ES.X!4$L#!!0 ( %J& M$U'H65Z#Z@< "&PO=V]R:W-H965TFGF8 M?HB79F%_\Q(G\S"S3Y/78;I,3#@I@N:S(?5].9R'T6)P=E*\]I" YP'%%G]%YCW=>>SEA_(3TX&?5V1F9ISE M*4+[X\V,S&R69[)U_%LF'6SWF0?N/MYD_[TX>'LPSV%J1O'L[VB234\'>N!- MS$NXFF5_Q.]7ICP@D><;Q[.T^-][7V\K^, ;K](LGI?!MH)YM%C_#+^6"[$3 M0+ 6@;0M@&L#&!M W@9P+\/8$B * -$VSW(,D"V#5!E@&I;DBX#=-N H P( MV@80?],YOW7(MMF5;J,AFW:32K_1D$W#2>N.DTW+2:7G:,BFZ:1UU\FF[:1U MW\FF\:3H_'!]7A4GY468A66!4]9//[B_71ALC":I=Y]F"1A3H>?O?]Z?SY=>#_]Y^>386;WET<- MQV7N\W5NBN2^62T^>(3^XE&?^C7AHQ;AOD##+]J$$S3\LCG\+OSF$7SGOS=' M_[9,[,[Q0__89N4T&GYUN'8:H-'7+:+Q?=^TB)9H]&V+:'S5/[6(QCM^UZ+C M^''?M^AXP\X_']IY'E[TC 0UX0]MP@D:_MABWIA?%SZT0-E2A6ZI0HM\',EW M'H?)Q/O\XEU$B;6-.&G(R;8Y66/.IVF8&&^91&-3=SZN@W41G)O7VYG_@9X, MWVKVR+=[Y,U[+* 8I>G*3#SK>UYJDC>[^_07KR@FK:MCG5+LU,&HI,+WZVL1 MVUK$L;6\A;-5[9*L,\J=4J3 *Y';2N0/ZZW:YE1]>JO:]U9O]ZA_?&]UI;?$ MUPI=T6!;2_##>QM4>DL)7@GQ00?\']9=LB,9I$]_R^A6#2; (-(,H:-:7.9L MW6,"^"('^'5$E\N4K=L,9"/-:+O\&J59M'CU%G%FO&D\FY@D]?YW9^;/)OFG MJ>< +'* 6(T]OR^CV_4AM:?U^FWFL]%YHS M@2TWX(T:]$9""8V-)=RRMF9!'3P %ZM$^ MUG9/.V@;!;K1CN+690*J D>)D(((I"H (NVHTQO.H9(IC(P \I!U-K_4(7-*J\1$6 M^ 0Y61C@DC7C\N@18, ^UD?_+EF=_F$CP(!NK*/_=1@!5M5 3C6W'$"JVKF* M[:B![4> 56V0*TL!; 2 E\R1#3* '^MC@Y>LS@;1$0"\,6,FJ.J@H\:UZ M(54!$9DK&[QD51M4 2,$JPEXR1S)( /XL3XR>,?J9! ; 0YXX\YL\(Y7;5#Y MOA)840!$[DH&[WA5!I7R-6("'&C)';D@!_3Q/B[XB=>Y(#H .V_B.9/!3[PJ M@\*GG'&D*, A=^6"GWC5!86@&)4XL)([4D$.X.-]5/"6=U%!#FCCSE3PEE=5 MD)% 4H44!3#DKDSPEE=-D-G+$^3] &D%(Y$4 #W1!\1O!5=1% VH0S$;P5 M51%DC&F*$$ #(4K#[P550]DTKH)4A*04CC20+'S*48?#;P17310 -J$,PV\ M$34:J GU)5(4P%"XLL ;4;5 +0*&.( 4@I'$BB >Z*/!%Z++A(H 6W2F01> MRZH$:GLE*) K00DPE*XD\%I6)3!0S,?6"4@I'4F@!.[)/A)X);M(H 2T26<2 M>"6K$A@P10A" DPE*XD\$I6)9#X#+T,D#L?[CJR0 G@DWTL\$)VL4 );)/. M+/!"UGWP2SG1B'-)P*%TI8$7LN8-04*E1%9* 2R5(P]4@#[5QP-'JHL'*J"; MA3?3QPI+IXH *X M*6<>.%)5#Y0^"S0V #M??7'E@2-5]4 I.4.HI("5RI$'*@"?ZN.!YZJ+!VI MFW;F@>>ZYJ-A(3G%/A720$/M2@3/=54$B;(7)\A4:F"E=F2"&LBG^YC@1]W% M!#7 33LSP8^Z[NU '@ALM0&'VI4)?M1U;P<*="B!E;J9E;M?#&]J-W!.-W/N M?I6/CA>_>&FQP.7AUGU5MLRTO\[YO^U!%=L]U&Q':[9[K-E.[6^W?TP[7R(\ M()6-(_Q01N^/L(_\?=; 3MU1&I=ADD7AS/[\-C>++%_CF7FU+[R8IJ^7/>@: MA93HL@2 V: 9LW_GMP\LLM3+8F^Y2L;3,#5EU^O:'53)*AK:$P!8@V:P%B=- MOAKC]3"G.PM76T@-305>!\ T:(;I=CW*GF$#\[G,\]W (!=U 9 V./JKARCL M'LN<#2?7?C5 X.#HKU5CD_I8II3?%?-=*<.=^V#R6^CNPN0U6J3V9'BQ8?Z' M7"N3]5UIZR=9O"QNC7F.LRR>%P^G)K1_ZO(-[.]?8OO7KWR2WVVSO3?P[/]0 M2P,$% @ 6H83419X_2(B P 6 H !D !X;"]W;W)K&ULM59=3]LP%/TK5K1)((WFHTV:HK82+: Q"82H& _3'MSDMK%( M[& [+4C[\;.=D(:1!L:T/J1VXG-\SKW.S1UO&;\7"8!$CUE*Q<1*I,R/;5M$ M"618]%@.5#U9,9YAJ:9\;8N< XX-*$MMSW$".\.$6M.QN7?-IV-6R)10N.9( M%%F&^=,,4K:=6*[U?..&K!.I;]C3<8[7L !YFU]S-;-KEIAD0 5A%'%83:P3 M]WCN#C3 K/A.8"L:8Z2M+!F[UY.+>&(Y6A&D$$E-@=7?!N:0III)Z7BH2*UZ M3PULCI_9SXUY96:)!D=BF4RLT$(QK'"1RANV_0J5(5_S12P5YHJVY=H@ ML%!4",FR"JP49(26__BQ"D0#H'C: 5X%\-X+Z%> OC%:*C.V3K'$TS%G6\3U M:L6F!R8V!JW<$*K3N)!+8BG@H0 JT=E&704Z. 6)22K0%>8.9U$GXKTA[J.U^0YWA.FYZWX'0?_(6@DFC.Z 6[>3K9""\FB^R_H)&.%.AGE,]F>OI+6-[2Z M:&RF_5'@>U[8']N;%D%^+@SX:O@AX.W-&@/>)AK2;\>S4BP2I2B A1M$L)7TD9!GY_-&K7,JJU MC#Z6??0+W>G"]+X#X3J[.NAT;GA5:"YM?%O1[[=<4;TX\X[^M7MV&\78[11Q M]@@$@)0SDD$#3&J+!.*8I:FF N4*Z$F+^WUN-PC;*AS>IZ_1YNWT^9]."/5 M627+%(YRSC(5.L:?$&52'9WWI&E7+=WN>G>.55RP>4-:O9?HH.'=#]QP7V)V MQ='MKHYO%HPW$ZWKV+8C6]W!GQM6AJ!(NVP_(S7=^NVZ<0T"_9N>=ES76*^ M)E2@%%8*ZO2&ZH#RLHTI)Y+EIA-8,JGZ"C-,5.L'7"]0SU=,):R:Z WJ9G+Z M&U!+ P04 " !:AA-1BH8^3S," #;"0 #0 'AL+W-T>6QE9A;T6QKVV!/CQ9SIS^^NG#<9RT M&:$/6_IBW7ONU;E'5\)2W.@U@X<*0*..,]$DN-*Z_AP$358!)\V%K$&82"$5 M)]JXJ@R:6@')&SN)LV :AO. $RIP&HN6WW+=H$RV0B?X(I\? M1_XW;D<=] U*XT**W3Y9P-0F'-"*L 3?$$:7BMI9!>&4K3T\M4 FF51(FPTR M8B*+-$\^''G/[EW/PZF0RM7V%?QWV:?O!3:>%4@9&P1.L0?2N"9:@Q*WQG') M#GP60KV]6-=&8:G(.IK.\':"&TR1I50YJ*%,A#=0&C,HK!Q%R\J.6M:!#6HM MN3%R2DHIB-.PF=$;AC8#QA[LP?Y9['!WQ6A70[NG8C"-H-[T--ZQ_&,VSSVB MO7H5+:KI2NJOK5F-<+X]*W"OH*"=\[MBJ'^(/3K,3NJ:K;\P6@H.?NU'%TQC MLIF'*JGHDZEF3TIF % 8K4!IFHV1WXK4"^CTYC1UQ6'-TS>H^=_VN00!BK"Q M:'/T3[G+KU9\^>E_278_E7W!+VKL+ZM3%SE["R+G)RDRZ'_HHUMCY\X84&3O MY@3?V7< VQ9%RY8R347O533/03R[.@R])DOSTMKA-_DY%*1E>C$$$[RU?T!. M6WXU9-W;1O196_N[75XT=P6WS[GT#U!+ P04 " !:AA-1EXJ[', 3 M @ "P %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">, ?0(8@S9?$6!/D!5J(/ MV!(%BD6=OZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]$%)I6M6X 4BV)8]ISI%" MKM0L'C6'TD!$VV-#L%HL/D N&6:WO606IW.D5XA-/E_G;@2=&A(E@6FD7)TZ(=I7\=Q_:0 MT^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0 ( %J&$U'8 MB%]C7 0 ,HC / >&PO=V]R:V)O;VLN>&ULQ9K?=\=B9V^WHC@VPT 40ED5SZU]\*SA.1X)U[V>0)(S!\+&B_ ME>#3@])W>Z7NV#]569M94%C;7$XF)BM$Q% M$+8J)]%T>C&IN*R#SY].Q[K1$W]%69%9J6IH= W?I7@P3]O=*KN71NYE*>WC M+.A^ER)@E:QE)7^*?!9, V8*]?"'TO*GJBTOMYE693D+PG[#=Z&MS%XT;QWD MCN]-UV+Y_I8#R"RXF,(!#U(;V^W1'9\#X[V G?NUUJJOLK1"+[@5OVO5-K(^ MNL/ 54R\R^CB<%KV0;S4_R>,ZG"0F5BHK*U$;?LX:E$ZP-H4LC$!JWDE9L%I M%\;KG%W7%H+$EG5_*-C772F<>IGW5VT!UXNAOI2P02_S#IP.<@[KJI0YG#UG M7WC)ZTRP+KB&O?OF0T8(9/2&D']''F2,0,:O"+EU$.X/AJD#VS1">Y ) ID0 M0V[6V\UJN;C:72_8=@>+OZ[7.[;Y"BN;^9\>9(I IF\6R3DWA0=Y@4!>T$(N MA,FT;%R[ ]L5@LU5U?#Z\1?#OK0>Y'L$\CTMY+:M*JX?'>!6'FL)?^.0D*ZR M3+60D#S(#PCD!^+;W6KMTN25,="A/::/"--'6B:0'_192-A=[O[1RL;]P4_9 M4RQG3VGI5H(;4:@R9\NJT>I>/(=#A4)LE%O7"!WWAKOXK12O#?Q^Y!W%$R*F MDY#8)PNQ'X0+LT9(KPT+%8KK "O)^UK*9\-D$1+;8F,+H5VVT"W%'XG M#3%1A,2FN)7'PKKL]LV(E_DCQ/00$OMA@-9UV',!Q/P0$@L"E%6!P+9697<^ M$Z:#D-@'*W'D)8,,G F10]<8! MS0D@LA6V[-^)'Z[KJ];VK2/SJ&/-!1.P# M5/.#^CC"S! 1FP''C'U,=+!!/=H8U"/LWG$Q-(Y4U:,/9:8=F+R,0R&.YQ@ MHDF(13.@&B:S8 M4X?I)*%_.7*>DJU]3$PG";%.D+K;L?J8F$X28IV,UMUCMQR324(L$PP2^I&/ MB
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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 69 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 70 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.2 html 157 285 1 false 50 0 false 5 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://advanzeon.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - Consolidated Balance Sheets (Unaudited) Sheet http://advanzeon.com/role/BalanceSheets Consolidated Balance Sheets (Unaudited) Statements 2 false false R3.htm 00000003 - Statement - Consolidated Balance Sheets (Unaudited) (Parenthetical) Sheet http://advanzeon.com/role/BalanceSheetsParenthetical Consolidated Balance Sheets (Unaudited) (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Consolidated Statements of Operations (Unaudited) Sheet http://advanzeon.com/role/ConsolidatedStatementsOfOperations Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - CONSOLIDATED STATEMENT OF STOCKHOLDERS??? EQUITY (DEFICIENCY) (Unaudited) Sheet http://advanzeon.com/role/ConsolidatedStatementOfStockholdersEquityDeficiency CONSOLIDATED STATEMENT OF STOCKHOLDERS??? EQUITY (DEFICIENCY) (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - Consolidated Statements of Cash Flows (Unaudited) Sheet http://advanzeon.com/role/ConsolidatedStatementsOfCashFlows Consolidated Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 00000007 - Disclosure - Description of The Company's Business and Basis of Presentation Sheet http://advanzeon.com/role/DescriptionOfCompanysBusinessAndBasisOfPresentation Description of The Company's Business and Basis of Presentation Notes 7 false false R8.htm 00000008 - Disclosure - Summary of Significant Accounting Policies Sheet http://advanzeon.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 8 false false R9.htm 00000009 - Disclosure - Current Assets Sheet http://advanzeon.com/role/OtherCurrentAssets Current Assets Notes 9 false false R10.htm 00000010 - Disclosure - Property and Equipment Sheet http://advanzeon.com/role/PropertyAndEquipment Property and Equipment Notes 10 false false R11.htm 00000011 - Disclosure - Leasehold Improvement Sheet http://advanzeon.com/role/LeaseholdImprovements Leasehold Improvement Notes 11 false false R12.htm 00000012 - Disclosure - Related Party Loans Payable Sheet http://advanzeon.com/role/RelatedPartyLoansPayable Related Party Loans Payable Notes 12 false false R13.htm 00000013 - Disclosure - Debt Sheet http://advanzeon.com/role/Debt Debt Notes 13 false false R14.htm 00000014 - Disclosure - Contingent Liability Sheet http://advanzeon.com/role/ContingentLiability Contingent Liability Notes 14 false false R15.htm 00000015 - Disclosure - Other Accrued Liabilities Sheet http://advanzeon.com/role/OtherAccruedLiabilities Other Accrued Liabilities Notes 15 false false R16.htm 00000016 - Disclosure - Right of Use Assets Sheet http://advanzeon.com/role/RightOfUseAssets Right of Use Assets Notes 16 false false R17.htm 00000017 - Disclosure - Right of Use Lease Liabilities Sheet http://advanzeon.com/role/RightOfUseLeaseLiabilities Right of Use Lease Liabilities Notes 17 false false R18.htm 00000018 - Disclosure - Common Stock Sheet http://advanzeon.com/role/CommonStock Common Stock Notes 18 false false R19.htm 00000019 - Disclosure - Legal Proceedings Sheet http://advanzeon.com/role/LegalProceedings Legal Proceedings Notes 19 false false R20.htm 00000020 - Disclosure - Subsequent Events Sheet http://advanzeon.com/role/SubsequentEvents Subsequent Events Notes 20 false false R21.htm 00000021 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://advanzeon.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://advanzeon.com/role/SummaryOfSignificantAccountingPolicies 21 false false R22.htm 00000022 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://advanzeon.com/role/SummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://advanzeon.com/role/SummaryOfSignificantAccountingPolicies 22 false false R23.htm 00000023 - Disclosure - Current Assets (Tables) Sheet http://advanzeon.com/role/OtherCurrentAssetsTables Current Assets (Tables) Tables http://advanzeon.com/role/OtherCurrentAssets 23 false false R24.htm 00000024 - Disclosure - Property and Equipment (Tables) Sheet http://advanzeon.com/role/PropertyAndEquipmentTables Property and Equipment (Tables) Tables http://advanzeon.com/role/PropertyAndEquipment 24 false false R25.htm 00000025 - Disclosure - Leasehold Improvement (Tables) Sheet http://advanzeon.com/role/LeaseholdImprovementsTables Leasehold Improvement (Tables) Tables http://advanzeon.com/role/LeaseholdImprovements 25 false false R26.htm 00000026 - Disclosure - Related Party Loans Payable (Tables) Sheet http://advanzeon.com/role/RelatedPartyLoansPayableTables Related Party Loans Payable (Tables) Tables http://advanzeon.com/role/RelatedPartyLoansPayable 26 false false R27.htm 00000027 - Disclosure - Debt (Tables) Sheet http://advanzeon.com/role/DebtTables Debt (Tables) Tables http://advanzeon.com/role/Debt 27 false false R28.htm 00000028 - Disclosure - Contingent Liability (Tables) Sheet http://advanzeon.com/role/ContingentLiabilityTables Contingent Liability (Tables) Tables http://advanzeon.com/role/ContingentLiability 28 false false R29.htm 00000029 - Disclosure - Other Accrued Liabilities (Tables) Sheet http://advanzeon.com/role/OtherAccruedLiabilitiesTables Other Accrued Liabilities (Tables) Tables http://advanzeon.com/role/OtherAccruedLiabilities 29 false false R30.htm 00000030 - Disclosure - Right of Use Assets (Tables) Sheet http://advanzeon.com/role/RightOfUseAssetsTables Right of Use Assets (Tables) Tables http://advanzeon.com/role/RightOfUseAssets 30 false false R31.htm 00000031 - Disclosure - Right of Use Lease Liabilities (Tables) Sheet http://advanzeon.com/role/RightOfUseLeaseLiabilitiesTables Right of Use Lease Liabilities (Tables) Tables http://advanzeon.com/role/RightOfUseLeaseLiabilities 31 false false R32.htm 00000032 - Disclosure - Summary of Significant Accounting Policies (Details) Sheet http://advanzeon.com/role/SummaryOfSignificantAccountingPoliciesDetails Summary of Significant Accounting Policies (Details) Details http://advanzeon.com/role/SummaryOfSignificantAccountingPoliciesTables 32 false false R33.htm 00000033 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) Sheet http://advanzeon.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative Summary of Significant Accounting Policies (Details Narrative) Details http://advanzeon.com/role/SummaryOfSignificantAccountingPoliciesTables 33 false false R34.htm 00000034 - Disclosure - Current Assets (Details) Sheet http://advanzeon.com/role/CurrentAssetsDetails Current Assets (Details) Details http://advanzeon.com/role/OtherCurrentAssetsTables 34 false false R35.htm 00000035 - Disclosure - Current Assets (Details 1) Sheet http://advanzeon.com/role/OtherCurrentAssetsDetails Current Assets (Details 1) Details http://advanzeon.com/role/OtherCurrentAssetsTables 35 false false R36.htm 00000036 - Disclosure - Property and Equipment (Details) Sheet http://advanzeon.com/role/PropertyAndEquipmentDetails Property and Equipment (Details) Details http://advanzeon.com/role/PropertyAndEquipmentTables 36 false false R37.htm 00000037 - Disclosure - Property and Equipment (Details Narrative) Sheet http://advanzeon.com/role/PropertyAndEquipmentDetailsNarrative Property and Equipment (Details Narrative) Details http://advanzeon.com/role/PropertyAndEquipmentTables 37 false false R38.htm 00000038 - Disclosure - Leasehold Improvement (Details) Sheet http://advanzeon.com/role/LeaseholdImprovementsDetails Leasehold Improvement (Details) Details http://advanzeon.com/role/LeaseholdImprovementsTables 38 false false R39.htm 00000039 - Disclosure - Leasehold Improvement (Details Narrative) Sheet http://advanzeon.com/role/LeaseholdImprovementDetailsNarrative Leasehold Improvement (Details Narrative) Details http://advanzeon.com/role/LeaseholdImprovementsTables 39 false false R40.htm 00000040 - Disclosure - Related Party Loans Payable (Details) Sheet http://advanzeon.com/role/RelatedPartyLoansPayableDetails Related Party Loans Payable (Details) Details http://advanzeon.com/role/RelatedPartyLoansPayableTables 40 false false R41.htm 00000041 - Disclosure - Debt (Details) Sheet http://advanzeon.com/role/NotesPayableDetails Debt (Details) Details http://advanzeon.com/role/DebtTables 41 false false R42.htm 00000042 - Disclosure - Debt (Details 1) Sheet http://advanzeon.com/role/NotesPayableDetails1 Debt (Details 1) Details http://advanzeon.com/role/DebtTables 42 false false R43.htm 00000043 - Disclosure - Debt (Details 2) Sheet http://advanzeon.com/role/NotesPayableDetails2 Debt (Details 2) Details http://advanzeon.com/role/DebtTables 43 false false R44.htm 00000044 - Disclosure - Debt (Details Narrative) Sheet http://advanzeon.com/role/DebtDetailsNarrative Debt (Details Narrative) Details http://advanzeon.com/role/DebtTables 44 false false R45.htm 00000045 - Disclosure - Contingent Liability (Details) Sheet http://advanzeon.com/role/ContingentLiabilityDetails Contingent Liability (Details) Details http://advanzeon.com/role/ContingentLiabilityTables 45 false false R46.htm 00000046 - Disclosure - Contingent Liability (Details Narrative) Sheet http://advanzeon.com/role/ContingentLiabilityDetailsNarrative Contingent Liability (Details Narrative) Details http://advanzeon.com/role/ContingentLiabilityTables 46 false false R47.htm 00000047 - Disclosure - Other Accrued Liabilities (Details) Sheet http://advanzeon.com/role/OtherAccruedLiabilitiesDetails Other Accrued Liabilities (Details) Details http://advanzeon.com/role/OtherAccruedLiabilitiesTables 47 false false R48.htm 00000048 - Disclosure - Right of Use Assets (Details) Sheet http://advanzeon.com/role/RightOfUseAssetsDetails Right of Use Assets (Details) Details http://advanzeon.com/role/RightOfUseAssetsTables 48 false false R49.htm 00000049 - Disclosure - Right of Use Assets (Details Narrative) Sheet http://advanzeon.com/role/RightOfUseAssetsDetailsNarrative Right of Use Assets (Details Narrative) Details http://advanzeon.com/role/RightOfUseAssetsTables 49 false false R50.htm 00000050 - Disclosure - Right of Use Lease Liabilities (Details) Sheet http://advanzeon.com/role/RightOfUseLeaseLiabilitiesDetails Right of Use Lease Liabilities (Details) Details http://advanzeon.com/role/RightOfUseLeaseLiabilitiesTables 50 false false R51.htm 00000051 - Disclosure - Right of Use Lease Liabilities (Details 1) Sheet http://advanzeon.com/role/RightOfUseLeaseLiabilitiesDetails1 Right of Use Lease Liabilities (Details 1) Details http://advanzeon.com/role/RightOfUseLeaseLiabilitiesTables 51 false false R52.htm 00000052 - Disclosure - Right of Use Lease Liabilities (Details 2) Sheet http://advanzeon.com/role/RightOfUseLeaseLiabilitiesDetails2 Right of Use Lease Liabilities (Details 2) Details http://advanzeon.com/role/RightOfUseLeaseLiabilitiesTables 52 false false R53.htm 00000053 - Disclosure - Common Stock (Details Narrative) Sheet http://advanzeon.com/role/CommonStockDetailsNarrative Common Stock (Details Narrative) Details http://advanzeon.com/role/CommonStock 53 false false R54.htm 00000054 - Disclosure - Subsequent Events (Details Narrative) Sheet http://advanzeon.com/role/SubsequentEventsDetailsNarrative Subsequent Events (Details Narrative) Details http://advanzeon.com/role/SubsequentEvents 54 false false All Reports Book All Reports chcr-20200630.xml chcr-20200630.xsd chcr-20200630_cal.xml chcr-20200630_def.xml chcr-20200630_lab.xml chcr-20200630_pre.xml http://xbrl.sec.gov/dei/2019-01-31 http://fasb.org/us-gaap/2019-01-31 http://fasb.org/srt/2019-01-31 true true ZIP 72 0001731122-20-000897-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001731122-20-000897-xbrl.zip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
G-VA38+[Y_HT7+4"KE:WLRD?![ P,(J\U#.?11W -%^@,3*(5 M]M!'\&\8K.B?WH.'WSS/\4$5VE7>>.^F_C?@GBO7;&?MO"@D"U& A.7LF_N>CC&)/QV\B?-_N=3K= M]G^^C";> UK EA\RPWGH:"O%:A')=4]/3]O)M]NB7,GG*0ZVSSAN;^'L:J;? M^HKR&23$/R,)O%'DP3CA7?L8("W!_FIMB[781ZUNKW7[I\+9(PQ_1U'(FD.;?=NF#*T6*(S/P]EE&/OQFM&%%PE:JD%2 MW0-&\\]'K"6T&/V==\<=]LQ7)K+Q>DD;,O$7RX!:I+TOS L8,)M.'A"*B0Z7 ML' =0&X@INH_H-CW8% *E5"R(HC]*"11X,^8JV =#C&.R'@^7B*<<*,UH'D- M=4(>SR=QY'U[B((9]9J7WU>TA0W0W/=\ZC?7>^E@5F7-//0A>;@*HJ>]:> J MJ CP !$/^TM&,'U(M%C"<$TN5L0/$2&TDU] XM/'WV!$*! S%[%_E14I-5DM M%A"O*?/^?>A3JB%U6)X7K:C'"N]OJ'TI^5HJRM52$?0Q=1"XO\+,59P38N#Y MY!(50;K!$?4!\9JY?-I[EJQ%ZD"I9"J"-4)T2&2]>KA8XNAQTU%TN)1"%0&[ M10'KO=3=Q^M1!$/J^-=PRJI48]/)5=;CIUKZLF6J\XRLVU![CWPXI1%J;.+. M92)5]C;:I_$*S;;/,/ ,&K&JVI%__T!'KZ\$F3D"6?G*X22=J(2Y])*5M;'% M(@J3X5[?MKBBE?FE>QA0_^4E:^T:&Y MVB&ZIJ':[.%WS(57I$B^KMHB#C/(.KD:HP\S@'K).B,1,XP&HC5')68XS:0K MC%#,8/$EZXM6S!!I!>N-7$IT79UP35&,87M32M4>T90%J99O=+P9H!CZ044# M3J$R&XI<0\SR3X_:Z=-AM5;E-[+CH2$5*IG:QGA#;%K!&D=Y0X@&HO6#-&ZE M9>JH,SPQ-*Z);(TPRUJW3!TUQU6&!C84KPCL=12CD@ 5(O6!ZNZ!JEL_K-X> ML'H5PV(A;]ENH9*I+V V'?ZTDK5#-#9DB2KJC?/+#-]:Z9HB?5,/J!:K%YPQ M\Z;RM4]-2EM54T%3@+4NW;R&IB!KW;UY#=4GN,N[+JUH31GG\A,Y,WD57 \& MWBI(UI9'].^?PWA:N;3;W[<[C[:H@XB+XPF6[U^F>ME$0D^TG+?9)J]--]SN]2C_^;>.! MTUGI]@$!G*(@>>QO:;E"L;8]P&SSAASGYMLBO$PK.,<>B/ ,X<]'.Q\(L9?C MGM\ZEI9H$Y878=6T*&^+K?P<1PN5M5++1 *D6:/1AQR!)\3\8 +.HI'37 ^Y M11[R'UD$?HUB?2-12IF1TK-*BHG>SI&U"4S-^K&HK!DQQU:)D>OH'!VWB,38 M]ZA?5[NJ8CDS&MY:I4&L6X44\!$,^^2W%-5-A#<[X0HS"(&1F9A6RLSD)W9, M;J1!4P1L4ZTW =P$;\6-: 73*\I;[)I25-?"-I2*J:6LQ1H:,PO[KXD!G'.H MPKSYSS@B1,Z92L9:(+(/8WKEG>,KOV-.-I=P)4J718(UQQH2/UMP\-=1Z$E# M.B:@*.]&O"T:U;1*FMG93IPJ4DC?J5WKHYGTFG;.("IK$7IV72BSXL?0!9 0 M?^[3Z%2G4ZE*;#LJ.5D%I[6':9QKF=LI>*J&<=*A6-ZV^S,F3:VP<_R,:.BQ M6[KSULF"& SZ$.,U_2@YF*KW*"7JL.WUC7DL;QCGN)4L<1IFE>1RME,;QAR: M&< YWMB>!"U)N4*V,Q_&C A4<\[\Z;'>\#ZWB/X[4DK48YYU4W.)>FOWJJC/5WCCG^)0!RJD1EK:: T1Q1 MZ\X27$E4ILK\"@K;]@%RXW/)7JFJSK6HS(X:#2=\2=L]W9@0F9+.L7$^F_E, M;QC<0'\V#/MPZ<.6Q#<:3 *'E^3)$4 &&"6ED M;/NS(OKL\I^1NLZ-/OV(Q,QW73XO44A4C80O:1GV>)Y:5XTY4\QV\Y$9FYLA M")1SKN5,4$#KO/\9A=3?!52K\]G"#WW:"9(S!:F.BI2 H;SM,=Z0M'+F<([- M 5IBY/D;LU+P"[;9\/?PZ.8LJ#<,8843B%,M% MA''TE'U%'*^-0L1Z)S(BJ-#^M"9PKR$.PT<*F$VP-@IN55"1)I.P[BCVXTQM M .<&J)$?^_>)-28HIO-H!EWK-Y1"MJ.)O7@S,$.5O4TR#[^B.F^.L4VF\-*? M!NRM*.%R7.CU<;037:/8)+XK%+,]* E1BS98Z0ET,M(S MTD\1#;J4X#WD[?ZY].A),3TZOIZ,1\/!^=WE $SNZ(\OE]=W8'Q%_QCW__F/ M\6AP>3OYX=6'7O?]1W#YKZ_#NU_!Z\'EU; _O+SN__IC+G5J(1_,7PZ0T_>= M>3J8U022JAQ)![.SS!33#8X>?6JIB_57@F;#<-=FSUD*4[,=JDP=__>@Y3U, M28**!P"$+LJUX$PXOZ(N:@LR/&$\#+*0]_Z>1LQWP'TRF MF6&6.!8(KO,[=5*@F M42CH:+9Q/RX5IG&:TNQE']DK5M5\\E*.9AOW(U-F%.>8O$7+="PW:-@T^\(*(1!V)_O-3,]DW6X=_F%-$FTB 5!\+UH1I:9^%V,#'6=URK9&+,JU+!!KR3_+HJ,5YNT,OA3>IH MRL"9U]"(L7)CUD8"%-(?=7C1>QBD\]G?&2V$DUPAV64BG@L\/H?+ KA$E M6-BF BR8.$Z;,:\@X%,!%0R@?-C7G ?AXS\5>&YXE4:!S;3L0CBH@'[,C;J" MH+!AT,7H4 6?&W+5,6(CFI@-LL5[<'-J'33*IC6[HR-_=6I.66X0WD-9L'M& MO4XM&U@H&>2GL87(H@F6^&!(B9D;G"680=?FD:RJ[VX\Y+1P,N#?1GTG5]#V,I&>!1ER1ZFXP6@)_>V+ M6K0=4U+<]I*5,2U*=9TC)Z/6%^K?41# $$6K4OY3+&A[8X$Q888FJ) ZV;VL MF[?VCM*19#- 6;$79&&70Q*4$9.F87YNJ".YJ93G9SM$,WHREG#6VH=O_MR3AP65&-SVXHNR#,IBL''RYK*DFG-Y%L$*$WHT.P M.JG2HB$V9.L#*D+>\NE4U0)!$[1D#QXHH7.IU,U2@26,73%(+C&: \D24\W" M[(EA"K?7O,#LU;XF9-3QWG))RCS,AG*J_$*1LIWR64KA2E$3[58.76-X;M*@ MU*$A(B0+7THRN)%4L?+EP 2(UXX&#PEDHYO/J3/EBV<)KYWG:F M>R\C%W1PM ^DJE'VJ4&"._B\NP69JFARL;!Q!;9?A'5(3REI):>6-(K;P90! M/9=1$NX':V)R)8&MF5EQN205_J8R2=*M;2HJ3M1;\P1[VQR88$DNZ%9$/C(! MNWL9V"')Y,+A\?QJ%5/S?_%#?[%:Y%ZGQ=X#D7PPA=ZW.PSIE,)C#4:Y]'1P MU;8G8!J*^8T2U=BR_GCD!ONAYR_9=<8;3%_@3+8J+REK>W)ER(U" Z?'+XG[ M%.>*3TKO#6XFBZQ51YQ3/N$/E1JJ4V^V.7,TSFB$/N'/W&2.RC4]-!>/IIFI MP.7-N:-JNQ MY4L29R9[RK;LM8+"B,W\#_M#7XYW+.0[P0SUU]\VOORL'_^<'ES MLV=%L>W/;"_PT:<]/]C[VW_^Z[]8^+_?_FU_W[H,D1VCF35=65<>WNY;SW%\?/'@X-OW[[]@M(&\_3[7YQ@:>WO%SN[=I$W^V@- V?_ MQI\'OUIW]A)]M!Z")'30K];_V%Z"_^D\.>$OW^?AK]80__1'Z^CPZ/#?CX:' M'_ ?@[/'P8>/@Z./AT?_)]EY;,=)M.[\\/MA]E\J_AO&^O4C^6-J1\C"!O.C MC]\C]]->0;%OQ[\$X>+@Z/!PTM/==GQC.07NY%.F%)3I%\6F[J8#*3)?+C6%[Q*8/3PC%D0@7LW$30,9VB-5_ M0K'KV)X2*J9D31 O S\*/'=&1A7R;B+"432:CYY12+D1&E"^AR8AC^8/<>!\ M?0J\&1Y@K_Y(\!,V1'/7KKW@V\XT5#JH"? 014[H M/A."\8\$RV?;7T472>3Z*(KP2WYA1R[^^7&((@Q$;HC8OR1,I L63J0G6+<(ND;S5-\OG,'A)7Q01+JY03<#ND4?> M7CS6VPO6]=>XHGL[',< Z) MU/FVX7L/?Z$B&Y@0!J7SL<^A(IF$LL6=LSMEP& M/G7WXF>KTK2V<6EA>WC\9$9(J'VKKKE> M%]V0JY;[\4D2+FOQF8<79%P0[,8R>>-*]7XC$85)%^^57\S1+'M>C4Y MG*W.="AR9XZQHVB/Y2D@B?3F(^7Q"84;-#+2T*4$&T>I/13 MJM)'D],32>/*R#8(4]6Z*GTT/*^2-+"D>$U@[X(8*0+DB#0':K #JD'SL(YV M@'54,RPRY55]+7@RS4V89=V?4+)QB-*&5.BBV7F^BOL62C M9&T.F!TTCWO]8_NS8&F[BJ"KTBT@IK^TOT3+*0H5X99%F\=J>YX:0BK0/"X_ MB,]5H>4RK3Z3:&XG7KSS0YF+ES'CCUW?):DEM_B?)=SH>XS\&9KER$F'K\V6 MPQ^33K(UDYN)O_IKG'N:@O< I(?5(\F,0,I\.RNK:>?84>?2W)UEC5ML# Z _%O,Z M.+"S=MN0-X_(>9B#SUX-R?$G?1\_.G@]@Q^J*X_^&GZGT:*8J3,/@Z70GIGM M JX&10-C('M6$,Y0^&EO<+C!X@41FGW:B_%BQ0R6+CT[BK+TP?/OKLQS5A6I ME3OF#$+$59D"@"=(5P9E6LDIXAQF$Q*(%5;;6NFHSHU$7(!F#H3((3Z.#CM, MR&3 0%\7)_G4X+6#WT@WH[U\O: 0KQ.O1SC+E$8DF1C#/MS-FT&QSE8 M:,)Z#E_'9'DJ#[#$>54")>S@^Z5WP$MA#W?AB2DT83UWYO$$8P??IUUYJD8@ MR">3>T1 DJWC'$G$-3T1XLI,3DRUO!QTR/ G>E^0-!Y[/HWBT'9B^)THMYN< MZ2%#>@;-@ L1H->1I$#S' %)&K::ZV(#-C*+#!9H0V?)=O3$F8;A;_5:G&/) M@ T5],Y:[7R/L *N$Z,9W^+E=AVQ/0,TZ'OUCD!IEE=TCQSDOI#5[AV*,S4Y M Q%'JB,,"54 77:]4Z7L)\=!F![ZV]HL!29+ BG3.9!5 >+@5.L[DV8&%%6% MWY1J6].YX0.'&'EGSCQ*E^3YZA*9[6"D4[0I6< M'A!]'\RD[X[I@T0:W^GS04HL2!)X)_!'9UJY8R8:_ST,(LZN"RS30=X$RO V MT.J0)Y%_@.."&@43NH?=?,SU<$-+_>Y7_Y MG#TT5^M&<(MO9[T+_$)B)7ZDJN5\Q-,SV1Z,#PLK*0+2N>OZOW8ZI[<13/A*E:A$P/XE5X]J:H%4JPY%)'% M%3--I$.IY?9=(HZC LQ/%RKER7>)30!-R8 MU9N5 )Q\E-SK@.0ZQ9U8$Y [O=D+*GQUFR-57O2&.X#1@!NDX@\D^N-5-8Z* MDC&K(V-B*5)OE0'$O'YYS2=$;S1DEW"6>0&LU].U8RSK2&\TI)RF3&>VO*W& M2F-] 4=UAB#X(#5ZHQB%$^\"7K9;=HD4)G:0$;TQB_/9C!K0]L:V.[OQ+^UG M-][ /00+YJ/WHGF2KMO8W9W]B>E&P03SL7 6BM^L([4RTO!QTR_#N]+TCY0<'+E%%( M1^X9#4:.4?CPA)Q$]!Z/ZY60^+^-N6 MZQAO3/AFSL19P&^B*%'E*I7I)$\%Z.#LP3B.1DE,+X;'0[T:407!3K*UC1^< MF)NR9ZCNRR2$C:=.5@=P'F@*??(NC"/4);J4G)?>I(D*:I'G @2Z1X^$SS(F M:4+!8?&DND>2K*O:-9D"JJ*SA>,>12A\8;X6M/8,T-Q<>PM10X8NI$.TNKU7 MW)Y;JX<7\UD"*/Z6O&9.F7QB=*.:YK@0(YO ML)4\W59R=/#:V'1_R_SU=WC];H&O]C=/E?_QC=#J_N'_[RTX>C MP?M?K:O__G+S^$_KY^'5]7[W YIKW/+D&#V04,'3KLPYV.K$!^EH&F]D'!2:Q MV3X?GF6\H#!V\8@@N7=&I.6$)WKFM_RW(]A%"S.'O<(47;3366G:P M5'SE< MT" 7FJN;L]/'1<1PQ70E"ZB0)%8 =$MZ"=M.&1.I9.(;/^5=R=2Y4!=-7L)>]VXE9'K;0Z/Y[^2B8I]9%Y+"+34R MW+15K&;N**9 Z9- MSN+(NJIS M9$&/NX28!O^CL)MZH\RML)FC?&L;$'MRG8F MN=[GV@N^ ;N9[^1W,TE/%NVJI=W,(8JWQ"5M;_7^SG(/HULO*?H?=Z MTQ\B#N,P"]T M9VWZLS8=-J81K5>6UV J%=8NHS_;1I_)6+E08PCSVN:LLO@EC(/#;8RY:'H' M_$:X,:S,ZP388 ?;8->R5D&X0:R%2KFKVP#[K:P**QONT3;<3-RB\A;MP%KW MT.#(,P7(/ZX.)=,FS;#2/EHR;V$GA@VU MXJE2"2L3:7#T7-@>'K,=A$B$##!DQ1-1,:LDU^ $8!JA/Q*R/_P"CNU'%4>T M$;-R.,I4 MG%]Y=M8&8-8TC0>YXA;9D[4VH#-G;3SL%2_)G+NU 1V:Q/'05QTG/)5K0P/A92P2IP7C&I!26(E0]#FK?CW134EODP,OFT+LY:++XC15M: M0"^+X((Y6;@EHV'K28UR;T,@Q R.8C47:QD_V>'2=E;TF/!GV[<7]#%["+R$ M'FVZ\1UNWJ^T?.N9BTI,J*L"CFN:\Y^<)S1+Z [C4Q#&CRAY<^C66BQ#97X,D'LW72Q0>&31U0TK87#X4=:A[ MPB:DA%[UE^ZV*_(!2G:%#+X"X)BF;]=[>WN$M\9GA)RKFR2MQ=VJNR4\[)6 M-+AGTDI$:&OSA(/\N!*G9FRAM(MY>R^%A[X2I.;OJ+2AB%Q8>DA2^#U JU?% MI;.>^Z!8'Q3K2E!,F:7;P%_$^001_QC__#:[M:'!,2[F5H)CKV9#=" 8:J_G MO#;7TGQ2##^G70\O1@;+ZN+.Y$K5A6/,Q=O-Q2>#.6*:3G +7ISM4\("!=I: M<>9A""GKTX4:+*'K>+:VN9;G"^DZ=BUO? G\M4$S0\,/&Q3:Z3DS+6[<*%QSR&XM:746QNR2\7MMN2&/4T6A^[?JV[[BV=^-' M>%)-DTXX=Y"6@T'*/4X&F@8AU3#7CIK5'1RNQXV3QW,#^=(.PQ5>L)\OR0%%/,]<\9=QK0\@2NA9XNUQNJ6A:<%HI3'='SN'&[@O[8,1Q M)?5RAWB=M?Z-/G+71^[>;.1N/2I KVDA1^^XXB8'<,3ZFJ:4UL#3K=] M/B.;C&>S$3FWGH0A'K?H8D(8L;%Y-\.X^8R7%14QY#D\.K^5F3L4=F?H43*Z( JT!04XBU M\9&D4G!!9(16?)Q4"NJ][2^@/4+\?>%K0R<499 22ZDV#*S_5UHVV(3 M':G_ N-6X($>3N_M=^4X'']QS6IKJ!/D( ;'$(-XN+.7P@P,6$+/BU%C77K3P^6%A;>NJ,.P%B5 MU_[.@T@(D7/[0GJOI%C4; *D-8#(T'SU,BDB.[RYQ/,/@EB46<1L;BY!0M00 M*9HO6L9XO_BN/"5;C3M!" LS1$>AD'F[AU"+]=.XI^ZJ13JW"JBM3]:U6?*- M"[E2A R ; W:+OO&A5VI/@;5?6O!XASP@JRO2DTR@1;%#*^6"]EQV:B>G@8N]"]6XG.F4L)F!]<5]#0V$+G/T44I83PQ>A1)),CMP M=K5I-DV.VC?*N,DI6XC:R2>+\C!V_Z2?A[D0@:,>RMX2^UV M(@90_7A>T."D6C:,5T"^A3A.L6H!%WFE9%A:2EX/Q $;8Z4 6 DCB>89$,CH M8S!]#$:"I;[B?5_QOOE@25_QOJ]XWT)(H_F*]R:768F M9'4IM;=Z4DG?+R],^_*:_0*UN=J7 MK@V6_NALY8\6%ZE=N=M#Q:H*MWNT7_:LCQZ;4'RNCQ[WT>,^>FQ* +-MG])@ M +.]HEV2[U5"ZI4\DQQLXC1YGH;5TF0O VO6<-U'N:J]Z#D)G2<[0N>+$%%5 MMB'S!C@%<1W^AV/[8!<=#')%;1%GKJ.JE]Q6?=9GA"'YKA-=V/Y7KG=BM-3A MA]3?D4"L VAMO>5OUZM=>D$C_C\OV%UI:WQJ'P#9S%VP\GHZ+VIVCU45$",0 M-)XE&?Q=""$7D5/E9V,\N<)?X+GI+NQM]]%A(IFJU!U[Z,N JI0!U5]W/:WI M2&9'H]!=N!@U^32M4S?@OS!<47.Y4M( (F[72I9]_5;%^JUZJU.6'Y(,."EV MNMXO4GM1X![,I6X712 VWYG-9IJME>;_O(;34C_=9[:J#L3O>]VUL!R$9M$U M-@4MK !36&EJ/$MLQ! 1'^KU3_A'_T1^=BWSA>W9OL.:39.VK*;F&I>+&#+N MF:X2O0&]$YOJ8T]=SXU7W H>U:JWZPZL=0^M5/2 D0N2%2L5<+DJ],F+??+B M#Y"\>!M$T?H]<%P47:SN[!B_'W1NG7V\XB_6B"XW33*P!_-KX-PB4(2@OA'X.&?X>=2 MPA*:$BIE7I9 6H&Z1T:H0F,9=%9) 2YI04L>\F0,K]8HA%[W-AA@=SR'?D[B MS34]&1+ XD!KLVW- ]W2TSW&BR),]7F,!7RTND9@!)?1TFSK0H E]H]:72/3 MBV'P6A[/T6?Y I'DL/'6R94+2F@G5M:+5>BFE<7RO;MXBD?S+Q$2WVQS4KF4 MA$I;P=S"\FW>R .@%JSO*X5>>?#[Y7V_O/\!EO>7@4=*!(>VQU_";[YG. MULJTI?@&I6@)5VVI9]$-V!4RON&KZ=WM;_*Z>2>.3+Z Y#R)@V6 9T5(>.U( MI6GK=5E$[T @@1=\76I>08SF<]?AG^HL-M&U9A#9DHD3?)9U7\L214$XPN[. M)NMT>M/ $$5.Z#['!:_'NIN%*VA\L1,9_"V%)\9XP8X1TW-$HSE% BVF],,3!"N](8F )48=_2 MKM1J_-O=C@;8OS\H-56,[-C M5DR=3 M9K4&*(B:5AGH"5FRC H8W/%RUJ^U-#E;MP$^KN1MW^*,!-T)2:*$I M-P-Z?@,09$O+0?*K1T+C'6FZW$7->D64H/D:L-^QT'['>B.=DO8[;C*^V<3B M.+I.2([39VR_9;(S*D-;)^,5X5[Y&AR+9 M\CV82] NBI@YD02TD'VYU@+F M#DD0;W.:&0A;I],0/(J2H+ISGR MKCEED2X@"RVXYG>J++S+LQ/>@',NZ0*NL%OPSN]567B?(W\#WKFD"\A""][Y M@RH+'W+D;\ [EW0!66C!.Y^ILG"6(W\#WKFD"\A""]YY<*A*0RXQ.7H#_KFL M#$A$"PYZP \7<20FQV_ 19>5 :.D+?CH@?(2.I>8'+\!+UU6!B2B!3<]4%Y% MYQ*3XS?@J,O*@$2TX*D'R@OI7&)R_ 9\=5D9D(@VG+7R6CJ7F!R_!6==4@8D MH@UGK;R4@8@X:<-9*Z^H!D,(WSS$%P'X1B_[J[M96>X2(&@ MA>V1ZKKTU! PFJET83 /NZD"!DGJI>EWB:=APZ?[ M7\V&^!9>=GL]#HEK:3XIAKNB>G@QV0F]FKM6S^87%M)CK(E+KH%9D60"_@%: MD9BN"MR%0U !\B?0.;I>>'46C>;;),4IO.Q%<$ B+F.UTA+K6MR79(#G" M&^QX0GI\D-CP$D09[HWJYLIDOU0CGR8OD#*\HH51J9FVJ_,D7IE !ND0>]J MB#C@&S^*PX0\E->V@\Z70/GG3 22,+Z$,!EZ0,^;,=DQV4%2T3+W/; MH91XQWCC:6%FP*&,_X8D#*.(WH%&33#+;D*S%YPM#?D^.D:G4!4SPQ9$B]ATKUN23[Z<\?Q)P(?XJCGID3GE MXJ:8E,AF:BOON/!VXW2#/WUEU'V;<1[<7;ISEQ>7ZT51'HA M.Q+*CLD^)W],[0CA3_X?4$L#!!0 ( %J&$U%*>+61VS\ .:+ P 5 M8VAC&ULY7UM<^-&DN;WB[C_4-=[>V-'2&ZQVVZ[ M/3.[05&4S1M)Y)"4?3['A@,"BA+6($ #H+KI7W]5A1<"J%=09%5J;R+&ELG, MXE.H!UF9]9+YMW__O([0,TZS,(G__F;PU<4;A&,_"<+X\>]O[A?GP\5H,GF# MLMR+ R]*8OSW-W'RYM__[;__-T3^][?_<7Z.1BGVC<_24YYOOW[[]].G35[@06!7??^4G:W1^WFSL.L11\#VZ2OSS2;Q* M_HKNO#7^'BV2;>KCOZ*?O&A+_M-_\M.O/J_2OZ(K\M/?HW<7[R[^]=W5Q7?D M'X./R\%WWP_>?7_Q[O\:-IY[^3:K&[_X?%'^KU#_&\'Z^_?T'P]>AA%Y8''V M_>8)A&>XQ5BW?P^WVT(E[)PO8DH*/;94XI7 M8C!1FKZE^F]C_$C)1G_H(_VAP0?Z0_]2?GSC/>#H#:*2]_.)M%\?6VV52F]M M@YWA-$R"<7P8ZJZV(_CDW4GS%W2@J6^]"\LD]Z*#P#_2=- M9AA\V)-N:)X$=LY#[OUXQ<\UHA_>D+]:$/'G',]L#:W6;GCYZW(>T//K[%49Y5GYS33\XO!J7Y_I?R MX]_H!(G7.,Y'D9=ET]4B3_S?AY_#K/HQUM._OS&0?]OM!=4=5&E9)I8?>HI5<' ZQM!B[U"HTT B-DI@$#WGX$&%4ZZ-? M"V509+OJ33:)AGVR*:'S9!.* R.;"J.$;%2<4\D 7)=$5/2FN*2=9AE2;I#3/_4,]WB*4ES M$FZOM1S2BUN;Y0Q UW.<0M8Y:0P!1(J71JKMPD7EP!G..(K>=Y M:;Z3TT6G88TQ9M!KTJC%8?#&"",_JQ&EFB^E&F)ZP)RC:R],V=[,Y6Z89;A8 M_U!X2 IYF].:%G9S2I,*.V>8*<(NOY@0*A:A(#E+9%K=D"EV-R-H\V$7& <*5R6C.6I7F#=.2_NH0C M'_TV)RA%P5SG.QOD$<*A%&E]X9P((C1<5$^_/Z51,1K;VS .U]NUT&P(OK9_68M[^W-N8B6/68-[^$,>8"1-R8%S+ M7%'I]'2YTRS;&6F"<"+XKA@Y$GLUYQSKCU7F4)PAILO\BEH;X K@#?8R_)1$ MP62]29-GMDV<*1U:I8;5U60]]-:BLEP<#._T&+E@O-) 314 $]XHB;,D"@.Z M.#".\S /L2CT5HO:F@9U8*L942;GG$ &X 0KQK4XJN2=^\8S+Z4'59+UQHO% MBX)2*5MD44"L>"(0 4$1.2YN$29X]N(_<1*C0N?4Z\*S)R]=>_Z.+13=>K'W MR"S9(HFV]*1Q-HE]^1)Q#V5KJ\6].U0O'!MK.J?407 YCZG4+T[1HWT+J&X" MD3:^@N7/TPW=29SEZ99"5;CO(D&;7I(<:-,YXJ6:RG1[ MGM.8;=(:;'=V).WO= JA\IN<+3'G--!C4VQM$G&VO0EL,> FR3+B?N5A_(AC MG[A=E[L[+]^F>+K:?[Q3'N4Q;\#N 9^^'6L?^S'5=L[*@R'SFZE9AAJBJ% _ ML?%*XNGJ.DG7.*5OQX\D?,2IPH*IQ.V9,3WHO2V3RSJGCB% SJH15SQ9H4*G M,&J%%C#;-DHB>B @]2*%_>H*V3TT)@+8/B76E'!.&"4L/JJOA$ M,PZW>;). M'L((JQ<7!7(VN2&%V:0')P2&(3)D7'"_ESMU7#]=K4)?X1VWO[%'!.!14J[A6G,BS) MP6E=R3ORT4#^>K>^MO9V"T#5+W?C.^<#*@'4'4LJ<&H[35&\4X_C.R?C^$XQ MCN^@C>,[W3B^ V:@ZZO!=(\ZW]&=@22F.X@FE[3%.DXN:JO@"R]KBQ2<\Z@/ MRBZY"E&TEP7E_Q-8ZR367Z 5R-F-#24PV^%A1P@,;V3(^""1RA77^T^UGS>; MT7L"BCV[MH"]?3D1L/W>6_-;Y^,JA<3MHQC7.<;NAU$)HE2WKF M0R1F[[R''.3^K J\.']T["A_>*\.$]I)'E 0G"A_?0PH?M M0X;_V%)/]9G\0W.262IM-6100VX%"V)1YWPQP\=M(-72B(G#.XOA.QRZ,332B.KP3ZI ;NO+I]K]#K6)B!3^/6LI%-P3IH^ M*!4I*LXW^Q05\5%35!QIN:)(E/>SEZ9>G$_3>?CXI#KDIY"WNGRA@]U:QI ) M.R>9*4)IWL)2 R4I8CJ@9KD2G')VZ\C8Y) 07I,W+0$P7!&AZO*CHL6))ZW+ MQ$N#Z>HJ3+%/=.0SE430VO2D!%K/24(IY^.NA=8=?":+IBM42=L9?<7>J$S2 MU?C+=DS%8E890/R&AZ3.YFSZ*&$Q0;&[*I-TQ039GJM8##(3U!NRMI@P)MX' M/>"[/^JIB%\4PM;XH 5<4T(J"6.&T,'C=E%+>1:5H*="X]0.@P"DPEBHI%T2 M1&8TY**@#(<6)E2J*);=5=(NJ2);E)>+0J>*>N4>"E6^[D65KR%0Y6MSJGS] M.JCR]:N@RC>]J/(-!*I\8TZ5;UX'5;YY%53YT(LJ'R!0Y8,Y53Z\#JI\>!54 M^;875;Z%0)5OS:GR[>N@RK>O@BK?]:+*=Q"H\ITY5;Y['53Y[E50Y6,OJGR$ M0)6/YE3Y^#JH\O%54&5PT8LK>W&79.F"5K&EDH5.EPY.L'Q1[-\HQ9WR1;:3 MHY %SQ?UG@X8OO1;N!V 6+GM@E;RY96LW0Y>Q^+MH-_J[0#$\FT7M)(OKV0! M=_ Z5G '_99P!R#6<+N@E7QY):NX@]>QC#OHMXX[ +&0VP6MY,LK6N[@=2SH#OJMZ Y +.EV02OY\DH6=0>O8U5WT&]9 M=P!B7;<+6LF75[*R.P"XM%N6DV]=+]&67N^E:2]99:^N[/-6&JG!.%K7"ZND M-/M(4IK]*)DICI3"+ A"FH3&$SBD;<)S02\=2,HFF8QS\FB <1YY M08^]+,OGXY 7(T+@R)20NH6;N.O$=!QSK?VZ*#$%9%@]:7((9?A(AS12H91(7<#O85SOPT MW-!Y2]6;EICUH1> Y!C0D(%%!!Z8G \-62>T&&U36C7N.LQ\+_H%>^DX9AFK M!?V3B]JBAPYL11&9' B::,!QN3(*<53((ZI /- B8[@3QE2^,,U*)>A>^VM; MS!"!JMC0_ X$ P2 I $'E7$ZS#.AX_-,1<9<>DU2^!MJ1LL\"#B)/A%H$&!>ZN!1T2%$EZY 1BR<<1;0, MBQ?+"=$6LLL'$< V'9H2@-@@@"4A Y-$I:A++JR]*+K<9F&,,[EWT9&RS 81 MQ X=FB*0^"# )2,$%465K$-&C-RP]I\BE_TID)B;1=AB@AMYDB% 7$ M&!4^"7,J%53H # JD]A/4N( LS,"K%08*_.2[D9)(-^?UVC9I911%]K44JH MHI@)3@G56JIG++;!-(=UV0"B+3CE':TK[>?A,[[R[% 3&S\O4"I9+EA1B# M#G268Q0:@ AF %.V--,H*4A,%U-T81VSKPII+[R'JSI4R(2<%35L A15, MF81S[BAA<:?^*R'T*Q,#4I&AAG5#HH,)^5-;^;8AZ(0='% A0VHI>"SI0E,P MA8HB)@N$+L,LPWDF.8 M$[)ZYT,(L'7)HR4!AAY"6-PAI\5BO%Q HD+I41DQ M@I.U3PP)7)X?'4%@-!&CX\XYW<_GX[LE@L2:D9<]2;I6?&6U9E0#3*L\%/D< MS(@WP' #3+Z",:QS3)@8^CD.% /<%;)[7TL$L'U/JRD!9OB%L+I$V LA'PPG MAKY/%V^R.?9Q^$Q]WCN#)<,0 IN_#$5E-8ZIZIW M6>"8T=,-23Q=L>IUT]5]AMFN=&,:U$B(L:2-@"3&+$TV.,UW,X*7 MW83^8QMNUOJ@V$#/)H&,N]$DE58)C 4R1=KEW6P^G8WGRU_.T.QF>+<\0\.[ M*S3^Y_UD=DMB:^ ,O./\)C,5$+R[P_TH=P? ;^H!DB-:J<(2(N!*_@S%4+RE M&^QEF*;#FJPW:?+,EJBS']*$.]UEHF"387K@37[)I<&P2PNQRZU: 84-C:-P M2Q+-25\ 4:"A$+86P6D!U[&;5!*&4V6$4>Q=;4JM,[2A>F=M4W0BIG2BRCLR M3D(?6R=LC2E:P#53I)+.+8D1/&Z57(WGB[^@J_'U9#09WXU^ 4=7LSUTE8(C2AKLILNE(=*NW[YZ@W P.$5S M'&:8I6F<>2GK6.1E6;@*<:!>P.S5@DW6'="U)@U[J(/A97_,_+9P MD:ISX]%UA2CQXHS\O3O&)MYQMXC+7IIM#G>%76P+BP&+-H3;DF#(I80GV02& MQ9TK_* Y3="2L,D2 ;0F-1I?@^$#CXG+94$D8(S\39)EHR2F21!P[.\(.].M M%XV\--V1CW[RHJW&DO1IP*IKU;MC+5?+6!L,ZWI#YERQ2CE'4>G&'>5ZXA'. M%FPPON; J .M\P=*#3"D,X)I<*HEHNK@:,<.6M#W M" =\8*,\G2%7LG_41=(46PI\W.,XPD',/QO1R32DS M&CFFCG8YUI@S[9,RT5X-!FTDYE>Z[]-##\#T*-X-,E:"8ZT,D7*+L./A8ERO MC/T">X.H\4KI7SIG-DMCK,!:*>7.$;BUT]X;1E"VB/IM"KV";:#>&S^P-WK: ME>%83"OIN%#2[E$\*=3V"3Q.# QYY-CX\W95Q;VL2-SP3(5A<*:1BT)%&%[, MZNU)"2(#QZTLLM4?)D/]Y\=7%@.ZF%%SY*QJ<75Q<5/]'69'Y MP]OF3TD:_HD#(O#^C SQV3??O:N^)?_'Z3,._M>_##Y<_+7XYV#PX>S;;P9G M7[__R(Y89\5=T/O!_33P<*'D,)HHNJTW*.Z*J/,EK@>&=,5151'.PCLJ,'A2OY(Z=L@[( M6=G5 ,I&"4PM"_<1-ER^35C$WN,Q5 JN>=8&KN-8(0V:7RV(6FX5*RUP>27/ M%VRLY9IADHS!ABJ@N:;/&)*%PV M*1VW-I,@>6T]2CR8J3CED\99 UW).CS2R]O)= M:N#N$UU*!)USPP2=FA3,+ZKW\T_$B_+ .*MD0Y/\[N^!RLZGF:M98TN/3M3$ M,="!P2%SH(++2UD2A0';O*RK/F1HND+E\5LB &-.F^-G'&^QKO(#+V9WEUP, MLKTGWI9QSB$-,/Y*=R'V_8GLS93^_):="%I$&&^&FQA[U8^*Z*]1L&9CC(#7 MUD4I[9P3QA"YZT)['911)>11+?3%=#$$$L%+N,1_[<)RJ"P&K+UG#1&*4PYI M*01CY$=)EM.-\G%YBTTSE\C%[<9#:M#M6$@LZ]R>& +D_1,B7N0 +!5>/.L< MCTG35?D**/K:D+'-&0Y>ERBU "AV=%&)*4%3^H,R+0L<1;2T,8Z)VQP1A@^# M=1B'E-UT+BSY+NFWJ;+50WF].M0ZJ&>D"89TO>!VV5AJ,1/EM?1@T/(*;U+L MARR0HUU;T^0!?[+_E#P.I8;=%#9:Z.V4-E)Q,%338^13WNPU"I(U=&!0K#NE M&\[\;ITH$^<)EKLM02>Y>L_Y33"X4M_IIL76U_A&GKE=*.GD=CT/57B??B\& MBS=R@-S%>?(5H@\!)<#6_NZ2.&EWHWP+- &<@9[=#)*&W6CGC=0H@9G=3)&* M,\R$3 -]41JL+X$$>M6B>MF5RR1-DT_T?I#D(2CD;5)-"[M),:FP'6I]+*@5 MXT>Z#:&R93J@7695\M4L"(52SP03W6@IWI(*I;33,G&[A%*#;O-)+ O&4FD M2FE4V"@8++H)\_"13=(+G.<1V[A3KS(H->S>R])";U_)DHI#,U!ZJ'Q=G$=Z M&;"6/M&FVC7I2E$[=?'@C<.'Z";QXF'P[,5^ERX&\M:VU$Q@USMJ*F'GIL<4 M89Q6TN!RB\>3RAJ711EZA!L,8,1=.ZO_)(A.-DO6@F6V2RSFF"BF =%; \$^,462NVL$G44'EZEJG#H-S/F%; MP\'PF.(N!D3#VW,)D%?UN$F;P]K"0R=7P2_R_*J,52V MAHKFZ#&))N;#.DE#T2=0.F0EJV^0"1>"9-@D7MIKG);C]JS[KMUZ45P FW3 MZUR.[W 97=QR>UO+E%J&M[5*EI1W>SM!X;EP*:"J-"&JV2%%7R5JDPB0O"FG=GK^&8&EWH&HI4 MXI"ITL%H3!F6 *$P)"^^,R&CCQ?AZ>IG+TV]F*M0+92P1P\AM#T=6E\#&7X1 M)FZXB1#UR#^58D \"@:=49'>!@R#\NC/'/LX?,;!-%X2M)GG*\Z,]FS#JB=R M2/=:7DJ?!IRS\26H97QEEXW!D;45,)>)&B;]N&K0A".J&G=.PE2M/D2BFH)6 M\O18#OBQTJPF1>L":^<_J[X%PQ,.TB';4O\_+]N\O!M M8R&7!V/+#4#RH7*IPK8TB!)B6NC72N\_8)"-S$(4'9FMGHG/'5SN[C/JQ-27 M,(8T,T*1KUUS=>& ABR?QH.T]&G [@7)OAUK7YDTU0;#T]Z017ZW_T0^ MH=5EXY*E+&E%M"]K!F6>YSH[]/UD2V:$8D>-+E :/R>1JENJRCNC)BFO!^U& M9@_,@L*>3)"ZJ:4D5#*R"UZC;9H2SUHY@YNI.K:;TLYH+":G!Y^,4LSB)!E^ M(0EJ1J^M_@WMTLS;L?!.\@1DPDXR^P@!"Y/[M"2AL4J)DKM^57Z-B)\84?GF M9 N#4'*33< ?--'6>C!FV4XWS*;84@FP^R=&*IU5-X485,XQ@UMFUF^4V>UG MV47Z "97>;<,9EA>&=JR?U_@XKG6*\2!9= SWW9Z\;X5U W%EVTD@KMPWP^W M,(C6+9:#IFZ1C.D(>^/*A@!0V:"C!I16M +&-S@8NFYO?'+WTWC18V_)D/_CVV88M)Y\B;FNQGI4$[SMI)/-U1$=L"Q1P-63XKV[ECK)*FQ-K2H MJC=R+M(BH)YH@)6LT*;4/4,;JGU6I.:M&H#!8/.7]L5O/51S_#(S_"H\"SEN MK6<15JJOQ;.X#F,O]H_@62@; D!E@XX:4%K1"G3/0@]=YUE<3^Z&=R.0GD6: M^!@'V35APEV28\TJF%S<\OT2)>C.;1.A+!C2:0!R$W\I7N12)U/_.LRR)-VA MF.K"(]6\42_R"C]('52EBBMRR<#+"-:5!TDR"4@UT6:S&CI M2D$J7LQNT3TQR';QO;8,M#A%@D^U[Q,0,1@L:9*^N FZI"NVVW3'CL\9O"I" M+5?&2-$%F3T2J$!;3C>#^PINCYL[CR_V/J&&!2\+!UY%A"O'+8UP-V43Z&&' M5I4ZN"B7=G88!_1?=.WIF;Q@=+>57>'L;GE)'EF_)JP6Z#J@E*/HB*(6_I(LVE-^0Z3LD[W":[LC[]I,7R4NIFNFZ)ZRD.WJF=A0A MIL+K URXW'*.+O%C&-,LOM0S^ 5[J:.+C2<>/("7^/L!%P[?\.X*S<>+Y7PR M6HZO4#FD8_+I]!K-QO/)] J&I5EL-YNBFHH751?,)_$J2==%Y4W-Y7]3;:MY M /IUJ942P$P5S$)(/[QF L&13:3 MF1<&9#J7GFSJ2+FH*=>!**HD5XJ X908%V?E6"Q 1%"P3>DDE3]A5%A7>H/O M>U0U X4R]'KNTOM,%Z35K.$%+9]"E #M'#?L2 &BCP3: 0QB52YSVM2),GO2 M&]PI3=,S7(>T9;/+]Z].'7M MD5;]"('(:[D_^! ']1+1),=K[9D >^A?0_B? )3%\ MT0.[JM="W_BO\4K*.]9].Z_&B]%\,J,5 M)ND:]?+',1I-;V?#NU_^LD"7]XO)W7BQ8.O:E\/%9,'6L>?CQ?AN":@J97EA MEB5%CD+?(*V?0L%JAB8M\%9V)JDT&-9J(4KN.M, H]( 9^P7X6,G6HM5-BI F&CKW@WMLAU8"H7=4X?,WSB._&E!AI" MRC_#=47K>*HTK/J0>N@M=U N#NW,J!XJMU9Q/Y^/J05:+,9+5PFOI7<\59Z+ M5@E>8FQSR(([!^5-5J;+@MQ:&YQS(^VG>93:KPG+)\][=\Z(MY CQP- MTQ3[RU]8X#?^Y_UD=DL,#PS"LFTZ78#7%;)).C' )JW:$F"((X35I48A!,Z, M%;"FJQM,IE)L;KL,].QSQZ ;/)T42L 8ID?*D6X\7(Q_G-Y&8 MH^9%Q$8A/IV!TJO9O>5GUHGVK3^U#AC2&0+ESW/Y\-J0]W,QW>+TQ'N$RO?S &%W2QS%=T-\C4JV3:U5L'O8R =\\RJ62=VYK>H 4',,JM')4 M)9_=P; WM+;7OD^[?8]D-^!5"E9#22WP5@PIE79.*V.('*FF;)N.+IG?3(:7 MDYO)\I=3;M7QV9.U^W4J%;N;=GKP[9T[N;QSPO0 *=[#*]70#;2\_PQ> U6/ MDV0FFM8W]LRZPFWPJ=6<\Z\_5HZ&RQ_')WNI %S^9>)^9%@ M8RUK1LR\"[4=TZLXIU(_G.)(+D^$9VI/=;>N<[5*9IATPO9NQ^D [Z^_R21A MT$0'CULEFOSPXY*>;KI?C W.%+R4$PE%QC8 &B91SPZ=FEV>F'6BS1BU#B#N M& %5LHCMTUB8KQKW>M2AOD#,8G@O!=D(Z3D9*&L]&GQ\!,^N0BW@7(5B4)Z2 M*,!I1L] Y.R^F+G+W$/?ZN'=OMUJG=\U579NE@Y%S"\"W-Y.[]!B.1W]XT36 MZ 8_>E&9 C*,'Y4^LUS6FEW2P:V-DTS0.3=,T/'G5H@X:LC#,%(,UJV7YX3> M-/E4<_54?W;%2-?N^94>W6F?83%0=$Z\0]#R9UE^&-Z@V7PZ&H^O)G<_ ,FA MO]@^9/B/+8D,Q\\&=X'EXG9S?JE!MY-\B67!D$H#D$_C58FC0A[<5FVW0UJ' M2R[ODE1JATHF#)96^FM/EXOQ/^_IKLGX)_)/(/:)A*;3U3C+P[672_?>ND(V M:2,&V.1*6P(,082PNJRX+ZITU6(P2+%,O8!F *DV>SI5Z]E-OYVDVX:Z-BG4 MJSM-9ADI@B%<'[32VLA[>1A4G&-B7;>89@5[C$-Z8*_HA_[DI5;/[GE+PVZT M3UEJE,!0SQ0I?QB8Z:%TKPB#=M++/F;L,U<'<6W+@(NFNF HV1.P[+9A^YHA M#'(6USR*2Q]F?%1JV%W(T$)O+U](Q<$038]1>->+KKVBR9H6 ,%PJ'7MA2E+ MR'[+ZNS@_0MC1K0>^C9IU[M;31(:*X.A9%_$78)2?<0:0(T6@ 0GHR3+IRM: MY,G0^*D4K-;MT )OU7N02H.AF18BOYF9L6R^I=MGZZP,F?V[V^]JYAS9=E!Z[T3?AG'@OP\T%'U5R:;H(4[3%O#W6&KQ#JG4J>#.K)Q=WDH#?P.+) M9)W3SA!@EU]EQOWE,3+N'VOJ) ,6YRG+<#@/L]]'*0["G/XE-?$*#;N3IQ9Z M>_:4BH.ADQZCX#K/7H-:KD(#4148#%L\>2F^)/8S&"7K#8ZS(IGFILRP.6'X MPV=,H_),N8Y\4$M6][,.[VIKIZM_,V 8?#AV;G>,'D="A68Q"__LI:D')NBH MDOA/5ZVR9=3YJ/9N@CKJ*NLA3^(L3[GQ/T2E5^PB]_A;U@N/H%M*+A_C/[#2JUJF\UA/O?@O8:S@G\-/0)?'%] M0?.7K4=+;EZIWET5OSC&S0!\/?IB5[T$K%(6?0'2NE% M6KW?18DLNPWB^@; M<,-GTXZ)::S3!LA>0\@JTB;L JU?)L'U "7!E>ZS';Q'"FUW]+!]47B$-(:J M(N*FN2^*JQ;.4(R![&!-"3R/'AL^-'5AGP:LWNSNW;'6!6]C;3!\[0U9Q=NH MWG,-]WNN@&C;]'7$>1.BUS*6Y8+L68 M74O?% G&H+%Z\92D9*))US2&-6>Q3,T-:]6=$+-4K .0E4J@ZJ*61^2=9$MW M#_,RQ=[OR38O5D.41K&7IK6MVWY=J;=KS=2<\ZH_5A6U'JCZ.=&G_Q&<+M_= M'C#+[3')LBT.^G!+H>: 6-I."%@EU8%&*1U0O:D*F3*T&;*=ARW$V>6ND9;- M?,HT;L?-'-JSF^))U; 1Y]1]*7+E8OX^MV,$*[=C-T&74>2B4W*91$T?E:@U MP/#0"*9^';*JWAP=[XR4=F)FBP#EB:\L2_R01CX_A_G3]3;?IGCF[8H2G5M\ M'P>DDVS-0#V3'-BD@PG]19T73/8'M>>LD[2Q%]UR* M?5';;KST(SP.L>?^@H:=OV6GZ(WJ32O?HW71?/GBU6_5_HUJ35B%E/>88DB7 M=HJMF_8#J3/2WWJDG^3?1J_502W9O^)X4%?YJX^]F@'S@AR.7?4ZK O%L#BE MQDU#)_>]A$?RZA3 C7-YJD1U+VK.@:=U<*<%#E;OMD#E['QY/_Y+'\ULGTVM MSK,.US2MB,1,J%5LEQ+2@>_6$Y+)@['"!B"Y"R85"PLIB,RJWSFC7C>DW?&) M@RRG4BT*E$5=?%T"U:81->Z0$\,US'./6CNC:QTG&)@LS7^;$Z!X^#ELK0&T MOH!3+ET,B[\U0_PK\L1],B$T+NJC7ZD6D&R%TE.']QE>;:.;<"5[DXTT09P0 MY;MB=$1TKP;F;3?'*LAD1P00E8!!O%$2DQV5U%&#W=?1 M$B#53CAH0Y3I@06J MC,)2&XB'XF5/UU>3$0FO*#KE6HE$UJJWHH+;\EE$@LZI98*.2XO+OJ2+;8P^ M#SM$->&PYSX.#;G#2=IFC@1JES<=,5"L$6/C J%*BMTJ1@\>^=8_U;GXUJW2 M*YQ[8:3Y7WA.]E^UJ]Z)5L2\!9 M']/@X_-,UU?]1YJK_B2OXA,XQ:Q=_>.W\9#L/;':QEDI/HT)>D M:4#94_(I)E,R._I GGJ61&' EIRSJ@AKL:%&9%=1\NE4L<1-XL79,F%':H5Q M94? 7B$R$;!]];'FM\X9(X7$Y4RF,K3F+CN!#&3/VY6#K >_]*)NF<"4;P^#WL6AYM"H7ZO! ,LS%+\<8+@_%GFC(/EYZ@=$-& M*&MWVTL!M[W1)1!T3B(3='SU!R:+<"$,9+HI"ONP@.$VS'P<$!NUHE5P'#+S.<7::U1&D='(/J2W;&QVQ(JM[9C0QS&B*HXD(%PNX( M3/G46C!>=^E>_ ]IDLE*]>F40)R7:'7 Z*@$TP#SJAO!5%84PK J"@U]?[O> MLF0RQ-LF5BADF7S)WQ$ND_D.U]27^I-]+NV_Y'D=KWF;]#WV0VD2_5AMVWDE M/A:O1(P?*6"5W3URO_C*25FQF5?^!@WZZA]Q-&5*^W"')5ZR7![:-&J$UKQJ=9!6MY_0@[(UHC>@X[5I;FSOF8ZB7\8[1*!1WXM@= MTOH17J.A4^T75?@:KUG#16AMB,A$[>TAJ<'N=Y/$7QI>:8BY^+5-@WCQQE.PR1@]9^R._R) M?25;DC15MKHMWJM#K=UR(TTPM.L%5WY 'V#B3'''V-&B QG9U05 2'%W#/C8 M5H1.1R%:;@$AB2*OS(8 A(/ME-GI6DHX@:#=6H4RH.U2A%TI.+R10>/V4\OL M,H@>"83!DO8-^NH"RYS@4U%&J^4NGX&T"_*\!IP*&&:9X>07,S,_#3?5X:+J M7A%*7P'K:-8 '!##2ZMS>H]FB334#<#@HJQC9K3L:K\"ADH@B])$-"Z_ 2-I M<64OH^?ZTO QC+V(?EIL.^B%*)W=6&J#TUY/OPJSS9;8(6J69L6&A@B^4,S:V"M MUD,OD($Q\G)@G#=>2C(?Y\3E^JK?JH)5@['G1*V/OP0LQX&.'"P>B,%)N5"O M"9R6#S,:4H6F&U M>WC2??UF-;3=D-:5\J)6F@#E=K^I-L"#FOVQ2_(DG* ,G#3C00MS:6+$1T=, M%"QF1# WLB0H)"&PB-CI(+5CEY\@69MP;S)6H3<23!3@VLO'O\Y27_'*>'0 MFIY+*X[15J10'PDSTK09L_?H2G,.,5!S/L'WQ\KOBL?>8W&@U6]HPR!AQV55 M\TXF;)-J:L!-=HDEP1!*"8\S7V71SSIDB)/X/,7%^?F-ET*I/KOG.K'&XL!3 M+6J32BJP32*)Y,#02 &N2Z++Q$L#>F+B*DRQ3QAPE,E05KJ)[GO+8LW&E_;* M*G4![8LD5=\X'U0A'.&) D!^3&F;"/=(OZ*E]QE7:1^&<7!'1D4YIQAK6[Y] MWJ=+G%W-9ZES$IZX,&.)(@,D\ MET]DELK*G)+,;8'!DQ)>LUYO'!B2QU#7@>$RZX[ ;*D58>5'Z -9O'S'TEG2 MW3C&T _G.KJ]9P6B9VN[NN2Z8HLT7)9:ZZ2#F[M.Z M0D3!(#7T"^C V#FZ*YXDX.#>M:I:A9+K6J4/6QZU)+>-TN.MSIH.+2=%]E:]SMW:&: MK<::H%;4^Z)6WK<6,Q*&VZ?LJ,SA5>M8#1Q,X+>B")6"ZN1.RV&09CP7 MBMD[N2,'N=]+YF6<QHX/L4 M$Y$GR#@#9"IJF[F?,>TA#H;$)_0>\568L3/)]&9C>:?1:)(V:<:=9V3>2;FS MI&_#.6-?"+S+Y,DQ[ZIJ+1S#VES$,UH;DVLYL'>Z+@C,GDS%.9?ZX52NH3%= M= -M:Z@]YU]O\VV*;\,X7&_7#/',V[%%DH47%=U_\/S?EZD79Z3?Q*S+[TV] MN%W+E46.\Q@Z54A>UJAS_A^[)X9K=ROV ^5"W:9L^V1A11C[X<:+JC[<>H$D ML! *6@PM%$ ;P85 RCF/M-#X *.4K89$^ MA?E3&*,DQFB'O136N*E/\&J57LWH"2#S:4CBQ_,I7O]T]A[*")D"%:^(P@[!E'G*V8E:R<,P4020R%O0$>.L\DP+C$]E#%6> M3;Y(208KG3R%-$M#+CN52,!NZNXNL';*[NI;./SH0N(NCU$!$O2$)TL[U:#H M=9+./.(3UNN?](C%HQ?1RVUL.A/-@OWT+5X?[-^MQ@U#Z0(0:>GL.+4%)*3\V4M3+\ZS93(CC^B)S,*%R11U M72YKC6PZN#6Q9((P2*1!UR5,)8[R!&U*A2-ET)30HMS=&R7K=1(W*"_JC%S6 M&BUT<&M:R 1AT$*#KDN+GZH]4I\I%%FLC^2_:,Q%@4ODFB&)96T X+"Z>Z9%OEX=@Y6H>Q 84B$PU;O:*)VQ:M0: M6&"?5JJ2W^U_::, &-[S 1A;;6V+T-^!?MW0OA3!OM(*;>WU&//4O1J]>]'\O?H(S9[3+>EU[/B[*U$B>EUS<7?$U'K2\U-I>%@P% M-0"YR@E$@%ZNTFQFNF)05?GRRLL-KO<:ZKKCEJ8[:#G*%B)D%UHS!FC*9C MQ8":5(O3*=F<(\PZT"2I6@.,+V($TXAY1SU<(=F<&$5>EDU7Y;KX-&4GC.3[ M5DIQ:YL5!J#K30N%K'/*& *4'[_Y5"B!.G\C[,_X,YE*PZPX35)_F97?9E*# M=5A;5NW82[K;,F^'-.2*Z=WUK9^'SW@18;P9;F+LS?$SCK>"HQ5*Z=^"Q+SG(C#;$O,V(>+=]R('=H0K,%\82^X\\=5 M<_TR1*(OAHM[1%L^OWCWI2->K+TPIHN39*K#:8H#=O+C%M.I5##X"FEH(ZR' M*GI=UTR O*O5G;6T:HC>8BM:*D['N!FO;KK=..AF#YDE4>COEOAS?DGS=!+"1/12_H$:D'R49O19+WM:R7BP;:*8N?)%I;G7N@@$()I@/^"L95]WP MT;>5M!>2XTI69)2TC M(Q\V,S588]@+,S>@PE%\H V=DY;H?]#M+L=C6+@&A>7)LL0/Z8KHSV'^5%S+ M;]S'WWL2@G(X+VL/ZJB_I#-F="A]J-(:U[_![L)620[JW"[TDFSA>N5/Y<4P MUR: R_5U- X=U"AH(KVD1WW8U)C*7R.E:&7T$J1ZD EA ZPV7C3RO#5 MRC$$KTU\25XM"6N$=#"55W4+,WY&"RV66DX&Y2;QXJPLZS+@B+9$[2!M"K7*8CJV?^,L#]<4S;47INS\4S9=78>Q%Q-#'NTW M.^4I0U_0%JSA?GE'N!-G98OTE<55FVA%&BV.)V8_C&,@V8J?-;3IR0*)NM-FCQ+*G<= MHU%8HW[$'@E**)7D\/8_@H+&K]#*(^7OL#7?5LD!=L_^:9>%/BU&4.[P9*QR M.(L*XR1=DV\(#X*MSW[F89N%,4WC16]=IPGY&*/') F*!>7JQH\;XUP]MW#_ MW.XP[R-)Y&!Q1@U23H.HTD,-13*/8CS)(PSR=\QOVQL@K%5FB)#?3!8UKKHGOB%/Z;O](W!&:MK;1JK?C!(XHDX*%A$PV/ M5F%*[-T?6Q)TN1E'=HM):.7J;V"-3Q>68BPR*LILF--9WD919U!#U!>V8DE" M4-V0SDYI^+#-V0N5)\79IO-D=5YOHR'Z]%%2P7"XOG5HL5)0XRD':%:T%,+N M\L'504&-1/]W25$EU,V"_)'N98$:%CU0[?VL#!&/@%DRIV%,@H&"/D[=3(5(*/QWGPTWH,?C2Y"@]%X#VHTOC8?C:_!CT87H<%H M? UJ-+XQ'XUOP(]&%Z'!:'P#:C0^F(_&!_"CT45H,!H?0(W&M^:C\2WXT>@B M-!B-;T&-QG?FH_$=^-'H(C08C>] C<9'\]'X"'XTN@@-1N,CJ-$87)@/1R4+ M>#PXB 8#4NE &1'9$HA"%O*(Z!9#%#I01J1'4#Z 'Y5S$$U&!%90/H ? MI7,0348$5IP^Z!&H#^!'ZAQ$DQ&!%:L/>@3K _C1.@?19$38R-;C,)T\%* 'J\"7/=1-T1=61(!:LT3A_FH M39ZQHT?+,IX7)]XS:J;RG>@)\U* 'K0"G+"Z42GZ%U0(HV'GY.O,@T%U,G&8 MC8Y.!]!8&4-5O"GL1G,A[FB01-FFN]\!>N@<)/YT?R'@Z'&.DHPE61V71VA% MC[4K ^CQ2J'QM2:R,L%K)>KH@==7"2:QGZPQO9PC>N8",4"/786N^^1K650( MHR^HN.WT]17RZBYGR8++)$V33P2<R5G,V\>/K+# MZ NS$B(<7&W3'#>GD9@11"\4TW M1EMZ!;W,;=6$NTQH0LTDSDGS$>->89C-HL!#6@8TWD?ND$FT>8;JGT#E;W#T M:?\,JG['%9]8,;3I-L]RCR4R$%*C*P1IE*78N %CDF>H(>O,1?13>LGS"A?_ MGL3#HGI$-L<^#I^["4WZZ &:^GK!Y7W(0@E]4:E_2?.C52V@?1-@!I'-V>5: MJGQ1WD0/]" JX!H.8N'^'2+ \TF@;$RH/'JC[G7ZU6V@]SO0A"7>N1E3[,T>0X#'%SN[C.:\JHF MX)!6Q9,.K;DVH+$] +0H$*%MH*H1]+!#7]P7>4*_1/O7=]^6H_&M#,O[QQ7U6F*8EOB?:^V#*"QDD(39+FJ7KEDA:BH*WN9 M)C[&079-/EUXM-K"DD[>VW3'UA2$1E*M F@X3)$*3E4QO2(/%=6DHU3I%K7; M81G LAK&@090H UH% \ W=, UDVY-X 4)9FRZ;_H7/M,N$>,Q RG81)TG73A M[G4/?4!C?!!L;M>;CC#U4M@?C7:("\-:0H(@Q>4N4VOA0ECJS$ /4MH] K[ MCM4VH!$_>I>X\]&-:B-7K6HC5ZUJ(\U?.8,55 *O8.-^7^OX?5&PZ.#&'4X0 MHX2$SFE&D!5_L?3Y5=6X(@WN0#9CF.@",BB](0OGE'T+9ZAN ^T;.4-%,Z\] M)3J0=]<,)'L'UZ!/>UNM+ IMO"RW6V_ M6$ND#N3%ZP]8NB6J:\'A]+>WV[=>ODW#?'=%9O(KG/EIN.D.9"]%0"]D/[S" M6:\YOU4-(-H"=9;K-@0#V?SHAOQ%/JX^(O]X(,0@G_P_4$L#!!0 ( %J& M$U'/'7&MHRP )3^ @ 5 8VAC&UL[7WK<]NX MDN_WK;K_ S>G=NMLU?4DC>[&W_[]^RIPGDB<^%'XRZO1#V]> M.23THKD?+G]Y]>7N9'PWN;IZY22I&\[=( K)+Z_"Z-6__Y__]4\._>]O_WQR MXDQBXJ9D[CQLG(N >&D<.9=^0#M(_K=S?3TY<1[3=/WI]>MOW[[]0(H&B^+W M/WC1RCDYJ79VZ9-@_LDYC[R3JW 1_>SW 3XE"%A_A#%R]>G;]Z,7O_WY^L[ M[Y&LW!,_9(KSR*LM%>N%1S?Z^/'CZ_RWVZ:MEM\?XF#[C;>OM^SL>J:_]27M M*YPD_JL]^^I@AE*Q*FXW!^$:9^NF%PQ:N<6RI! MWMUC3!:_O&(CX83!_^;'MV_8-_\"H4TW:SJ0$W^U#JA&7G=E\\P-F$[O'@E) M$Q5?W,8F&)FY,17_D:2^YP9:7'$I>V)Q$H5)%/AS-E4P@R,,HV2ZF*Y)G&.C M5""\!Y,L3Q=W:>1]?8R".9TU+W[/Z @[)PO?\^F\N>DD ZQ+PSA,W.3Q,HB^ M=8:AU4%/#)^3Q(O]-0.8?B1:K=UPDYQEB1^2)*%&?N8F/OW\+"8)900V173O MLB>A[K+5RHTW%'E_&?H4:I=.6)X7973&"I/HJ3 4 M%5]2HIX8NR4!LUXZW:>;Z\@-Z<2_<1]8EW+>5'2]6?R#$KYJF_YF1F8V5-_7 MOOM =Z@I9#H7D?1I;=2FXXS,M]\ S P*LK[&D;]\I*O7EX3 )@)1^][9R8U( M0UUJRM[&V&H5A?ERKQY;K::]S4M+-Z#SGT<(.^$_)Y1([IX M@LR0HO;/NC3WNT0;6JIA'[]G4WA/@M3[,K;C@+&LHC.X^X QJ*8TN1.!\0@@ M-;PK@?$)H^YQAP)CJ]W2W&X%QI&2T.S.1<-T5<2&=C' \2:E,KZCT6523O^L MZ\TY25T_Z&G!:71F0Y ;-V;^IR?E\>FP7ON:-ZKK(1 *&8VQ-1[(FY+0X"H/ M9!% :IY)\"C5ZF+V)4J+)H(3$'%.C M#ER-S+-UVH&MTY[98EM>7;.0T9C;,$.7/R6E<1;!BM3HPNP^7V?Y5E(;VNE# M9T YF5GFP,A#Z8T?3;2UJNC@N1A63NGP'IZ+9>5T#^^A?P>W_M2E)#7D<=8_ MR,'H9>RN*Y?+U_0'-1+R/27AG,RW'3&N#XV7H3]FG92A32/GQ-E25?_JAG.G MZ,*I]E&ROF4^B+P:OP&+)(IBE=[83WZ3\3I^2-+8]78W>X'[0(*\^]\8+8ST M=1=FF6X3JMP\N"DAW@_+Z.GUG/BO3]^,/K*_G+"_G+P9E:%-?Z$_^JU@XI8L M??;M,&7A9!S6:5-^RR:GU3$QCCTGBN(H4@5?52%IX?@PF5)':#*VHTW_^3;&0@M)H"41CA@T$@ MM14J[$LRD4'NM)5#[;U%JGR.S%1!* MO^.EGWAN\ _BQA?AG$4D\X$0MP:"\0X3&"K9K0"RE>6>]LL'H=X"J/CWF!3/ MD]&JLF\>+0DMWE(*%:L6[*.8N8D+?)^I&<% 040EX^8<('HP"(X MEWY ;K+5 XEE@%1;@<]M^%!H"VM9\_&$+F++*):>G!L-H?I'>'#FBFP1@KM' M$@1E(HH,@7H[* "H3M!B@6WJ?^4&P38!2 I O2$4 52G:(G(%B&X6)%X21>D MO\?1M_018 L" B@DJ,[2 !58A.8J]**8[A=R*?*4OPF+68LWDV@N]73]URUR?'BD\!!0G5&1VB!)L'D?U-Y]TCU4$RS=*\ MP@(U?NEQ1$H'10K5Z1VN$ Y>?WO=$O2:_L#_5?+0+_V0\N>[P2Q*?,6%;$D.H^YL83V*=U]-594(4K93F5-K5/9K4UKJ MK9N50*#J>1@#'M0:R17]*V_#W12ATA89+K51)4*@PO[N5A,)"I/ 39*R L7X MNP\!HTTR1$S:4E0N^BTB4^7K/%JY/N]:MVS,:XL,"]'X:L#"DV0?_F+34$CL MDV0RHUT2NG^)JOFFHA:]CTUT7QB==\%(0&3M0KX; M1E+1#\5($,=W2QA;+'%M^^U$JG9&I*"Q=AL/UCI "$R&442"JS?QS7:V A,E M^R;NZ.?+ATGWV\Q$( 2MYM:"$^4:YL$@$!4'&JPZF60?E?_66D B2(T1AV-, M&KXEE&'?2\EUM MD XV$/D-;87*K\Q82 4K*=A(Q1)LAI14MK=#(.V#),%D)T7&854TL77PVEJ+ M6>Q@$V)9<6 !A*$; OW?%U$(.<_;2*'6#O*55V+8E(F:! M6USX;.M$J+>Y %)K08\=X 5K H>]"=F]X:Y2*B%O-%:I_F,AM2$ 0G>#;<7B MECCY>QQQ0Y5*(AF-O<#) R%3*\+0!D_(L&!K)VEO+VJRJ_(5 ME>TD3NR?H> M]"8*/>$V(_?JB=O;B[,\!#*E G!,;O5*P**]G\U02WU/F'VCZ&GAV9>+H*.N M_4B!>KL'[\%>W*:NTUE7*SCLK,(UV"PM[;9WE[H9U?(Y)+C0(<5I5-" M4FL$Q<&8[T(;!XZ,.)1_34]UNV)VWB8O$><&$S>.-_1'^5-M2FQT^H!"9\R/ MH0V=OH9P(%N^UQ4N:R7)-FIGO((.?'V+!D&8)I"@QB_4"+Q"$=-!43/F#]%' M#:0)'*CI('4(.L9<'_JS(@2109[&!;.%U+,EGV@Z.+E.C?E7^IH]L3JZ.(]* M26T0#HDQETA_1^R78H-=?& ]>+U.L7I1AN+]JL='YWMCV7TGIS$4*6->$6UL M)#+C *62]:E I-T2"H[K+-Z*EJQ $%HH;,;\ M']JPP36" \&V@#I[!HU :30(B24>^CY0M6WJ?B,*Q_DY/"(';ONENNEU#-@M M!3'+U?I(4M^KK!NUNA!ON]6%FLUV!HB-H(@7@!>LJ M23)=H+8TMDM7' 1277"\ ,FKM$H$[%*FU=BV[B"H8'59[=XEZB]?(&+;M3# MN&FH AUV\&5+2F1[6]X%*]P+5HM1U6HE)+!=/Z,[-AC7*1 ,&@6-[;._ M4(,16 1,B[4$C(; ]D_T*M6W&&XI>I"!/9,H25G8RL7W-0D3R&PEIK!VTC]L MVE*I (*B,AW1(%5*3Q?.6' M/A.'3<6E@+)K-1B][:.\)F)Z:L$!Y3FA2O7\0J64XQ6KX_E'_D\Q?E(BVV=\ M3= "L"!5%,N^*ID_U3?8>KCB3KT#<8N:Y$](;@BU](J?MS&UCP&AVTK)((/ M'=.;*(SJTI6C5KU[!)!:*[!Y&-Y@I>"86K<2EDR>17$IJJQ\+6PW)D@T=^]9Z%3Y1 9E/KU#,5F09T"(*Z]4\N^,L5P(.H[SV M4W]9O+%+TC3(';'*DX64R'HMSZZ 51ATS0%/LE+^J'B,8:[!_?"?PBN(S<< M,]^]QT.0T# M+)4%U2@)K1<"50(@QTN@"1RP_4I8274R'S_1*6=);C(6R#]=Y(Q7(D_ :';M MSWJ544V0#],;VM"2,@&DEMM>%)Y@Y3CYL2;OF[$FTYN[Z?75^?C^XMRYNZ=_ M?+ZXN7>FE_0?T\E__L?T^OSB]NY?__+A=/33S\[%__UR=?\/YZ_G%Y=7DZN+ MF\D__NW@.)3><\.[E<@"D6/(@QUZ=GB'(A[']' DJ-/#BZ$TB5;K*&31 MZP"27'0<^[1/!5>@%&3N2ER\ZC],T]A^R ME.V#[B-68#L*4ZJX('>[JFY/^^H?S9+7.G$HRQX>HM#.;NDU77$CYJZ(4_O. M:8WDM.X9:?;3VR%I:%90%.U5V5 M\AHO([9'>_(]8;*(J#&:]5.(CHS[?J9B M+?U>A<4XT=+SG@C-0MA!WTW13>G=#\IUXGKRV'+-;FQ'F\-7AR[J08=L[?ZF M3(J_T@86T(OMB/4NN(*5@P/661PM_%0>]%%M@S];G<,T)H4/X[#UVZG%L',[ MQRTFB);O?F9YLO"=L0[)*AQJQP0?%6@CI7 MJ$-?6"IN2M!LQV9VU!B.%=YL**VQ2-KN6C<96OM$XHXA_(#4A+V/>K-T,U^S[47M;8R9! /')&(M)=^8D]8H9@--YV?N 98" MM'WV()QOW7H5C^DTG@2N+PMOT^S&MOOX&4=")P7C&!O543M=T%.J&RY9U,PX M20C7H[W5KH+.MI/[&=&'J1 'W%3ZF#UC?4Z*/ROREJ$=ZEV#3A^V?>:][07T M%8<5\+'G11DUB^(V0!YF#J.V[4#O@(T*7+&27D)A@I:Z6/+II'C-7C7QPZAM M._ -# FQDH8_)';*N6:RSMQ-OG"*!X&HO6UG_L&PRQ4Q?*#%,QV5M>M:L".U M[LXWN!(T](-U=<]GJ3*QN?)"KO9\SNO">A4:4[.Z6%_#]RC"=\!]W A@J'S3 MHXM94W-#+^T@D+@HXM3/+9*T+_M5=PR/'8 F<2PLVYW/?33V?L_\F%!)J!+2 MS2QPZ?8WG+,(B#5K(@GHT>C#?MV>[H!%G:5^*;M*N/+ZF"\P% 3J:[3H:^Z% MKC'E:_*]K#'2ONR5'.H]5@&@,R2K21QYA,R32ZJ+FR@EZL.FF,)ZZ:$#P&C% MCDJU@@^[VTJ%K'/R(%O[I536*PL9P5"D'1PXWI)UN3.9+N38M5M"\3+FU^L- M+Y$6AK\'JX[$(E'@GKDXLGB3WTG#3)5+"([G08\^4$F-_VEXM&BUPMTO)C/M(9OPKOH MZ66.C3$UD3C>4&O(7WO6'10MAH$&C&=E;^< :#1E+0J?G$\YZ' MPPO+_J;_QQ-0W LJ+"(U7OW._,0*8%IMX5B8R[!_4!L1.(; M*NK!HH5CEN(Y7=RRBM+3!3T#%!%?7T*JJCPT:+R,29'>.$XR"MR/;TXYJ+#^ MNG<'!;8PZ.4U:!=0O,WGPFM<3>AJ MR)#1U@I^1BL_2:)XP[SJ+#.G_LY#V93,[Z-*'4J!]?;0+S@ERN#S)9H81;TJ M0 C\LR>ZGY/$B_UUD:G!*BNZX28YRQ(_) E[!92]#9!,%[/*-W?LUU+??W). MG',_\8(HR6+"_K'OF>6[WS\2I^S_7]UUE/R<.-O/.&XX=_(/L8:U3UD, (Z7 M;ECFL.S3^(O$MBJ+TT4Y!U!_?_Y:O%[ MOHI^=N/9!K]RXUZKYC-ZTS2?+6F^7]X36XVPX ?RJA M+*];8"S;$23:JL*PB.7N-E:\\&JUCJ,G4D]KK!GBJ&F(.UJG0FS1#G-^ #O# M9CN;#XSGK$P7U_3\3XB660%(+=L2'X_FN^)0#6"PEFHD)WM"NQ696S.8TZ;! ME.1.3N_D'3C;'FP&@.Z%JA0*!AB2FM)J7"N?.2TCT^K$LKE!<6Q%OFKK"8,I MUH)T:V;WMNV"?;"Y+%5#^"'70KS65DO!/>CM]X0$ENU#AD.K@IM4YJ$?OB91 M[ETAK+IQD=G.?RYX]*[ENMA1.GO2?F_KBOZ9UV?_98470TEEO\V> M.TF$M8S&IB,#B$YSAZ?4 (;U1%7OH687[YMVD5,[);E3I>_;N]=F$>+BDU'9 M]O-5F-*[#X,06_?[J?'B.?]@.L%@-\T@'K[!_-@Z"C$R=NE$"0TXPO.U_C[2 MNY-FE!#"7F/*&NJ3C?L\?$K1^F M%HAAC?J(IU/0^%=1#M028 K!8!.\**Z:$;3"# H*IR#I]<"PXT1Y2."T1/42 M$QLZ6CL@C2[L'AN$&"F?4E+H!(,Q7).E&Y09Q.R-9;Y%M*( C631Y M4MB&N+G5NQ'*U&E@8"E4U<,GZ'X$1&[3,%0HM:Y*-!2"P3+NLH>$_)[1 M_BZ>A/>*IZT+_CV94]+93&:KBP#)7A-16,W)JS,%65S$)+8?=5)@TLJX4\B. MPU0@,9W2V,[3U@4]/+;3^>OV;S;?7GM!89YT)S]=7"2IOZ+;?XFKM]EN:&&; M?#EQ)&G=Q^Z<9:-L_7"-POVYA!LQ-$!RVR^G:4.FI18<2-X2.G-GA.4.TFF, M:;;@$G2#KR2U_2Z9-H)@=>! 3Q@;!P81WH/U9\9TL=15#@Y(BVBM(G8+C**4 MR/JK8+K 52 ZM+UX_S,B.?\Y)F9#^XP,AI=&']?2]='+75@P/5292D]+3@ M!AH&**.Q_2"7-FYJ!9@J ]&XM:*3=M-IKT:$=_T%Z:?.K#]$I9\7VUUG MP_%KWC/'@\"KV52-:!G#5,#):I:8?2N+HYXU?YAIO_#T^?T0NB64 M'=^C0X9?B%3+'#4ZLQYVJY-N?X"ZD.RK=@((;$P+9G4?UJX\#H07JAT,LR6O M0()LOFREZO#+)$OWYZB4<-83!4YE"0&26GQ.T#BN5MX(46=IE"]_(G,)OM5!;2&EE&#$6C MND)3@*K3'8/^J061O/PU (-*6QPX\$>1"($*^]77^OI#(8G3"@+T7TWMTQ_] MMB_02^8785ID27_W>?JGS<6MAX" 5("*XP0!!.?1RO5#. C;]I9AD&H8!,96 MD/W>XIG1F.4"EG7B/Y/5 XGY,' ;6HMG5:BSI7N)F(9B=V:/;KQRO4T1\.6& M[C*WU+LHR/)=V57H"=7-.M"@MQ:)JH6"IE XO=YWCU&:9\,BWXU=) MDI&Y)A@22MN)$KI(*)6 X;C-*<8F.WUS*BNT2[(9N1U_>;79]B.E7J.,Y'7FCF97&2W5 M>;IGV^O8]> -\""58G,H%3Q_]D-_E:UN&0[!5H#+*&[$7^C??1_4O=7@2_VA MTJ_PF(9+$7539WAW O_L4BFW1WEP;KQF9];\,0<-A0/TAF&UAF4TG9/4]0/! MTGU02E/9\S&GZ1ATT2&YZ!AZ\:<)O=!?T*)PF6YOD.C'!"$8VVF;VBAND_/R,*J.P?9L)T[M2#*,JKP;J5R.9I5I7$=FNT097 M/$Q\4[%*LQG[OCP>J=[&=A$UN&:YPAF/BN FT.].L)4L>H7[\J >T<<6'2QA M"\T^7LFSL-[72RMLRS&,5^S,)5[NY516W7=]H-I^*5&E(ASNNCJG.[&A.%8( MK+K=3$/84LS@?&XW=!"ZK"02W_G6*BS2P?GF[+YQ=,,=W7!'-]S1#6>B7N_9 M)H]JF 1N(DJ'*FDD) /"1"(%#J_C MDM"VD]&TZ4!+SCQ#(A,HP^_6#9>B"Q;Z^\JO<1BJ,JFUPG'E_&-#J[)\R5H# M^WFJK5'05.B656N9J&6Q&9BKT*U M/%DP^GWD^VA>VR',OQ+V*Y9N'@0^1+Z<#Q:C6V_7Z>% MAD!4#%?MM?+XTBR65L7YY@L=!V6JB.9<#GNJ"B12$LN#7C[*+1<) >B:,[AQ MS2SU)SW$ZFZVLQJGU4'S?#F''X/'?XAEG-8>1Y);$8#<:DA71SL#:P7#LM)^ M>D6ZMK3>5!"L+<[HA3T )8O#OX_RSXE.<8TVUFOB@-[HX3".:?6X8[?3?KHY M)^LH\25[TE;#@;V1Q)?3U,'97?NI&_A_D/DLBO/W+(LB$J(=G+B]U8E;;Y@K MI<8QY&VR4E-+)G-/D 'F@Y.NM#T[V(Z%!HQ&GK'D#2B,V;C$(+B*3[I[K7U M;)'H+3X$M3S^?(_Q_3V.$DD,B(KNI3W"5U,'CFES['G9*LO3;>F&-"9>$?U) M_QZ0\MWS\8IMH?[(?RX430QR?U^P?+BBY>[**N2"!LO7^F6-UQ) N^V'6^.GN)9:BW&N@:SA,5 M@W.7^V2N=(?<>L5 \&8N@@WR !_-'78V+>@-W&,&K>U@<\09M,+Y]6RCKFL' M(AX03B!Y<.37BA^*!Y3 Q'CP$UC?$+!1%.$RJO"7R6B&DI2@EMMF((W@%E73@\.547#AVD_7M@T6%K[3S_GRQ)\UIH M45PU?C9/WXY0=H? V M5:6\CREW%#7V!K/:@M24%FVJ6KBXPJA/DKR6B[_PR5P9(:'5B66[@^+8L,0. M>L)@FU6VI?;8>K2,Y9NB,+RJ"&ICX[>V_&# ]O5OI2%Q&ULV&)G^.6\$"&1% M:@PCOC6TW@&J64/7V/:C/0S^"D3#&(X7(;8=[,]W$0(J*S6ANXPH\.=L[W 1 MIL6+C,)"<^+60T! *H"1.XW.$ BO+P0R(+FQD&H8!(;)6PD0&K-(J:A-)[9HQNO7&^3)QM^=D-WF5OJ711D^5GG*O3D MCY? Z6U6OH.CH"D4JIN?H9\?X'<]@SL]G/)/#ZV'#.JGA]/CZ>%X>CB>'M#N M78^G!]L('$\/Q]/#\?1P/#V82T;_LYP>[M+(^WJ5)!F9GV?L,8<9B?UH?D>E M(? <'-GI#Q1(]*Y5N*]^ M<$01-W0\0!X/D,<#)*X#I#8*QZ>)%/;QC;(>%Y>D-T<.0]'=\\ M'-;;V"ZDKJ-3KGA&C@A'AV 'AZ"%5^V.#L'^'8*#<4KU/R<-U"D%-)6,O3BQ M9F'7;)J5S52\EH.9I7C,&WGJ#?;N)EEGL??H)F2\C$G.>I-%V82E08YA_A(/ ML>KSG7"9S$QEGPG]>NA[R9D;?I5.6MR6-J%4G:TD5_V0_+HG*&7_?JSF>)]MH35FX_]I4\993\M7IX:R4U% M06K;K:)E(2 U&#:,YWJ/T>*;<\_Q'J,)VRAY94\6[CS+>B8BZV$PK]/I*L5F M79QG&@9%U$81"G#(8&CT QP2/^$?$EP%X;#Q61QYA,R32RI]7NQ!C!^G*1"B M#]8A$HII:#VCW_F#A&//8W/!F1NXH2=ZNX??%*C9CW;7,9F8&$)^J"VF?KC, MQ7 ?_"!_P$E2?:']JMJN V?7@Z%W.[=?\IBK><>#ZNE.%56?@YKVO\[HQ,:V M*F7PBX M;DN;[ZT!M5L=VQ)I#4T:VR]N#Z@P';=:6WU8[0!%"\0V=4E.)Q+* MZ#BE!"'97!+A88/;TNJS:AV4+!$7QT;D.DJ2O5P;NJ;$F1O4GNL$I%W"^[#Z M_IHF@!W$,W+X0+1^*R)X6P],21?R0R-Z!["D_ZFC=KN;W#%ZUW;<*.+HW?I\ M3(?5V>;&3>F@RAU[NVE:&M6KT\> 4-,1"T<4<&-Q+;A5!0)+B7# I3](Y;N. MNHR&PH39R[^74;PB,3M]_4<4T*_(8X5E%+9OFP%#JQ8SK);>T)FHP6AY$!-O MNXNWR:4TZ&,Q #+8=^2_4(>!%DA'-X$QU<*< X,\019/+K.3,N6[//BQ X#, M"]QZOS#OQ"E[<2K=F'$%"WA6G!N55!8W5[]&\5<2)ZQZ @F3$MGR%*[TZH"( M;3J7@7@U]E4:.L'AH6M,O$K<1.VM^J>[8247'0<\^[P#.G^+=P)E_4Z2T@;'X?PF"CW5 M7 3NP%K$7G<+T%0.#D1S42LRBJ%KM[06X]<=(Y&X.,#@B!/.X0@!R:V%^!UL M6C#%=#XJH7CN_=9?/J;3Q9>$C).$R%^G?M=ZG3JG=J*%0^F=H@,S9Z,FFXI# MD;AYGQN">P;@K$ COX:=+IH?_D*Q*%Y?VV5LB;8/G7NS>092X5+=9!RH+D.[ MNNF:L#O@<)E_ML&0XI6S?(:!TUL] >D@I:V3X4<[2T66[%+D9%8/5E#$8:(( MC1#+DJ4(#6F]$BE;NPQ%AMA=Q?[TL2":!G$, K$=3H X"&1"S]R4N=@-Y($> MS78#TGZ3=1P!&WNN5%$:[98XE,\?.D+EFZSTK>\RR-)H%=$C,$F$@1G;0W2[ MJ>T$9M'8:1[_14*:.H(L%KXG+XI7;V([OUBEQS;'F-Q>UR1)HL89YYPD7NRO MY:]9*PG11[U !3$ZW.LN@/SCHM@*7LMAA*U(A#2D5GW711_."LLA+'J^"33^ MA5\)XYO,QT_TITO"SJ4LE9*5)BF+DD!=#I">;"^[X'FIJY)P>25RYH%!1^_? M2-T2>5?F(X_$O(,]%&)"JUGNU4GX,F,!N)_]T%]EJYS?F;O)7NO[:#;:,?';GXNT%MRT2-ST4&(DD M>!? 7<@;=)VK$"!QJFL:CD+^EW*++%C\1OS5;]1Q]7-&Q_5/V^:2VFR]G2G. M,XD3']S!(-VDL\2"SPY3;5?[+\N]/NVY7.[XY M_R?;KKZ(T!)-FSL&F=@./,:DT6Q NF]PCB/"9,>4*L"D MU1"'YKFC1J1XLQ4];NB/1M+ AEH+VU>[ N1K);S;$IFJC4Y_=*K4W:FF[HS= MUP)U=_ILNGNKU-U;+'%)0-V]Q1A-\_)]C(?=8A_=BHBB<@[S)+XL5\>0O)"' MF6!_EVU(_!>3:+6*PKLT\KZ"DE_>OVW7164].'D7YNNA[KA5UD#EM,1P"AZ> M0T*B]*,' MDI&+$'8L?:Q>\9NP:(5NLH9!L8N4="039$;/B2X/!8-'A3^2T$ MS9&A(AMQ#9 $ J'(F*E,Q*J,&4Y3V]MJZPU\]OKT^.RU M,8 &].SU6>3&\^GBW(^)1VFDSC%!6VN5? Y]^EHJNR'_2^.;ZV.';7*C5, SLWNMB]U[[LG\(V+T?(G8_ZF+WHRYV@]AN_#A$['[2Q>XG M7>P&L5?Y:8C8?=#%[H,N=H/8JWP8(G8?=;'[J(O=(/8J'X>(W>B-+GA["G!X MW1#0:RIB(/#)_8]2"BA\@]BP-!4Q$/BTW2LC7?_*VT'L69J*& A\VAZ6D79L M\B"V+4U%# 0^;2?+2-?+\G80.Y>F(@8"G[:?9:3K:'DWC*W+(#TM(VU7RTC7 MU_)N&%N703I;1MK>EI&NN^7=,+8N@_2WC+0=+B-=C\N[86Q=$+E<^HKMC;RO M5TF2D?EY%E-I9R3VH_G=(U5MDK]VQ0%]%Y*FIAU*OA9<#S@R[G+&9K'OR3(2 M*FULQY#"@6@)9BA^H8+X913/Z'S@[THGLF+-2S=@CV'F^6""B4^O"_R)4_HR M&47H5Y:)%*;)?30K9_'"' 5HB)O;3NV%:5XEKB$MEU5<*X';!?H"+8N;VWZ0 M *9EE;B&QW+Q,='$71T&M99 W?;_[&FG$'8F?*.O2U":] M?JP%3?>Z#1(J"#6XN<$?CJVH&R"T/V&%5JX>U,@6HW(2A?0TE5!ULUF=_3WU M'P)R1SS:5/YX\:']6HO,[]6LP0I$/1CR<=S_6(!V"QP*'[$.!3WU87AKXRY[ M2,CO&4L2?6*IH; B".^:11#VW3A%/[U50NAIN#?$E%1/V"(LI,"00SZL*@I* ME0IL[%A- 4G&_C6^:@KUL71/OZ>HHR B&!(>(AEPU$[@L*>JGR A08*+?)RI M 4)50:'!GZJ*@J"Y=2^X:IS)4<%8^N\Z"I4=VP2V)Y\K&:S/8UA7S\5!V] M4!7@F*(F@9LDTT7IG9X6==H5+[:+27!8!^SQ=K$4E;&$#1GED^XR(ASH*$<< M!"A4^Z^2-=6^J]',]I4@8'PUD.#*B6,:8]/R59BD<<;L_M+UR'@EJ-Q;DH@I MAA*6HY(9(S*?W92Y2S=Y+6_(D_) Y2XO;4Z0-_'%$'H5[28-A?HY3[9#+?JZ%ZE3Z2#PB=?FR?';0&A;Z" MAC\PJG=K^1T<<""HZ&QOL<# PQ1@*/R*NQ&4QKE)*881C@40&L?^BZ M//A)$0N\^V52_C:1F4RW[@83I'60NK2N[LO?L/\]N FA/_G_4$L! A0#% M @ 6H8347@W3C21<0 JD & !$ ( ! &-H8W(M,C R M,# V,S N>&UL4$L! A0#% @ 6H834> Z*VPH#P YZ@ !$ M ( !P'$ &-H8W(M,C R,# V,S N>'-D4$L! A0#% @ 6H8341(V M L[.#P I\< !4 ( !%X$ &-H8W(M,C R,# V,S!?8V%L M+GAM;%!+ 0(4 Q0 ( %J&$U'[C8X&41T %WL 0 5 " M 1B1 !C:&-R+3(P,C P-C,P7V1E9BYX;6Q02P$"% ,4 " !:AA-12GBU MD=L_ #FBP, %0 @ &&UL4$L! A0#% @ 6H834<\=<:VC+ E/X" !4 ( ! MJNX &-H8W(M,C R,# V,S!?<')E+GAM;%!+!08 !@ & (H! " &P$ " ! end